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Abstract
ARV-based HIV prevention methods available in pill, gel or ring formulations (broadly referred to as microbicides) offer the
possibility of protection against HIV for women who find it difficult because they cannot ask their partners to use condoms or even
refuse sex. Partial efficacy of ARV-based medications has been demonstrated in a number of clinical trials around the world among
various populations, building the evidence that ARV-based technologies will contribute to reducing the AIDS epidemic worldwide.
Disappointing results, however, from two trials in sub-Saharan Africa, where poor adherence contributed to study closure due to
futility, have raised questions about whether women at the centre of the epidemic are able to effectively use products that require
routine use. Also, there are fears by some of risk compensation by decreased condom use because of the availability of micro-
bicides when only partial efficacy has been demonstrated in microbicide trials to date. Of note, sub-analyses of biologic measures
of adherence in trials where this was possible have shown a strong correlation between good adherence and efficacy, reinforcing
the necessity of good adherence. Research conducted in conjunction with clinical trials and post-trials in advance of possible
rollout of ARV-based products have examined social and cultural factors, gender-related and otherwise, influencing adherence
and other aspects of women’s use of products. These include HIV stigma, women’s perception of risk, partner and community
influences and the differing needs of women in various stages of life and in different circumstances. It is the purpose of this
supplement to give voice to the needs of women who can benefit from woman-initiated methods by presenting research results
and commentary to contribute to the global conversation about optimizing women’s experience with ARV-based prevention.
Keywords: women; gender; HIV prevention; ARVs; microbicides; PrEP; risk compensation.
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Introduction
Many women around the world find it difficult to protect
themselves against HIV infection because traditional gender
norms surrounding sexual relationships and practice make
it difficult to say ‘no’ to sex and difficult to ask that their
partners use condoms. A request to use condoms can be
interpreted as a sign of infidelity and lead to abandonment or
violence [1]. For women in these circumstances, an HIV pre-
vention method which they can use without their partners’
permission or knowledge, offers greater possibilities for pro-
tection than do exhortations to abstain or use condoms.
The use of anti-retrovirals (ARVs), commonly used to treat
people living with HIV (PLHIV), in gel, pill or ring formulations
offers the possibility of greater agency for women to protect
themselves. Partial efficacy of ARV-based prevention pro-
ducts has been demonstrated among several groups: hetero-
sexual women [2] and men [3], MSM [4], sero-discordant
couples [5], and drug injectors [6].
Reducing HIV transmission among women in sub-Saharan
Africa is key to ending the global AIDS epidemic, where over
70% of all new infections occur each year. Out of the over 16
million women living with HIV globally, over 12 million are in
sub-Saharan Africa [7]. Disappointingly, however, the initially
promising results of ARV-based technologies to prevent HIV
transmission were absent in two clinical trials with women in
this part of the world: FEM-PrEP and VOICE which tested oral
pre-exposure prophylaxis (PrEP) and microbicidal vaginal gel
in women living in areas of high incidence. FEM-PrEP tested
daily dosing of oral PrEP among women primarily in South
Africa and Kenya [8], and VOICE evaluated two types of oral
PrEP and a vaginal gel among women in South Africa, Uganda
and Zimbabwe [9]. Adherence was so low in the FEM-PrEP
and VOICE clinical trials that no determination could be made
of the efficacy of the products. In the VOICE trial, less than
a third of the women took the pills daily as prescribed. In
the FEM-PrEP trial, good adherence (defined as having the
amount of TFV in plasma estimated to be equivalent of a
participant four or more times each week over the preceding
28 days) was found in only 12% of the sub-sample [10].
Because of expected challenges with adherence in these
resource-poor settings, concerted effort was made to under-
stand participant perceptions and address these challenges
prior to and during these trials through formative and on-
going qualitative research and adherence support counselling
[8,9]. The extremely low adherence rates found in spite of
these efforts was a surprise and disappointment to researchers.
Even with community engagement and education, results
of qualitative research with trial participants during and
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following these trials has found that many rumours and mis-
perceptions remained throughout the studies, indicating the
strong influence of cultural and social understandings and
norms on emotionally charged issues [11,12].
The expressed concern about women’s lack of use of
microbicides has emphasized adherence, but in reality this
has just become shorthand for describing a number of issues
that prevent women’s effective use of these products. Though
many women who chose to enrol in the clinical trials were
able to use gel or PrEP effectively, there were often social
and cultural barriers, gender-related and otherwise, that
made it difficult for others. Based on data collected from
women who were trial participants prior to and during clinical
trials, we know that some of these potentially addressable
issues for women’s use of ARV based prevention included HIV
stigma, women’s lack of understanding and misperceptions of
how these products protect them against HIV, mispercep-
tions of their HIV risk as well as negative perceptions of an
investigational drug and lack of support by their partners and
the wider community [1113].
A tension that remains in the discussion of the appropri-
ateness of microbicides for women relates to the partial
efficacy of microbicides found to date and the fear of risk
compensation reducing the role of condoms in HIV prevention
[14]. To date, all studies that have been able to measure
efficacy have shown only partial efficacy [15], and so for
optimal effectiveness, and to prevent other STIs, microbicides
should be used in tandem with condoms, if possible. This can
be a big ‘if,’ however. As noted, the initial motivation for
a female initiated product was that many women live in
circumstances they cannot control and they cannot ask a
partner to use a condom without fear of rejection or violence.
Optimally, microbicides should be introduced into a service
delivery setting in conjunction with larger efforts to change
social and cultural norms and involve men in supporting
women’s microbicide use if possible [16], but changing norms
is a long-term solution. Many women  especially in places
where there is high HIV incidence  need the best solution
they can find now. The fear that the availability of micro-
bicides will reduce men’s motivation to use a condom is
relevant and real in places where it is normative for men to
use condoms, but an examination of DHS data on men’s
condom use in the 10 countries with the highest HIV pre-
valence finds in most of these countries significantly less than
half report using a condom at last sex with any partner [17].
Sub-analyses of FEM-PrEP and VOICE trial data indicated
that greater adherence to the prescribed dosing regimen 
measured through blood drug levels  correlated with greater
product efficacy [9], an indication that efficacy estimates will
likely improve if adherence improves.
Dramatically improved adherence to these ARV-based pro-
ducts is imperative if they are to be effective in reducing
transmission in this population critical to ending the global
epidemic. The results on adherence from the VOICE and FEM-
PrEP trials have led people in the field to express concerns
about whether a female initiated technology that requires
routine use is a viable option for women at all [18]. One
strategy to address this concern has been to focus efforts
on methods for women that are less user-dependent, but
a more effective strategy that recognizes the differing needs
of women in different situations may be to increase the
options that women have to protect themselves against HIV
infection.
It is the purpose of the papers in this supplement to give
voice to the needs of women who can benefit from woman-
initiated methods by presenting research, analysis, and
commentary that contribute to the global conversation of
how to minimize challenges and maximize opportunities for
the effective use of ARV-based products by women. The
supplement begins with a synthesis by Mastro et al. [15]
of what is known about the efficacy of various ARV-based
prevention methods in women. Social, cultural and policy
issues related to microbicide development and potential
rollout guidelines and policies are reflected in the remaining
papers in this supplement  women’s perception of risk,
community influence on participants’ adherence, adherence
support, understanding the needs and preferences of groups
of end-users who are characterized by specific circumstances
or at different stages in the life cycle, the tricky issue of
partner involvement and potential roles for community, pro-
viders and the private sector in optimizing women’s experi-
ence with ARV-based prevention.
Perceptions of clinical trial participants
In exploring adherence, issues among participants in the
VOICE trial, van der Straten et al. [11] found that the way
community members conceptualize disease transmission
and its treatment can influence participants’ behaviours in
prevention trials. Use of ARVs was confusing to many
community members and contributed to stigma experienced
by participants and community mistrust.
Another proposed factor related to poor adherence is
perception of low sexual risk. Among the 68 seroconverters
in the FEM-PrEP trial by Corneli et al., half reported that they
had no chance of becoming infected four weeks before they
tested positive. Rationalizations for perceptions of HIV risk
were examined in qualitative interviews among 51 of the
seroconverters [13]. Some women were assured by engaging
in preventive behaviours such as PrEP or condom use, while
others made assumptions based on prior non-infection or
trust in their partners. Some women did worry about infec-
tion but felt unable to protect themselves for a variety of
reasons. Study findings point to the need for adherence
counselling discussions of HIV risk tailored to the specific
situations of trial participants.
Increasing adherence
The development of a vaginal ring for microbicides delivery
is thought by some to take care of the adherence ‘problem’
by requiring less user involvement. Clinical trials, however,
indicate that perfect adherence to the vaginal ring is not
automatic. A commentary by MacQueen et al. [19], presents
a framework for considering the coordination of three inter-
related types of research relevant to increasing adherence to
vaginal rings in clinical trials. These include improved, theory-
based adherence support interventions; validated, general-
izable self-reported psychometric scales; and development
of real-time adherence monitoring using ‘smart’ or biometric
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technologies to detect ring insertion and/or removal or
expulsion. A case is made for the need to conduct these
three activities in a coordinated, inter-disciplinary way, to
allow for the best thinking from experts in multiple fields in
order to take advantage of synergies that may arise from a
common discussion of adherence through multiple lenses.
Understanding needs of specific groups of
end-users
Several papers in this supplement report on research target-
ing various groups of women for whom microbicides are
thought to be appropriate in specific contexts. First, Tolley
and her colleagues [20] make the case for including adole-
scent girls aged 1517 in HIV prevention trials based on the
results of a mixed methods study in Tanzania. She and her
colleagues found girls in this age range to be at similar or
higher risk of infection to their 18- to 21-year-old counter-
parts but perceiving themselves at lower risk and under-
utilizing prevention services. Though some might argue that
these facts alone do not warrant the IRB complications
related to including minors in clinical research, the authors
argue that this age group may not be targeted for ARV-based
prevention services if they are not included in clinical trial
research initially.
A second paper, by Sidibe et al. [21], describes potential
barriers and facilitators of microbicide use by four end-user
audiences in Kenya based on a literature review and an in-
country policy consultation: female sex workers, women in
stable and discordant relationships, and sexually active young
women. These groups varied in the extent to which the
salience of HIV prevention versus partner intimacy or sexual
pleasure as a motivation for using a vaginal microbicidal gel
might encourage or discourage their use of such a product.
The authors make suggestions for tailoring messages to meet
the various needs of women.
Mack and her colleagues [22] also compared the interest
in pre-exposure prophylaxis and preferences among three
possible formulations  pills, gels and injectables  among
several groups of potential end-users of ARV-based preven-
tion methods in Kenya (females sex workers and sero-
discordant couples) and South Africa (adolescents and young
women). Her findings also support the varying needs of
different types of end-users and the importance of formula-
tion choice to create and sustain demand of different users in
various contexts.
The role of men in women’s microbicide use
The issue of how to engage male partners to support but not
manipulate women’s use of microbicides has been raised in
many stakeholder conversations anticipating the eventual
rollout of ARV-based products. Lanham et al. [16] identified
opportunities for new retrospective data collection relevant
to this question from male partners of female participants in
the three studies in Kenya, as well as a wealth of qualitative
data from various microbicide trials that until then had
been unanalysed. Analyses of these new and old data were
presented in a meeting in 2013 to look for answers to this
question. The meeting elicited rich discussion and synthe-
sized guidelines for optimizing supportive male participation
while protecting against unwanted interference.
Improving women’s experience with ARV-based
prevention
The use of microbicides and PrEP, as with any other medi-
cations, requires attention to effective communication with
users and with members of the communities in which they
live; it is within these communities that many people’s beliefs
about illness and sex are formed, as well as their beliefs
about how medications may or may not prevent illness.
The use of vaginal products during sexual intercourse, for
example, may be a novel practice requiring community-
approved messages. Woodsong et al. [23] describes a process
used for involving a community advisory board to ensure
local comprehension of informational materials for women.
These materials used visual images because of the low
literacy of the study materials, but visual images also are
subject to cultural interpretation. As such, comprehension
of these materials was improved by the advice of local
stakeholders.
Another paper by Lin et al. [24] considers what can be
learned from the private sector about understanding the
needs of the end-users, in this case, women, when introdu-
cing new medical products such as microbicides. One frame-
work offered is that of the ‘user journey’ that takes into
account various aspects of women’s lives that might play
into decisions relevant to the use of microbicides, with the
objective of creating an interface between user and product
that enhances women’s likelihood of effective use.
WHO guidelines play a critical role in the introduction of
new products within national health ministries. The last
paper in the supplement by Lusti-Narasimhan [25] considers
the relevance of gender norms in developing guidelines for
microbicide or PrEP services. The proactive consideration of
the influence of gender norms in the use of ARV-based tech-
nologies can help policymakers and programme managers
facilitate women’s full access to their use by considering
issues such as protection of privacy and confidentiality in
service delivery and reducing barriers such as parental
consent that may keep adolescents at risk from using them.
Conclusion
The availability of any biomedical technology does not obviate
the need for consumer involvement in the correct and con-
sistent use of that technology. Likewise, the development of a
‘woman-initiated’ technology does not really give a woman
control until all the barriers to the use of that technology
stemming from myriad social and gender inequities are
removed.The promise of ARV-based technologies to empower
women to protect themselves against HIV will be kept only to
the extent that these inequities are considered and addressed
in the development and implementation of gender transfor-
mative policy and service delivery models.
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Abstract
Introduction: Antiretroviral (ARV)-based pre-exposure prophylaxis (PrEP) is a promising new HIV prevention strategy. However,
variable levels of adherence have yielded mixed results across several PrEP trials and populations. It is not clear how taking
ARV  traditionally used for HIV treatment  is perceived and how that perception may affect the use of these products as
preventives. We explored the views and experiences of VOICE participants, their male partners and community members
regarding the use of ARV as PrEP in the VOICE trial and the implications of these shared meanings for adherence.
Methods: VOICE-C was a qualitative ancillary study conducted at the Johannesburg site of VOICE, a multisite, double-blind,
placebo-controlled randomised trial testing tenofovir gel, oral tenofovir and oral Truvada
†
for HIV PrEP. We interviewed 102
randomly selected female VOICE participants, 22 male partners and 40 community members through in-depth interviews, serial
ethnography, or focus group discussions. All interviews were audiotaped, transcribed, translated and coded thematically for
analysis.
Results: The concept of ARV for prevention was understood to varying degrees across all study groups. A majority of VOICE
participants understood that the products contained ARV, more so for the tablets than for the gel. Although participants knew
they were HIV negative, ARV was associated with illness. Male partners and community members echoed these sentiments,
highlighting confusion between treatment and prevention. Concerned that they would be mistakenly identified as HIV positive,
VOICE participants often concealed use of or hid their study products. This occasionally led to relationship conflicts or early trial
termination. HIV stigma and its association with ARV, especially the tablets, was articulated in rumour and gossip in the community,
the workplace and the household. Although ARV were recognised as potent and beneficial medications, transforming the AIDS
body from sickness to health, they were regarded as potentially harmful for those uninfected.
Conclusions: VOICE participants and others in the trial community struggled to conceptualise the idea of using ARV for
prevention. This possibly influenced willingness to adopt ARV-based prevention in the VOICE clinical trial. Greater investments
should be made to increase community understanding of ARV for prevention and to mitigate pervasive HIV stigma.
Keywords: HIV prevention; antiretroviral; pre-exposure prophylaxis; microbicides; adherence; South Africa; qualitative methods;
HIV stigma.
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Introduction
Recently, oral antiretroviral (ARV)-based pre-exposure pro-
phylaxis (PrEP) was established as an effective new HIV pre-
vention strategy. Nevertheless, adequate protection hinges
on correct and consistent product use. Adherence challenges
have emerged as a key reason for divergent results across
PrEP studies, in different locations and with different popula-
tions [19]. Further, across vaginal and oral routes, daily,
intermittent, or coitally related dosing regimens have proved
difficult to execute [1,3,6,7,1015].
Tenofovir was originally designed for HIV treatment and is
part of first-line ARV therapy regimens in Africa. Treatment
adherence has been hailed as a success in reducing mortality
and morbidity amongst people living with HIV [1619].
However, public secrecy of HIV status and concealment of
AIDS suffering and stigma continue to undermine treatment
adherence to ARV; patients may try to avoid revealing their
HIV status by concealing their medication, compromising
adequate use [2022].
Similar issues arise with regard to using ARV to prevent HIV
acquisition because it may generate social stigma, particularly
in contexts where this prevention approach is unfamiliar [23].
In Kenya, stigma was reported to negatively affect partici-
pants’ ability to adhere to an oral PrEP regimen [11]. Similarly,
Thai participants in another oral PrEP trial feared being mis-
takenly identified as HIV positive and experienced stigma
van der Straten A et al. Journal of the International AIDS Society 2014, 17(Suppl 2):19146
http://www.jiasociety.org/index.php/jias/article/view/19146 | http://dx.doi.org/10.7448/IAS.17.3.19146
1
and relationship stress [14]. Oral PrEP tablets are readily
identifiable as ARV and thus attract unwanted public scrutiny
[11,14]. Consequently, participants in prevention studies con-
ceal their tablets because of fears of negative reactions
[11,23,24], avoid carrying their study products with them
[14], or lie about the reason for taking the tablets [11].
The VOICE trial evaluated daily oral and topical tenofovir-
based HIV PrEP among women in South Africa, Uganda and
Zimbabwe. In September 2011, the oral tenofovir arm (TDF;
referred to as ‘‘tenofovir’’ by the study team) was discon-
tinued for futility. In November 2011, a similar determination
was made for the tenofovir (TFV) gel arm. The emtricitabine-
tenofovir (referred to as ‘‘Truvada’’ by the study team) and
oral placebo arms continued until planned exit in August 2012
[6]. All three products tested were found safe; however, none
reduced the risk of HIV-1 acquisition, given widespread low
product use, based on post-trial pharmacokinetic drug testing
in biological specimens [6]. Similar to VOICE, FemPrEP, a phase
III trial of oral Truvada
†
tablets, was unable to demonstrate
effectiveness because of low adherence [3].
We recently reported findings from a qualitative study,
VOICE-C, which examined the contextual factors influencing
daily use of vaginal gel and oral tablets for HIV prevention in
the VOICE trial.We found that few participants acknowledged
non-use and that social relations within the household and
the community shaped women’s experiences of trial partici-
pation and the trial products [25]. In this paper, we explore
further the views and experiences of participants, specifically
in relation to the use of ARV as PrEP in the VOICE trial and the
implications of these shared meanings for product adherence.
Methods
VOICE-C was a qualitative exploratory ancillary study imple-
mented between July 2010 and August 2012, concurrent with
the VOICE trial. As part of the VOICE trial’s procedures
(detailed in [6]), when the active products were referred to,
staff used a pharmaceutical name (tenofovir or Truvada),
or described them as having ‘‘medicine.’’ A number of study
materials, as well as education and counselling procedures
regularly provided during the trial explicitly stated that the
active ingredients in the investigational products contained
ARV.
VOICE-C was conducted at one of the 15 VOICE sites,
the Wits Reproductive Health Institute (Wits RHI), in
Johannesburg, South Africa. The research clinic is located in
Hillbrow, a low-income, densely populated, inner-city suburb
of Johannesburg. VOICE participants were recruited from
Hillbrow, neighbouring suburbs and more distant townships.
The VOICE-C study has been previously described [25]. Briefly,
VOICE-C enrolled four groups of people: VOICE participants,
their male partners, community advisory board (CAB) mem-
bers and other community stakeholders. The VOICE partici-
pants were randomly preselected and randomly assigned to
one in-depth interview (IDI; N41) or serial ethnographic
interviews (EI; N21) conducted during the course of the
VOICE study, or one exit focus group discussion (FGD; N40).
Male partners of VOICE participants were recruited to par-
ticipate in IDI (N14) conducted during the course of the
study or an exit FGD (N8) as previously described [25].
Finally, a convenience sample of 40 community members
joined FGDs. These included 17 CAB members who partici-
pated in up to four serial FGDs and 23 community stake-
holders who took part in one of three FGDs, both of which
were conducted during VOICE implementation. Each of these
latter FGDs comprised individuals who lived or worked in
Hillbrow and were homogeneous in terms of their profes-
sional affiliation: 1) community-based organisations involved
in HIV/AIDS; 2) local media, including community newspapers
and radio stations; and 3) a local neighbourhood improve-
ment programme. Out of all participants screened, one
female participant, three male partners and one community
stakeholder refused participation.
Procedures
IDIs and FGDs were conducted at the research site. The EIs
(a longitudinal series of 24 interviews) took place at the
interviewees’ home or a private location of her choice. All IDIs,
EIs and FGDs were conducted by trained gender-matched
research staff in the participants’ languages of choice; they
were audio-recorded, transcribed and translated into English
(when conducted in another language). The interviews in-
cluded a short demographic questionnaire. Selected survey
data were collected during participants’ VOICE clinic visits.
All English language transcripts were coded in Nvivo
(version 9.0, Burlington, MA) by the analysis team, which
included members of the data coordinating centre and site
staff, using a codebook that followed a socio-ecological frame-
work (SEF) (Figure 1) [25]. Coded data were concatenated into
coding reports by thematic area (e.g., ARV, PROTECT, SIDE
EFFECT, PREFERENCE) and by SEF level codes (e.g. HOUSE-
HOLD, CLINIC, COMMUNITY) and then summarised into
memos. Memos from each area were further analysed to
reveal patterns or themes related to the use of ARV in the trial.
The study team was blinded to study arm assignments
of VOICE participants until the last analytical step, when
participants’ perceived product assignment was assessed.
All participants provided written informed consent prior
to participation. The study protocol was approved by the
Institutional Review Boards at RTI International and the
University of the Witwatersrand, and overseen by the reg-
ulatory infrastructure of the U.S. National Institutes of Health
and the Microbicides Trial Network.
Results
Of the 102 ethnically diverse VOICE female participants
who joined VOICE-C, the mean age was 27 years, 68% had
completed secondary school and 96% had a main male
partner although only 22% were married. Women completed
a structured survey at VOICE trial exit asking about their
perceived product assignment. Although 51% were actually
assigned to an active treatment arm, 62% perceived having
received an active product (Table 1). The characteristics of
the other groups in VOICE-C, the male partners (N22)
and the community members (N40), are also presented in
Table 1.
ARV for treatment versus prevention
VOICE-C participants had varying levels of awareness that
active trial products contained ARV, although there was
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greater cognizance that the tablets contained ARV than the
vaginal gel. Among gel participants, about half were unaware
that the active gel contained ARV. Participants were initially
surprised when they learnt that the trial was testing ARV as a
means of preventing HIV. Lily (all names are pseudonyms)
recounts her feelings upon such learning:
I didn’t have a problem with the tablets but I only
got scared when I heard that these tablets are ARV,
I got scared to think that we are now going to
take tablets used by people who are sick when we
weren’t sick at all. (Lily, age 40, Tablet FGD)
In some cases, women speculated that the products only
contained ‘‘some of the same components as ARV for
treatment.’’ Others such as Limpho initially misunderstood
the information provided by staff at the trial clinic.
(. . .) According to me, they said they are doing a
research to find out if they [ARV] work, you see, but
then in my mind I thought, okay, maybe it will help
protect people that have AIDS. I had not understood
correctly. (Limpho, age 21, Tablet EI)
Otillia used the acronym ART (antiretroviral therapy) to
differentiate the study drugs from ARV, in a conversation
with her friend.
I showed her and she said ‘‘Yoh! They look like ARV,’’
and I said ‘‘Yes they look like this but at the clinic
they said these study tablets are ART they are not
the same as ARV,’’ you see? (Otillia, age 26, Tablet EI)
When the interviewer prompted Otillia about the differ-
ence between ARV and ART, she first said they are different
‘‘because of what they do in the body,’’ but ended up
confused with her own explanations.
However, several participants reacted negatively. Thoko
(Gel, age 25, EI) stated that she would not use the gel if it
contained ARV and would drop out of the study. According to
her, ‘‘ARV are for sick people’’ and not for prevention. She did
not understand the reasons to give ARV to healthy women.
The uncertainty and confusion expressed by many partici-
pants like Thoko stems partly from difficulties in distinguishing
between treatment and prevention, particularly relating to
using ARV. IsiZulu and SeSotho speakers used the words
ukuvikela or sirelela, respectively, for prevention or treat-
ment, while others used the English words treat and prevent
interchangeably. With respect to ARV taken for treatment,
participants also used the English word cure. The conflation
of treatment and prevention potentially creates difficulties
in conceptualising the idea of PrEP, particularly when the
prevention technologies use the same ARV drugs, usually
taken for treatment. Indeed, in some cases, HIV-positive
family members stole participants’ tablets, presumably to
treat their illness. Palesa’s (Tablet, age 21, FGD) mother
acquired a sexually transmitted disease and, worried that she
may also be infected with HIV, started using her daughter’s
trial tablets. Tshepiso’s (Tablet, age 27, FGD) aunt was HIV
positive and stole her tablets when her own ARV ran out.
Male partners were not enrolled in the VOICE trial and
unsurprisingly did not have a clear understanding of the trial
in general or of using ARV for prevention in particular. Some
questioned the legitimacy of the trial when they learnt that
ARV were tested: for example, they asked why HIV-negative
women received ARV and suspected that their female
partners may be HIV positive because they used ARV.
Other male partners weremore concerned about the health
risks associated with ARV [27]. One man said his partner may
acquire HIV from taking ARV and that this would affect their
future progeny. Although he insisted that his partner cease
taking the trial tablets and end trial participation, she
remained. Others were more sympathetic, although they
too were poorly informed. For example one man thought the
study was meant to detect ARV in different biological speci-
mens and trusted that medical researchers would not give his
partner unsafe drugs. Despite the negative associations of the
tablets, male partners appeared to prefer these to the gel,
Figure 1. Socio-ecological framework of factors affecting perceptions about ARV for pre-exposure prophylaxis (PrEP), by levels of influence,
among VOICE-C participants.
Note: Some of the factors may operate at multiple levels of influence, but are only presented at the highest level at which they operate and are
not repeated in lower levels. The organisational level of influence in this framework is focused on the clinical trial setting.
van der Straten A et al. Journal of the International AIDS Society 2014, 17(Suppl 2):19146
http://www.jiasociety.org/index.php/jias/article/view/19146 | http://dx.doi.org/10.7448/IAS.17.3.19146
3
because of the unwanted vaginal wetness that could occur
after inserting gels.
The CAB and other stakeholders articulated their difficul-
ties in communicating the concept and providing the correct
information about ARV for prevention in the community.
They also expressed concerns with the side effects of PrEP,
and that women in VOICE would be identified as HIV positive.
Nevertheless, they said that PrEP would be acceptable if it
was found to be efficacious in preventing HIV acquisition.
PrEP and HIV stigma
All categories of participant (VOICE participants, male partners
and community members) recounted overarching apprehen-
sions with HIV stigma in their community. VOICE participants
sometimes referred to HIV/AIDS as ‘‘that disease’’ and ‘‘the
flu’’ and one remarked that ‘‘being HIV positive is seen as be-
ing in style’’ (Mandisa, age 25, Gel IDI). This appears to down-
play or trivialise the seriousness of the disease, particularly in
the era of effective treatment. As one male partner stated:
People they still die before knowing about AIDS and
people are still dying, they are still going to die, so
what’s so special about this AIDS, you understand?
That’s what they think. If I get HIV/AIDS I will just go
and get treatment and live longer than those people
who are not even infected, so why worry. (Antonio,
male partner FGD, Gel)
Yet, it also signifies a widespread view of the ubiquity of the
HIV/AIDS epidemic and the futility or hopelessness in trying
to prevent its spread.
Table 1. Demographic characteristics of participants by VOICE-C study groups
VOICE participants Male partners Community members
At time of VOICE-C (first) interview N102 (%) N22 (%) N40 (%)
Median age (mean, range) 26.8 (1940) 31.4 (2245) 38.5 (2060)
Currently married 22 (22%) 9 (41%) 17 (43%)
Has current primary sex partner 98 (96%) 22 (100%)
Length of relationship in years (mean, range) 5.5 (0.125) 5.9 (110)
Currently living with primary sex partner 44 (43%) 16 (72%)
Completed secondary school or more 69 (68%) 14 (64%) 31 (78%)
Does not earn an income 44 (43%) 4 (18%) 13 (33%)
Ethnic group
Zulu 27 (26%) 4 (18%) 5 (13%)
Xhosa 13 (13%) 3 (14%) 5 (13%)
Sotho 19 (19%) 4 (18%) 10 (25%)
Ndebele 26 (25%) 5 (23%) 1 (3%)
Othera 17 (17%) 6 (27%) 19 (48%)
Religion
Christian 94 (92%) 17 (77%) 36 (90%)
Muslim 0 (0%) 2 (9%) 0 (0%)
Other/none 8 (8%) 3 (14%) 4 (10%)
History of involvement with HIV research/work 43 (42%) 5 (23%) 31 (78%)
Type of interviews receivedb
In-depth interview 41 (40%) 14 (64%)
Ethnographic interview 21 (21%)
Focus group discussion 40 (39%) 8 (36%) 40 (100%)








Oral placebo 22 (22%)
Tenofovir (TFV) gel 21 (21%)
Placebo gel 19 (19%)
Perceived assignment to active product (N83)c 53 (64%)
aOther ethnic groups: KALANGA 1, KHALANGA 1, NYANJA 1, SHONA 2, SWATI 1, SWAZI 1, TSONGA 3, TSWANA 4, VENDA 3; bthe procedural changes
because of VOICE Data Safety and Monitoring Board (DSMB) futility recommendations contributed to several women randomly preselected for
VOICE-C participation receiving an earlier interview than anticipated, being reallocated to a different interview modality, or to stopping their serial
ethnographic interviews early; cperceived product assignment was assessed at the VOICE clinic exit visit, TDF participants (N18) were not asked
this question, because of early stopping of this arm following the first DSMB futility recommendation [26]. IQRinter quartile range.
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Local constructions of HIV such as these had implications
for women who used ARV to prevent HIV and feared being
mistakenly identified as HIV positive and suffering discrimina-
tion and social isolation. Trial participants recognised this and
went to great lengths to disguise their involvement in VOICE.
They were secretive and hid their products from household
members, co-workers and friends to avoid accidental dis-
closure, although this made taking the products more dif-
ficult. Keneoe (Gel, age 21, EI) hid her gels in the ceiling to
avoid detection and Tale applied her gel in the toilet, the only
private place in her home.
At times there will be a lot of people in the house
and you know how it is like in South Africa. The
bedroom serves a multi-purpose task of being a
sitting room at the same time. Hence the bathroom
is always the safer option where I would be able to
do my business [insert gel] without disturbance
from anyone. (Tale, age 24, Gel IDI)
For trial participants, explaining the reasons for taking the
tablets was often too burdensome because it was easier to
be secretive. ‘‘I hated that thing of having someone ask me
because I would have to explain everything,’’ said Nomsa
(Tablet, age 26, FGD).
Conscious of the possibility of unkind gossip and rumour,
and of discriminatory action being taken against her, Naledi
remarked:
The area that I live in has a bad influence because
they like to gossip about people. If they could see
these tablets, obviously they are going to gossip
(. . .) if they could see me taking the tablets they will
say that I have AIDS. They would not listen to my
explanation about these tablets. (Naledi, age 23,
Tablet IDI)
For some, the risk of being labelled HIV positive out-
weighed the benefits of participating in the trial. Gladys
experienced discrimination first hand when her flatmates
suspected she was HIV positive:
There is that stigma, discrimination and stigmatisa-
tion of those people who have got AIDS. So, they
[flatmates] started to change the way in which they
were living, you know. When we have drunk with
this cup, they will just not touch it  they will start
doing those things. (Gladys, age 33, Tablet EI)
This had implications for adherence and participation in the
trial. Nogoli (Gel, age 31, FGD) recounted a study participant
who withdrew from the trial because her mother-in-law
pressured her to stop taking ARV by saying ‘‘you cannot take
ARV when you are not sick. They [researchers] only want to
make you sick.’’
However, there are also several examples of women who
managed these outsiders’ perceptions by referring to the
VOICE trial fact sheets, undergoing HIV testing at a local clinic
with suspecting relatives, or simply discounting the dispara-
ging remarks made of them as a result of ignorance; such is
the case for Thuli’s cousin:
She says I will catch the flu [HIV]. I tried to give her
the papers [fact sheets] to read and see what this
thing [VOICE] is all about is. She is ignorant and she
pretends that she knows everything. [. . .] She said
that if I continue testing I will be infected. (Thuli, age
24, Gel FGD)
Overall, VOICE participants assigned to gel preferred it to the
tablet, while tablet users were divided about their preference
for tablets or gel. The association of study products with ARV
was seldom specifically mentioned when stating product
preference. However, six women did invoke this as a reason
to prefer gel over tablets: gel did not carry the HIV stigma
associated with the tablets, and is less recognisable, as
people don’t know what the gel is for.
ARV potency and safety
Participants’ ambivalence towards ARV was expressed several
ways: on the one hand they recognised that ARV are ex-
tremely potent, transforming the AIDS body from sickness to
health, and were therefore highly beneficial.
ARV are taken by positive people, they get fat isn’t
it? That thing encourages me because I live with
positive people in my community. I see how the
ARVs are working on them. So that thing encourages
me to want to take them. (Javas, age 30, Tablet FGD)
This awareness of the power of ARV influenced participants’
accounts of the side effects. For example, akin to the dramatic
physical transformations of HIV-infected people on treatment,
many tablet participants reported weight gain, which they
attributed to taking the tablets (although there was no
evidence of this in the clinical data). Others regarded the
side effects as confirmation that they had been randomised to
the active arms of the study products, whereas those who
did not experience any side effects tended to think they
had been randomised to placebo. Yet, the potency of ARV
was also regarded as a source of potential harm for those
uninfected.
I did have my concerns with these things since well
it is part of the ARVs and you know what the ARVs
does in your body[. . .] Even today I know that ARVs
can react badly in your body so this [gel] in the long
run, will it not affect me? (Abri, age 31, Gel IDI)
There also was some speculation amongst community
members and male partners that taking ARV could cause
one to seroconvert. Stories that circulated in the media and
amongst trial participants about ARV sold and stolen to mix in
with a heroin or crystal methamphetamine-based drug called
Nyaope (also known as Whoonga or Wunga) added to
the popular conceptualisation of the dangerous potency of
ARV [28].
I do not feel safe since there are people in the
community who smoke ARVs to get high. Thugs mix
ARVs with some other things [. . .] I heard that the
[thugs] sell ARVs and they get good profit. (Jewel,
age 24, Tablet IDI)
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These rumours added another dimension to the stories of
ARV potency and danger  that of physical risk  associated
with carrying ARV in public places.
Discussion
This qualitative study conducted in Johannesburg, South
Africa, explored local perspectives on using ARV as PrEP
to prevent HIV in the VOICE trial, which was unable to
demonstrate effectiveness because of low product adherence.
Focusing our analysis on the social meanings of ARV, we found
a variety of perspectives amongst trial participants, their male
partners and community members. Recognition that the study
products contained ARV was not unanimous and women’s
understandings of PrEP were mediated through confusion
surrounding the use of ARV as a prevention method, versus
treatment. Understandings of health that were articulated
here were often incommensurate with biomedical models,
revealing a tendency to conflate prevention and treatment.
Yet, the very fact that many participants knew ARVare used for
treatment, inferred a known distinction between prevention
and treatment. This apparent contradiction may stem from
the fact that ARV for prevention was difficult to grasp and
reconcile with the more familiar treatment model. In other
words participants had trouble distinguishing ARV for preven-
tion from treatment and yet were aware that it wasn’t the
same thing.
Given high HIV prevalence and stigmatisation of the
disease, taking ARV for prevention became a marker of HIV
infection. Despite a few participants suggesting that HIV
seropositivity may be normalized or even trendy, the strong
association of ARV with a positive status threatened to
engender HIV stigma and secrecy around the use of the trial
products and potentially challenged product adherence and
trial participation. Although trial participants had worries
about side effects, concerns about the social impact of being
identified as HIV positive appeared to be greater.The stigma of
HIV is based not only on sexual morality, but also on the
perception of HIV as an incurable illness [29] and has con-
tributed towards the secrecy and concealment of serostatus
[30]. The threat of a ‘‘spoilt identity’’ [31] from being
mistakenly identified as HIV positive influenced participants’
willingness to use ARV for prevention, especially in the context
of a placebo-controlled trial where the actual benefit of using
these products was uncertain.
The novelty of PrEP for HIV prevention combined with
pervasive HIV stigma [32,33] led to anxieties about being
identified as HIV positive, more so among tablet than gel
participants. Although ARV were recognised as having a
positive transformative effect on AIDS sufferers [34], their
potency was also regarded as dangerous, particularly when
used by individuals who were not HIV positive.
As growing numbers of clinical trials are conducted in
settings where there is limited experience of biomedical
research practices, the need for understanding local con-
structs of disease and responses to novel medical technologies
increases. How are these new applications of drugs such as
ARV understood and negotiated in contexts that are char-
acterised by stigma and blame, and what are the implications
for wider access to PrEP in mainstream public health care? In
this study we found that ARV for prevention was interpreted
with ambivalence. Although regarded as life-saving medica-
tions, ARV were also seen as potentially harmful; hence the
belief, albeit not widely shared, that ARV taken by uninfected
individuals could lead to acquiring HIV, or the association
of ARV with illegal narcotics and criminality. The result of
this ambivalence created uncertainty and doubt, potentially
undermining women’s motivation to adhere to the trial
products.
Other studies of HIV prevention interventions have
reported challenges with local understandings of biomedical
models [35]. A potentially fruitful area of social research
may be how biomedical researchers can engage with local
understandings of prevention, treatment and cure to im-
prove correct usage and sustained adherence to ARV for PrEP
in southern Africa and elsewhere.
Two seemingly opposite undercurrents of opinions
emerged here: one linked to HIV stigma and the other to
ubiquity and trivialisation of HIV/AIDS. Although South Africa
is a country most heavily burdened by the AIDS pandemic, the
relatively recent universal access to ART has changed the
landscape, turning a terminal disease into a chronic, manage-
able illness. Simultaneously, stigma and discrimination against
those infected persist and prevent HIV-positive individuals
from accessing the treatment and care they need [36].
Although these perceptions appear to go in different direc-
tions they may both work against acceptance of ARV for PrEP:
one because prevention is no longer seen as important
and the other because misattribution of seropositivity may
discourage those at risk to access or use ARV for PrEP.
There are several limitations to this study: VOICE was
implemented in three countries and across 15 sites, VOICE C
was conducted at only one site, in Johannesburg, thus our
findings may not reflect the perspectives of participants at
other sites. Further, in South Africa, ARVs have been the
centre of controversy, particularly under the leadership of
former President Thabo Mbeki and his Health Minister, Manto
Tshabalala-Msimang, who publicized the alleged toxic effects
of ARV, and questioned the orthodox view of HIV causing AIDS
[37]. This may have uniquely shaped VOICE-C participants’
experiences regarding both mistrust of research and ARV for
prevention. Given South Africa’s central place in the global
AIDS pandemic, this warrants further research. Notably,
studies in South Africa and other countries corroborate
our findings that taking ‘‘AIDS pills’’ or ARVs for prevention
generates concerns and may be associated with product non-
use [11,23,24,38].
In summary, socio-contextual factors influenced willing-
ness to adopt ARV-based prevention, in the context of a large
clinical trial. Greater investments should be made to increase
community-wide understanding of ARV for prevention and to
mitigate pervasive HIV stigma.
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Abstract
Introduction: Risk perception is a core construct in many behaviour change theories in public health. Individuals who believe
they are at risk of acquiring an illness may be more likely to engage in behaviours to reduce that risk; those who do not feel at
risk may be unlikely to engage in risk reduction behaviours. Among participants who seroconverted in two FEM-PrEP sites 
Bondo, Kenya, and Pretoria, South Africa  we explored perceived HIV risk and worry about acquiring HIV prior to HIV infection.
Methods: FEM-PrEP was a phase III clinical trial of once-daily, oral emtricitabine and tenofovir disoproxil fumarate for HIV
prevention among women in sub-Saharan Africa. We asked all participants about their perceived HIV risk in the next four
weeks, prior to HIV testing, during a quantitative face-to-face interview at enrolment and at quarterly follow-up visits. Among
participants who seroconverted, we calculated the frequencies of their responses from the visit conducted closest to, but before,
HIV acquisition. Also among women who seroconverted, we conducted qualitative, semi-structured interviews (SSIs) at weeks 1,
4 and 8 after participants’ HIV diagnosis visit to retrospectively explore feelings of HIV worry. Applied thematic analysis was used
to analyse the SSI data.
Results: Among participants who seroconverted in Bondo and Pretoria, 52% reported in the quantitative interview that they
had no chance of acquiring HIV in the next four weeks. We identified four processes of risk rationalization from the SSI
narratives. In ‘‘protective behaviour,’’ participants described at least one risk reduction behaviour they used to reduce their
HIV risk; these actions made them feel not vulnerable to HIV, and therefore they did not worry about acquiring the virus. In
‘‘protective reasoning,’’ participants considered their HIV risk but rationalized, based on certain events or beliefs, that they were
not vulnerable and therefore did not worry about getting HIV. In ‘‘recognition of vulnerability,’’ participants described reasons
for being worried about getting HIV but said no or limited action was taken to reduce their perceived vulnerability. Participants
with ‘‘no rationalization or action’’ did not describe any HIV worry or did not engage in HIV risk reduction behaviours.
Conclusions: Women who are at substantial risk of acquiring HIV may underestimate their actual risk. Yet, others who accurately
understand their HIV risk may be unable to act on their concerns. Perceived HIV risk and risk rationalization are important
concepts to explore in risk reduction counselling to increase the use of HIV prevention strategies among women at risk of HIV.
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Introduction
An individual’s perception of risk for a particular illness is a
core construct in many behaviour change theories in public
health [1,2]. Although perception of risk is one of several
theoretical constructs that may influence behaviour change,
the main premise is that individuals who believe they are at
risk of acquiring an illness may be more likely to engage in
behaviours to reduce that risk. Conversely, individuals who
do not believe they are at risk may be unlikely to modify their
risk behaviours. Perception of HIV risk has been studied exten-
sively in the field of HIV prevention [313]. Yet, limited data
are available on individuals’ perceptions of their HIV risk
around the time of HIV infection.
In FEM-PrEP [14], we explored perceptions of HIV risk
among participants at multiple times throughout the trial.
We also retrospectively explored HIV worry among partici-
pants who seroconverted. We wanted to learn more about
how women who were at substantial HIV risk understood and
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contextualized their HIV risk, as these beliefs may influence
use of HIV risk reduction methods. In this article, we focus on
HIV risk perceptions and worry about HIV acquisition among
participants who seroconverted during the trial from two
sites  Bondo, Kenya, and Pretoria, South Africa. We first
report how participants who seroconverted perceived their
HIV risk shortly before they became infected with HIV. We
then describe the context surrounding perceived HIV risk
among participants by describing reasons for worrying or not
worrying about acquiring HIV prior to becoming infected.
Methods
Overview of the FEM-PrEP clinical trial
FEM-PrEP was a phase III, placebo-controlled clinical trial
to assess the safety and effectiveness of once-daily, oral
emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) for
the prevention of HIV among women. The trial was conducted
in Bondo, Kenya; in Bloemfontein and Pretoria, South Africa;
and in Arusha, Tanzania. Details of the trial are described
elsewhere [14]. Briefly, women considered to be at higher risk
for HIV acquisition (i.e. those who either had vaginal sex at
least once within the past two weeks or had sex with more
than one sexual partner in the past month) were randomized
to once-daily FTC-TDF or placebo. Participants were asked to
take their assigned study product for 52 weeks and to attend
clinic visits every four weeks for 60 weeks. Among other trial
procedures, participants were tested for HIV and received risk
reduction counselling, a free supply of condoms and treat-
ment for any curable sexually transmitted infections at each
visit. Sixty-eight participants (34 from Pretoria, 27 from Bondo
and 7 from Bloemfontein) became infected with HIV on or
before week 52. Participants who seroconverted were asked
to attend clinic visits one week after their HIV diagnosis visit
and every four weeks for 52 weeks.
Qualitative research on adherence, sexual behaviours and
HIV risk perceptions was embedded within the clinical trial
protocol at the Bondo, Pretoria and Arusha sites. The trial
began in July 2009 and closed early in April 2011 because of
lack of effectiveness [15]. At closure, the Bondo and Pretoria
sites were fully enrolled, and most participants had com-
pleted or nearly completed their follow-up visits; the Arusha
site had recently initiated; and the Bloemfontein site was




We conducted a quantitative, face-to-face interview on
perception of HIV risk with all participants at enrolment
and at quarterly follow-up visits. We asked participants to
report on the likelihood that they would become infected
with HIV in the next four weeks. Response options were 1) no
chance  no possibility of becoming infected with HIV; 2) a
small chance  could happen but not likely; 3) a moderate
chance  some possibility of becoming infected; and 4) a high
chance  likely to become infected. The interview was
conducted at the beginning of the study visit, prior to
participants learning their HIV test results; the questions on
risk perceptions were no longer asked once a participant had
seroconverted. We also asked demographic, sexual behaviour
and relationship questions at baseline through a quantitative
face-to-face interview. All quantitative interviews were
conducted at the study clinic and in the local language
(Setswana in Pretoria, and Dholuo or Kiswahili in Bondo) or in
English by trained, local, female staff interviewers.
Qualitative interviews
We conducted semi-structured interviews (SSIs) with parti-
cipants who seroconverted at the Bondo and Pretoria sites
to retrospectively explore, among other topics, HIV worry  a
measure of perceived vulnerability [16] and a concept similar
to HIV risk perception [17,18]. All participants who serocon-
verted at these sites were invited to participate in SSIs at
weeks 1, 4, and 8 after their HIV diagnosis visit. We chose
these weeks based on previous experience in conducting
interviews at similar time points with individuals diagnosed
with acute HIV infection in Malawi [19]. In the SSIs at week 1,
participants were asked to describe whether they worried
(prior to their diagnosis) about becoming infected with HIV,
the reasons why they did or did not worry and whether they
took any actions because of their perceived vulnerability.
Participants who missed their week 1 interview or did not
discuss HIV worry during their week 1 interview were asked
about HIV worry at the subsequent week 4 or week 8
interview. The SSIs were audio-recorded if the participant
agreed; detailed notes were taken otherwise. Trained, local
female interviewers, who were different from those who
conducted the quantitative interviews, conducted the SSIs at
the study clinic in the local language or in English.
Data analysis
Among the 61 participants who seroconverted in Bondo and
Pretoria, we calculated the frequencies of their responses on
perceived HIV risk that were reported at the study visit that
was conducted closest to, but before, HIV acquisition (based
on the estimated window dates of HIV infection [14,20]). Of
these participants, 56 (32 from Pretoria and 24 from Bondo)
participated in at least one SSI, for an inclusion rate of 94%
for Pretoria and 89% for Bondo. No participant refused to
participate in an SSI; missed interviews occurred when
participants did not return for their follow-up study visits.
Applied thematic analysis was used to analyse the quali-
tative data [21]. Interviewers simultaneously transcribed and
translated audio-recorded SSIs into word-for-word English
transcripts (while maintaining the overall meaning of the
participants’ narratives) following a transcription protocol
[22]; 51 participants agreed for at least one of their interviews
to be audio-recorded. For SSIs that were not audio-recorded,
interviewers expanded their detailed notes immediately
after the interview and categorized the discussion by content
area.
To better understand the overall context of HIV worry or
non-worry, we reviewed all direct responses to questions on
HIV worry as well as other related behavioural data provi-
ded by each participant in the SSIs. Using NVivo 9 [23], two
qualitative analysts applied a content code on ‘‘HIV worry/
non-worry’’ to capture text from the SSIs in which partici-
pants spoke about whether or not they worried about HIV
prior to their HIV diagnosis and to capture other related
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narratives. Inter-coder reliability (ICR) was assessed through-
out the content-coding process; 22 transcripts were assessed
across the week 1, 4 and 8 interviews. Independent coding
occurred after the first three ICR sessions, at which point
the analysts had consistently and repeatedly reached agree-
ment on almost all code applications. The remaining four ICR
sessions were interspersed throughout the coding period.
At each ICR session, coding discrepancies were discussed and
resolved, and the codebook and previously coded transcripts
were revised if necessary.
When coding was completed, the content-coding reports
were reviewed, and a matrix-based approach was used to
display reasons that participants gave for worrying or not
worrying about acquiring HIV. Using the matrix, we identified
themes such as ‘‘having only one partner’’ and ‘‘trusting
partner’’ that led participants to worry or not worry about
acquiring HIV. The frequencies of each theme and representa-
tive illustrative quotes were then summarized in a data memo.
Based on the similarities of the themes and perceived vul-
nerability, we grouped each theme into broad risk rationa-
lization categories. Data from five participants (three from
Pretoria and two from Bondo) were excluded because we
were unable to discern any meaning about vulnerability from
their narratives; thus, the total SSI sample size is 51 (29 from
Pretoria and 22 from Bondo).
Ethics
All associated ethics and regulatory committees approved
the trial. All participants provided their informed consent to
participate in the SSIs when they signed the clinical trial
enrolment consent form; before each SSI, participants were
verbally asked if they were still willing to be interviewed.
Results
Baseline characteristics among participants who
seroconverted in Bondo and Pretoria
Twenty-eight (82%) of the participants in Pretoria were under
25 years of age, compared with 12 (44%) of the participants in
Bondo (Table 1). Participants in Pretoria also hadmore years of
schooling (mean: 10.7 years) than participants in Bondo
(mean: 8.2 years). Occupations also varied among the sites.
A high percentage of participants in Bondo were daily wage
earners (63%, n 17), such as through employment at a
restaurant or bar or by selling fish;most participants in Pretoria
(65%, n 22) reported not having an occupation. Table 1 also
describes sexual behaviours and beliefs about sexual partners
reported during the quantitative questionnaire that was con-
ducted at enrolment. In the SSIs, 41 (73%) of the participants
(n 16 in Bondo; n 25 in Pretoria) described having only
one sexual partner around the time of HIV infection.
HIV risk perceptions and worry
Fifty-two percent (n 32) of participants reported in the
quantitative interview, whichwas conducted at the visit closest
to (but before) becoming HIV infected, that they had no chance
of acquiring HIV in the next four weeks. Perception of HIV risk
varied significantly between the two sites (pB0.0001, using a
chi-square test.) (Figure 1). Prior to becoming infected with
HIV, the participants in Pretoria who seroconverted had
generally perceived themselves to be at less risk than had
the participants in Bondo who seroconverted; 24 (71%) of
the participants in Pretoria compared with 8 (30%) of the par-
ticipants in Bondo indicated that they had no chance of
acquiring HIV in the next four weeks. Conversely, 11 (41%)
of the participants in Bondo compared with one partici-
pant (3%) in Pretoria believed they had a high chance of
acquiring HIV.
The findings about HIV worry from the SSIs were similar
to the findings about risk perceptions from the quantita-
tive interviews. Most participants in Pretoria (n25) said
that they did not worry about getting HIV prior to their HIV
diagnosis, but many participants in Bondo (n 10) said they
did. Additionally, 24 of the participants (mostly from Pretoria)
in the SSIs said they never thought they would get infected
with HIV.
Risk rationalizations
We identified and labelled four processes of risk rationa-
lization from the thematic analysis of the 51 participant
narratives in the SSIs: 1) protective behaviour, 2) protective
reasoning, 3) recognition of vulnerability and 4) no rationa-
lization or action. These processes of risk rationalization
illuminate participants’ perceptions of their risk context and,
for some, how risk management strategies, or a lack thereof,
influenced their sense of vulnerability towards acquiring HIV.
Protective behaviour
In the SSIs, 14 participants (nine from Pretoria and five from
Bondo) described that they engaged in well-known HIV risk
reduction practices; these actions made them feel not vul-
nerable to HIV, and therefore they did not worry about
acquiring the virus. SSI narratives that focused on protec-
tive behaviours were mostly by participants in Pretoria who
reported in the quantitative interviews that they had no
chance of acquiring HIV.
Condom use was one of two commonly mentioned protec-
tive behaviours in the SSIs that led many of these participants
(n7) to not worry about getting HIV. For example, a parti-
cipant from Pretoria was confident in her reasoning for
previously not worrying about getting HIV: ‘‘We used to use a
condom when we had sex. Ja. So I was sure that whatever he
may do, I know I protect myself.’’ Yet, later in the interview
she described inconsistent condom use, which she believed
led her to become infected: ‘‘We woke up at night and he
wanted us to have sex. I never thought about a condom . . .
[but] when we were using a condom, we were okay.’’
Having only one sexual partner was the other protective
behaviour frequently mentioned (n9). A participant from
Pretoria said: ‘‘I never thought I would get infected with HIV.
My own behaviour did not give it a chance. I only had one
partner, and I never slept around.’’ Another participant from
Pretoria said: ‘‘I never got worried . . . I knew myself.’’ She
elaborated on her reason for not previously worrying about
HIV when describing her response to learning she had HIV:
‘‘I never thought I could be infected by this . . . [because] of
the way I behaved myself . . . My condition was good. I
behaved myself very well. I have one partner.’’
Only one participant, who was from Bondo, mentioned
that taking the study pill led her to not worry about acquir-
ing HIV. In her SSIs, she described that the purpose of the
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two-arm study was to assess whether FTC-TDF could reduce
the risk of HIV acquisition, but she hoped she was assigned
FTC-TDF because she believed it would work for HIV pre-
vention. Prior to seroconversion, she believed she was
taking FTC-TDF because she had repeated HIV-negative test
results. After seroconversion, however, she believed she was
assigned the placebo because she acquired HIV.
Protective reasoning
Narratives in the SSIs suggested that 23 participants (16 from
Pretoria and 7 from Bondo) actively reflected upon their HIV
risk but rationalized, because of certain events or beliefs, that
they were not vulnerable to acquiring HIV, and therefore they
did not worry about the possibility of infection. In most
cases, this rationalization led participants to think that
continued risk reduction behaviours, such as using condoms,
were unnecessary. The majority of these SSI narratives were
from participants in Pretoria who reported no chance of
acquiring HIV in their quantitative interviews.
Perceptions about HIV testing influenced SSI participants’
protective reasoning. Many participants (n10) described
that having multiple HIV-negative test results before or during
Table 1. Baseline characteristics among participants who seroconverted in Bondo, Kenya, and Pretoria, South Africa
Variablesa Pretoria (n34) Bondo (n27)
Age in years
B25 28 (82) 12 (44)
]25 6 (18) 15 (56)
Education
Finished primary school 28 (82) 4 (15)
Education in yearsb 10.7 (11), 414 8.2 (8), 316
Married 1 (3) 16 (59)
Occupation
None 22 (65) 5 (19)
Student 10 (29) 2 (7)
Daily wage job 2 (6) 17 (63)
Othersc 0 3 (11)
Sexual behaviours at enrolmentd
Type of partner
Primary partner only 27 (79) 16 (59)
More than one sexual partnere 7 (21) 11 (41)
No. of vaginal sex partners in past 7 daysb 1.0 (1), 02 1.0 (1), 02
No. of vaginal sex acts with primary partner in past 7 daysb,f 3.4 (2), 012 2.9 (2), 08
No. of vaginal sex acts with other partner in past 7 daysb,g 0.3 (0), 04 0.5 (0), 06
Had sex without condom with primary partnerf 15/34 (44) 22/27 (82)
Had sex without condom with other partnerg 0/6 (0) 3/11 (27)
Had anal sex with primary or other partner 0/33 (0) 1/27 (4)
Exchanged sex for money or goodsg 3/6 (50) 5/11 (46)
Beliefs about sexual partner at enrolment
Believed primary partner has HIVf
No 22 (65) 14 (52)
Yes 1 (3) 0
Do not know 11 (32) 13 (48)
Believed primary partner had vaginal or anal sex with other
sexual partners in the past 4 weeksf
No 13 (38) 3 (11)
Might/yes 2 (6) 10 (37)
Do not know 19 (56) 14 (52)
Believed other sexual partner in the past 4 weeks had HIVg (n6) (n11)
No 2 (33) 0
Yes 0 0
Do not know 4 (67) 11 (100)
an (%) reported unless specified; bmean (median), range; call participants in other category in Bondo are farmers; dreported for the past 4 weeks
unless otherwise noted; eprimary partner plus at least one other partner or two or more other partners; famong participants who reported
having a primary partner; gamong participants who reported having other partners.
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the trial led them to not worry about acquiring HIV. A
participant from Bondo commented: ‘‘I have never thought
of that [worry about HIV]. Depending on the days that I have
always come for my visits, I always tested negative. Even
when I came I never thought I would test HIV positive.’’ Some
participants (n4) described that knowing their partner’s
previous HIV-negative status made them not worry. A
participant from Pretoria explained:
I don’t know what to say, but I did not expect that at
this moment I would be HIV-positive . . . The person
I was involved with got tested and the results came
out negative. I was also getting tested and I was
negative so I did not expect it. I don’t know  maybe
he hid it from me because you can be tested and
there is still a window period.
Assuming to know a partner’s HIV status based on one’s
own HIV status was also mentioned by some participants
(n3) in Pretoria: ‘‘I never thought that my boyfriend could
be HIV infected. I knew that I was not infected with HIV, so
I never thought that he might be sick.’’
Trust was another concept that informed several partici-
pants’ protective reasoning (n9). Trust related to HIV worry
was multifaceted, was often interwoven with HIV testing
and was described primarily by participants in Pretoria. Some
participants (n3) described trusting their partners because
they assumed they were in monogamous relationships. A
participant from Pretoria who had multiple non-concurrent
relationships said: ‘‘I trusted my boyfriends . . . because I did
not see them cheating on me.’’ Furthermore, two partici-
pants also believed their partners would not infect them  a
participant from Bondo explained: ‘‘I also have one sexual
partner, whom I trusted and knew cannot make me get there
[be HIV positive]. And, I also would not like to put him there.’’
One participant from Pretoria explained that trust was
built over time through repeated, back-to-back HIV-negative
test results: ‘‘Because most of the time I knew myself . . . and
then I went [for HIV testing] after three months  isn’t it that
they say window period? They told me to come after three
months. I went back; then that’s when we trusted each other.’’
Later in the interview, the participant further described how
this trust halted condom use with her partner:
It’s that I am with one person. The first time we had
sex we were using condoms. And then he told
me that we have to stop using condoms; but before
[we stop] we have to test. We tested many times
and they were negative. So, that’s when I started
trusting him, and then I ended up being positive.
For some participants (n3), trust was also formed based
on assumptions they had about their partners’ sexual beha-
viours given their own sexual behaviours. For example, a
participant from Pretoria described that she did not worry
about getting HIV because she was faithful and believed
her partner was as well: ‘‘I knew I was behaving well and
I thought he was behaving well too.’’
Narratives from three participants in Bondo included
statements that demonstrated both protective behaviours
and protective reasoning. These participants were grouped in
both categories above. All other participants were counted in
only one of the risk rationalization processes.
Recognition of vulnerability
Eleven participants (1 from Pretoria and 10 from Bondo)
described in the SSIs specific reasons why they worried about
getting HIV and suggested that they were unable to consis-
tently engage in risk reduction behaviours to reduce their
perceived vulnerability. Most of these participants perceived
their risk to bemoderate or high in the quantitative interviews.
Participants described two main reasons for their HIV worry:
1) knowing that their partners have other sexual partners,
or being uncertain of their partners’ monogamy (n7); and
Figure 1. Perception of HIV risk reported at the visit conducted closest to, but before, HIV acquisition, by site.
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2) not knowing their partners’ HIV status (n6). A participant
from Bondo explained: ‘‘That [HIV] is something I knew was
there and I could get it at any time . . . because I know my
status but I don’t know his status. I don’t know his sexual
behaviour. I just know my sexual behaviour.’’
All participants described infrequent or inconsistent condom
use (n7)  or never using condoms at all (n4). A partici-
pant from Bondo explained that not using a condom within
the overall context of uncertainty about her partner’s fidelity
led her to worry: ‘‘I had thought of that [worry about HIV]
because my husband and I had got tested a long time ago
and we do not use condoms, but I don’t know how his move-
ments are and if he has other sexual partners.’’ Many parti-
cipants (n6) described that their sexual partners disliked
using condoms and they were therefore using them infre-
quently, if at all. Cultural traditions and community gender
roles, including limited sexual decision-making power among
women, were also described by a participant from Bondo as
a reason why she worried about getting HIV:
It was worrying me based on how I was told that
woman [her husband’s other wife] was behaving . . .
I had even told him, I told him clearly that ‘imagine
you will get infected with a disease that you don’t
even know’. I used to sit down to talk softly with my
husband, but he could not listen to my opinion
because you know I am a woman and he is a man.
So our thoughts could not rhyme. So I was really
worried.
Earlier in the interview, the participant explained that
because of Luo customs, she was unable to use a condom
with her husband during certain rituals.
No rationalization or action
Narratives from six participants (three from Pretoria and
three from Bondo) lacked any mention of prior rationaliza-
tion of HIV risk or examples of actions to reduce the chance
of HIV acquisition. Four participants described that they
never thought they would become infected; two of the four
described being in long term relationships.
Discussion
During the FEM-PrEP clinical trial, we were able to assess
participants’ perceptions of their HIV risk during the period
shortly before they became infected with HIV. We were also
able to gather rich qualitative data on participants’ rationales
for having previously worried or not worried about acquiring
HIV. In the quantitative interviews, more than half of the
participants who seroconverted (52%) did not perceive that
they had been at any risk for HIV around the time they be-
came infected. The majority of these participants were from
Pretoria. Similarly, most participants in the SSIs who des-
cribed not worrying about acquiring HIV were from Pretoria.
Generally, SSI narratives suggested that participants’ own
sexual behaviours and beliefs influenced their protective beha-
viours and protective reasoning and led these participants to
not worry about acquiring HIV. Together, these findings suggest
that many women who are at substantial risk of acquiring HIV
may not perceive their current sexual context to be risky and
therefore may underestimate their actual risk.
Several factors within the participants’ broader environ-
ment may have influenced the protective behaviours and
protective reasoning they described in the SSIs, potentially
leading them to believe that their current sexual context was
not risky. First, the dropping rates of HIV infection in some
of the study countries around the time of trial initiation may
have left participants feeling less at risk or vulnerable. For
instance, HIV incidence in South Africa had declined by more
than 25% between 2001 and 2009. Also, prevalence in Kenya
had declined to 5% by 2006 from 14% in the mid-1990s [24];
however, in 20082009, the prevalence was still high at 13.9%
in Nyanza Province, where Bondo is located [25]. Second, we
provided risk reduction counselling and HIV testing at each
study visit as part of trial procedures. Receiving frequent HIV-
negative test results influenced many participants’ rationali-
zations that they were not vulnerable to HIV and potentially
led them to believe or reaffirmed their beliefs that they were
not engaging in risky sexual behaviours. Third, based on the
theory of cognitive dissonance [26], participants may have
believed they were at risk of HIV but rationalized that they
were not at elevated risk to reduce or avoid the discomfort
associated with feeling at risk. Similar findings, albeit with dif-
ferent rationalizations, were found in a study among female
sex workers in Nigeria [27]. Fourth, participants may have
believed they truly were not at risk because they were
following two of the three prevention steps in the widely
promoted ABCs of HIV prevention  B for ‘‘Be Faithful’’ and C
for ‘‘Use Condoms’’ (albeit they used condoms inconsistently) 
and either assumed their partners were also following such
guidelines or did not consider their partners’ behaviour. Based
on these data, we conducted follow-up interviews with parti-
cipants in Bondo and Pretoria to explore the broader context
that may influence perceptions of faithfulness and trust;
these data are to be presented elsewhere.
In contrast to the participants who may have underesti-
mated their HIV risk, many participants who seroconverted
during the FEM-PrEP trial (48%) appeared to accurately under-
stand their HIV risk but were unable to act on their concerns.
Most of these participants were from Bondo, and their beliefs
about their partners’ risky sexual behaviour, as described in
the SSIs, strongly influenced their own higher perception of
vulnerability. Concerns about spousal infidelity have also been
shown to influence HIV worry among women, and men, in
Malawi [28]. Gender-based power dynamics, as have fre-
quently been documented in the literature, often impede a
woman’s ability to engage in risk reduction behaviours, parti-
cularly using condoms with her primary partner, in marriage,
or within inherited relationships (which are common among
widows in Bondo) [2938].
Because we collected quantitative data on risk percep-
tions during participants’ quarterly visits, responses may have
reflected participants’ perceptions for up to 12 weeks before
they became infected with HIV. It is possible that percep-
tions of risk for some participants may have increased or
decreased immediately prior to HIV infection given a change
in their risk context. However, in the SSIs, most participants
said that their sexual behaviour and that of their partners
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remained similar in the months prior to HIV infection. Further-
more, because of the likely emotional response to learning
one’s HIV status, recall bias or a bias related to self-protection
may also have affected how some participants retrospec-
tively reflected on their HIV worry prior to diagnosis.
Based on our findings, we recommend that future risk re-
duction interventions consider how to incorporate women’s
HIV risk perceptions, particularly their risk rationalizations,
into the HIV prevention discourse [39,40], as they are likely
important precursors for adopting any risk reduction mea-
sures. This is especially true for women who are similar to the
study participants in the Pretoria site, where many partici-
pants generally had low perceptions of HIV risk and low
perceived vulnerability towards acquiring HIV, but where a
high overall HIV incidence (6.0 per 100 person years in the
placebo arm) was reported in the trial [14]. A significant
challenge in doing so, however, will be aligning women’s
feelings about their risk with their actual level of risk [41]. For
women who are not in a recognized serodiscordant relation-
ship, exposure to HIV is often unknown. Moreover, many
women may have little HIV risk or not be at risk of HIV at all
(e.g. when partners are HIV negative, and in monogamous
relationships between HIV-negative individuals). Therefore, in
HIV risk reduction counselling and other HIV prevention
programmes, an intricate balance is needed to simulta-
neously 1) encourage women to more appropriately evaluate
the potential likelihood of becoming infected with HIV; 2)
ensure that couple harmony is maintained [42] (e.g. not
introduce unnecessary conflict within the relationship when
HIV risk is actually low) and the relationship is preserved (e.g.
among women who want to or who must remain with their
partners because of social or financial consequences); and 3)
prevent other adverse consequences, such as denial and
defensive coping [27], of asking women who may be at actual
HIV risk to reassess their potential risk.
For women in risk situations similar to those of many of
the participants in Bondo, where perceived HIV risk, vulner-
ability towards HIV and HIV incidence (4.7 per 100 person
years in the placebo arm [14]) were generally high, a woman-
controlled HIV risk reduction method, such as pre-exposure
prophylaxis (PrEP) and potentially microbicides and the vaginal
ring (pending current trial outcomes [4345]), may be more
realistic. Moreover, interventions that focus on 1) empowering
women and increasing economic independence while trans-
forming gender norms, 2) encouraging safer sexual health
practices within marriage and 3) incorporating male involve-
ment into the promotion and use of women-centred appro-
aches [34,36,37,4648] must continue and intensify.
Conclusions
In moving forward with HIV prevention among women,
whether in PrEP demonstration projects or in non-biomedical
HIV prevention programmes, perceived HIV risk and risk
rationalization are important concepts to explore. Under-
standing and responding to women’s perceptions and ratio-
nalizations about risk could enhance the use of risk reduction
methods, particularly in populations similar to those in the
FEM-PrEP clinical trial.
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Abstract
Women continue to be at special risk for HIV acquisition due to a complex mix of biological, behavioural, structural, cultural and
social factors, with unacceptable rates of new infection. Scientific advances over the past decade have highlighted the use of
antiretroviral (ARV) drugs as pre-exposure prophylaxis (PrEP) to prevent HIV acquisition (sexually, parenterally and vertically) and
ARV treatment (ART) for HIV-positive patients to prevent onward transmission (treatment as prevention  TasP). This paper
reviews the evidence base for PrEP and TasP, describes new products in development and the need to translate research findings
into programmes with impact at the population level.
Keywords: HIV; AIDS; antiretroviral agents; women; HIV prevention; HIV treatment; PrEP.
Received 21 March 2014; Revised 24 June 2014; Accepted 22 July 2014; Published 8 September 2014
Copyright: – 2014 Mastro TD et al; licensee International AIDS Society. This is an Open Access article distributed under the terms of the Creative Commons
Attribution 3.0 Unported (CC BY 3.0) License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Introduction
In the fourth decade of the HIV epidemic, the control of HIV
transmission remains a global challenge  in 2012, there were
an estimated 2.3 million new HIV infections globally [1].
Women continue to be at special risk for HIVacquisition due to
a complex mix of biological, behavioural, structural, cultural
and social factors [1]. Young women bear a disproportionate
burden of HIV infection, notably in sub-Saharan Africa, home
to about 70% of new infections [1]. Over the past decade,
numerous prospective studies of African women in commu-
nities with high HIV infection risk have documented annual
HIV incidence rates of 4 to 9%, despite the use of the best
available HIV prevention methods [24]. A better under-
standing of the factors contributing to this high HIV risk is
needed to guide the use of available HIV prevention tools and
to design improved modalities.
Scientific advances in recent years have highlighted the
use of antiretroviral (ARV) drugs as pre-exposure prophylaxis
(PrEP) to prevent HIV acquisition (sexually, parenterally and
vertically) and ARV treatment (ART) for HIV-positive patients
to prevent onward transmission (treatment as prevention 
TasP). Clinical trials have added greatly to our body of
knowledge and several positive findings have raised hopes
that effective use of ARVs for prevention, along with other
prevention tools, can lead to control of the epidemic. How-
ever, programmatic implementation and scale-up are needed
to translate these encouraging findings into population level
impact. This review provides a synopsis of the scientific evi-
dence for the use of ARVs for prevention, lessons learned
from the conduct of these trials, the current state of imple-
mentation of ARV-based prevention interventions and an




Research efforts over the past decade have yielded extensive
evidence on ARVs for HIV prevention in women (Table 1).
In 2010, the CAPRISA 004 clinical trial of 1% tenofovir vaginal
gel demonstrated a 39% level of protection for women in
KwaZulu-Natal, South Africa, the first study to show that
a vaginal microbicide and an ARV-based product could
prevent HIV infection [2]. Since then, we have seen a growing
body of evidence of the prevention success of oral tenofovir-
based PrEP, either tenofovir disoproxil fumarate (TDF) alone
or in combination with emtricitabine (FTC) [57]. Daily oral
PrEP provided protection for women in serodiscordant
partnerships in Kenya and Uganda in the Partners PrEP study
(efficacy of 75% for FTC/TDF and 67% for TDF; similar for
women and men) [6] and for women in Botswana in the
Centers for Disease Control and Prevention (CDC) TDF-2 study
(62% efficacy for FTC/TDF among women and men) [7].
Clinical trials also showed that tenofovir-based oral PrEP can
be effective in decreasing HIV incidence among men who
have sex with men (MSM) [5], and in people (80% men) who
inject drugs in Bangkok, Thailand [8].
With the exception of the CAPRISA 004 trial that used a
coitally linked dosing strategy of tenofovir gel, trials have used
a daily dosing strategy. Data from completed PrEP (topical and
systemic) trials demonstrate a protective effect of PrEP that
ranges from 39 to 75%when adherence is sufficient. However,
while ARVs prevent HIV transmission, they have to be used to
be effective [10]. In studies that have demonstrated efficacy,
there is a clear dose relationship between increased product
use and increased levels of protection [11,12]. The modest
effectiveness of 39% in CAPRISA 004 was increased to 54% in
those with high levels of adherence [2] and to 74% in women
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Table 1. Effectiveness studies for ARV-based HIV preventiona
Study name Location Population Product Efficacy (CI)
Adherence
estimatesc Notes Adherence intervention
CAPRISA 004 [2] S. Africa 889 women Peri-coital vaginal
TFV gelb
39% (660%) 51% Efficacy was 54% among highly
adherent (used gel in 80% of sex
acts)
Monthly adherence counselling,
applicator count and self-
reported coital frequency










44% (1563%) 51% For first 8 weeks, self-reported pill
use was slightly lower in the FTC/TDF
arm than in placebo. Afterwards,
they were similar, each with a mean
of 95%. Rate of pill use, according to
pill count, was also similar after
week 8; the median ranged from
8995%. Dispensation dates and
quantities of pills suggest pill use
decreased from a rate of 99% in the
first year to 91% at study conclusion
Monthly adherence counselling,
medical history, pill counts
Partners PrEP
Study [6]











97% of dispensed pills were taken.
Study drugs were in use in an
estimated 92.1% of total follow-up
time
Monthly adherence counselling,








62% (2284%) 81% Drug efficacy was highest among
highly adherent (those who had
taken medication in the past 30
days). Similar rates were found in the
intervention and control groups. (Pill
counts were 84.1% in FTC/TDF and
83.7% in placebo. Self-reported use




FEM-PrEP [3] Kenya, S. Africa,
Tanzania
1950 women Once-daily oral
FTC/TDF
6% (5241%) 24% Self-reported data, at
discontinuation, indicated 95% of
participants had usually or always
taken assigned drug. Pill count
suggested 88% adherence, yet blood
drug level was much lower
Monthly, adherence counselling,





































































































Table 1 (Continued )
Study name Location Population Product Efficacy (CI)
Adherence
estimatesc Notes Adherence intervention
Bangkok Tenofovir
Study [8]





49% (1072%) 66% Participants chose either 1) daily
DOT or 2) monthly visits with study
drug diary accounts. They could also




















Adherence estimates are based on a
subset of 773 participants. Despite
an estimate of 90% adherence
(based on self-reported data and pill
counts), approximately 30% of
participants never had the drug
detected
Monthly adherence counselling,
self-report and pill counts

















96% (7399%) 79% of
participants who




Adherence to at least 95% study
regimen was measured by pill counts
Monthly adherence counselling,
self-report and pill counts
aFor prevention of sexually transmitted infection; b1% vaginal tenofovir gel (TFV), oral tenofovir (TDF), oral emtricitabine/tenofovir (FTC/TDF); cadherence estimates for all but HPTN 052 are based on




































































































in women with drug levels higher than 1000 ng/ml [13]
supporting the importance of both adherence and biological
factors impacting efficacy.
In the two trials that did not demonstrate PrEP efficacy,
FEM-PrEP and VOICE, while self-reported adherence levels
were high, measurement of drug levels indicated low levels
of product use [3,4,14]. There are likely many factors that
impact adherence and these need to be better elucidated to
inform future trials and programmatic use. Interviews of
women in the FEM-PrEP trial of daily, oral FTC/TDF PrEP
indicated that low adherence was linked to perceptions of
low risk for HIV acquisition, use of an investigational drug,
fear of and/or experience of adverse effects, possible
assignment to the placebo, difficulties with and dislike of
taking pills and influence of other people [15].
In contrast to treatment trials that have proxy markers of
HIV viral levels and CD4 cell counts for monitoring thera-
peutic success, HIV prevention trials do not have a corre-
late of risk or protection other than HIV infection, making
monitoring of the use of microbicides or PrEP products
challenging. Formulation impacts drug concentrations in the
genital tract; topical tenofovir gel used vaginally yields 1000-
fold higher concentrations in vaginal fluids compared to
oral formulations [13]. While measuring drug levels is an
important advance in PrEP studies, there is no benchmark for
what levels need to be achieved and sustained to prevent
HIV infection. In the ART of HIV-positive persons, maintaining
steady states of drug levels is key to success; for uninfected
individuals the levels needed are less clearly defined. This is
an important opportunity and gap that will need to be
addressed as the product pipeline, dosing strategies and
formulations for testing expand.
Other concerns raised about the use of PrEP include drug
resistance and compromising first-line drug regimens. Thus
far, acquired ARV drug resistance has not been a substantial
problem in those who have acquired HIV infection while on
PrEP. However, inadvertently initiating FTC/TDF PrEP in
people who are already HIV positive, especially those with
acute infection, has resulted in FTC resistance [5]. On-going
follow-up of persons who became HIV positive on PrEP will
generate empiric evidence on disease progression and treat-
ment outcomes with TDF/FTC containing first-line drug regi-
mens. To date the safety profile of PrEP regimens has been
good, with no major safety concerns identified [3,5,16,17].
PrEP has not interfered with the effectiveness of hormonal
contraceptives [3,18].
In the United States, in 2012, based on available clinical
trial data, the Food and Drug Administration (FDA) approved
oral FTC/TDF for PrEP for people at high risk of sexual
acquisition of HIV. The US CDC subsequently issued PrEP
guidance for MSM, heterosexual men and women, and
following the trial among people who inject drugs in Thailand
[8], added an indication for people who inject drugs. In 2014,
WHO issued PrEP guidance as part of consolidated guidelines
on HIV prevention, diagnosis, treatment and care for key pop-
ulations (including female sex workers). Generalized guide-
lines for women and country-specific regulatory filings are
eagerly awaited.
PrEP offers new hope for women
ARV-based PrEP (systemic and topical) offers a promising
female-controlled method of prevention. The outcomes of
the FEM-PrEP and VOICE trials highlight the need to know
more about individual behaviour, optimal formulations and
dosing strategies for acceptability. The central importance of
adherence in PrEP success has prompted examination of its
determinants [19,20]. A systematic review of 24 phase II and
phase III microbicide trials has highlighted that major reasons
for non-adherence include high on-trial pregnancy rates
(resulting in withdrawal of study drug), low trial retention
rates, low participant perception of risk, migratory partners
and trial fatigue [21]. Individual participation characteristics,
including young age, may also influence adherence, as well as
study product characteristics [21]. Findings from the FEM-
PrEP trial suggest that some women enrolled and remained
in the study for benefits other than the HIV prevention that
might be offered by the study drug, including clinical care;
reimbursement for study visits was reported to be a minor
contributor [22]. When assessing factors related to adher-
ence in a placebo-controlled clinical trial of a product of
unproven efficacy, it is important to remember that different
forces will be encountered in the programmatic use of a
product proven to be effective. It is critically important to
continue to characterize such factors, especially as they
pertain to target at-risk populations for PrEP, and to inform
the development of new technologies that rely less on
adherence.
While PrEP studies to date have not identified serious
safety problems, both the FEM-PrEP and VOICE trials reported
substantial rates of adverse effects (including nausea and
headache) suggesting that these effects may have contributed
to women stopping the drugs after initially using them [3,4].
Very low levels of adverse effects will be important to maxi-
mize PrEP uptake and adherence, as users will be otherwise
healthy individuals.
Notwithstanding the need to weigh the risks and costs
of PrEP and TasP and identify target populations who are
likely to benefit most from PrEP, modelling exercises offer
compelling estimates on its preventive benefits at a popula-
tion level. Effective use of PrEP among those at highest
behavioural risk could avert 3.2 million new HIV infections in
sub-Saharan Africa over the next 10 years [23]; and, in South
Africa, broad use of tenofovir gel could avert up to 2 million
new infections and 1 million deaths over the next two
decades [24]. Oral and topical PrEP can be relatively cost-
effective interventions [25,26]. In light of the continued and
urgent need for HIV prevention interventions that work in
women and the promise of PrEP for altering epidemic
trajectories, a more concerted effort on user and provider
needs and preparedness is needed.
In terms of next steps with tenofovir gel, the FACTS 001
trial, designed to confirm the results of the CAPRISA 004 trial,
is underway at seven sites in South Africa and is scheduled
for completion in 2015. A successful outcome could lead to
licensure of tenofovir gel. The CAPRISA 008 follow-on study is
simultaneously assessing the feasibility of integrating micro-
bicide provision into family planning services and is currently
underway. Draft normative guidance has been prepared by
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WHO, and the South African government has initiated plans
for local product manufacture for public sector distribution.
Discussions with the US FDA have provided guidelines of
requirements for licensure.
Next-generation products and trials
We are early in the era of ARVs for HIV prevention and we
can expect that additional products and formulations in the
research and development pipeline will advance to clinical
trials and, hopefully, programmatic use. Alternative new
drugs, regimens and formulations for PrEP are needed in
order to provide choices to men and women, similar to
available choices of contraceptive methods. New drugs will
provide an alternative to FTC/TDF, which is efficacious and
generally safe but is occasionally associated with increased
creatinine levels (indicating renal impairment) and decreased
bone density and is associated with side effects (e.g., nausea,
headache) that may impact adherence. Furthermore, FTC/
TDF is rapidly becoming part of first-line ART for many
countries. Orally administered TDF (yielding TFV in plasma)
does not concentrate in the cervix or vagina after a single
dose and this may reduce ‘‘forgiveness’’ in the protection of
women if doses are missed [12,27], and the emergence of
ARV resistance remains a concern. Therefore, PrEP agents
that have a higher threshold for resistance and/or in which
the emergence of resistance will not impact efficacy of first-
line regimens are needed. Moreover, since daily PrEP, in
either oral or gel formulation, may be a difficult adherence
goal for some healthy individuals, finding alternative dosing
regimens is a priority [28]. Therefore, development of long-
acting injectable products, vaginal rings and patches is an
important undertaking. Such products have the potential to
prevent HIV acquisition without relying on adherence to a
daily oral or gel insertion regimen.
The next generation of topical microbicides being evaluated
includes products that do not require use daily or are linked to
sexual events and monthly formulations. Such products could
be more convenient to women and could provide long-term
protection from HIV infection during unanticipated and
anticipated sexual exposures. A vaginal ring that is replaced
every four weeks and contains dapivirine (DAP, a non-
nucleoside reverse transcriptase inhibitor [NNRTI]) in silicone
elastomer is being evaluated in phase III studies (MTN 020
‘‘ASPIRE’’ and IPM 027 ‘‘Ring’’ trials). The results of these trials
are anticipated in 2015. Other rings including those that
contain maraviroc (MVA, a CCR5 receptor antagonist), MIV
150 (an NNRTI) and a combination of DAP and MVA are being
evaluated in phase I and phase II [29,30]. Preliminary results
indicate that the vaginal rings containing DAP, MVA or a
combination of the two drugs are safe and tolerable and DAP,
but not MVA, was quantifiable in vaginal tissue [29]. A film
formulation of DAP was demonstrated to be safe with
measureable levels of drug in plasma and tissue [31]. Other
products, including a ring containing a combination of DAP
and darunavir and a vaginal tablet containing TFV and FTC, are
being evaluated for efficacy in preclinical studies [30].
An advantage of these long-term dosing formulations, in
addition to the lack of dependence on daily adherence, is
the ability to combine agents for other indications such
as contraceptives or drugs for treatment of other sexually
transmitted infections. Preclinical studies are underway to
evaluate combinations of the contraceptive hormone levo-
norgestrel with either DAP or TFV [32]. Injectable agents are
already being used by women for contraception. In the future,
an effective PrEP agent has the potential to be combined with
an effective contraceptive for prevention of both HIV infection
and pregnancy. Such multi-purpose technologies formulated
either as an injectable formulation or in a vaginal ring would be
a valuable tool for HIV prevention in women in resource-
limited settings, including sub-Saharan Africa where the
majority of the world’s HIV-positive women reside.
Two injectable ARV agents currently in development are
TMC278LA, an injectable formulation of rilpivirine (an NNRTI),
and GSK1265744, an integrase inhibitor [33,34].TMC278LA is a
novel poloxamer 338containing formulation of TMC278.
TMC278LA is long-acting and well-suited for delivery via
intramuscular injection and is currently being considered for
both ART and PrEP. Studies have demonstrated the safety
of oral rilpivirine, which is approved by the US FDA for
treatment as well as the safety of single doses of TMC278LA.
The long-acting injectable formulation is also being developed
for treatment of HIV infection. Initial studies have demon-
strated the safety of single doses of TMC278LA in men and
women [35]. The safety of long-term dosing of TMC278LA for
PrEP will be evaluated in HIV-negative women in the United
States, South Africa and Zimbabwe in the HPTN 076 study
(www.hptn.org).
Another injectable agent, GSK1265744, is an investigational
HIV-1 integrase strand transfer inhibitor that possesses
attributes favourable for both HIV treatment and PrEP indi-
cations. In macaques, single, monthly injections of GSK744 LA
that replicate the human dose were fully protective against
repeated vaginal SHIV exposures [36]. GSK744 LA also
prevented rectal SHIV transmission in macaques [37]. These
data support the advancement of GSK744 LA as a PrEP
candidate for women. It is also currently in phase II clinical
trials evaluating the efficacy and safety for treatment of HIV
infection [33]. The safety of GSK744 LA as a PrEP agent will be
evaluated in men and women at sites in the United States,
Brazil and sub-Saharan Africa in the HPTN 077 study (www.
hptn.org). Both TMC278 LA and GSK744 LA have a pharmaco-
kinetic profile that allows monthly to trimonthly parenteral
dosing using a nanosuspension formulation. Another inject-
able agent, an investigational monoclonal antibody, Ibalizu-
mab binds to the primary receptor for HIV, CD4, and inhibits
viral entry [38,39]. It is being evaluated for the treatment of
HIV infection in combination with an optimized background
regimen, and it may also show promise in its utility as a PrEP
agent [34].
Treatment as prevention
The HPTN 052 clinical trial of early (CD4 cell counts of
350500 cells/mL) ART compared to delayed treatment for
HIV-positive persons with HIV-negative heterosexual partners
demonstrated a 96% reduction in transmission [9]. Protection
was similar for men and women; 50% of the HIV-positive
partners were women [9]. This is the most compelling
evidence for the effectiveness of ARVs for preventing HIV
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infection [9]. Modelling data demonstrate the enormous
prevention benefits from implementing these findings espe-
cially in settings with a high HIV disease burden [4043].
Access to HIV testing services and linkage to care and
treatment services will be needed to reduce individual viral
loads and onward transmission, but there is still uncertainty
about the coverage, uptake and compliance rates that will be
needed to achieve an AIDS-free generation alone and in
combination with other prevention interventions.
In 2013,WHO issued new guidelines for ART that increased
eligibility to HIV-positive persons with CD4 cell counts less
than 500 cells/mL, all pregnant and breastfeeding women,
persons with HIV-negative partners, persons with tubercu-
losis and hepatitis B virus infection and children less than five
years of age [44]. These changes greatly increase the number
of people globally who ‘‘need’’ ART and will strain health sys-
tems and resources to achieve full or even near-full coverage.
Women should benefit from the hoped-for population-level
effect on HIV transmission. However, achieving high levels of
HIV testing and identifying persons with acute and early HIV
infection remains challenging. On-going studies of combina-
tion HIV prevention strategies that include early ART for all
HIV-positive persons are intended to measure the effect of
early ART on population-level HIV incidence (TasP, POP-ART,
Botswana). Even with high levels of ART coverage, it is likely
that there will continue to be a pressing need for women-
controlled prevention methods.
A number of trials and demonstration projects are currently
underway to assess the feasibility of implementation and the
impact on HIV transmission of TasP at a population level (e.g.,
HPTN 065 in Washington DC and the Bronx, New York; ANRS/
Africa Centre in KwaZulu-Natal, South Africa; POP-ART/HPTN
071 in Zambia and South Africa; and MSF in Malawi,
Swaziland and South Africa) [30]. The translation of these
trial findings will be influenced by the ability to deliver TasP in
settings where AIDS-related stigma and discrimination are
prominent, health care delivery systems are weak and the
ability to increase coverage of treatment for those who need
treatment for individual benefits are limited. Additional
concerns include treatment monitoring costs and the devel-
opment of drug resistance due to poor adherence. Modelling
exercises suggest that high levels of ART coverage (80%)
will be needed to substantially decrease population level HIV
incidence [45]. However, ecological, observational level data
from Hlabisa, KwaZulu-Natal, South Africa, that indicate that a
modest 35% coverage of ART reduced HIV incidence by 34%
are encouraging [46].
An additional concern about TasP in settings where young
women bear a disproportionate burden of HIV infection as a
result of age-disparate relationships with male partners who
have been reluctant to practice safer sex is the male partners’
level of willingness to initiate early ART for the prevention of
infection to their sexual partner. Some of these concerns
were raised in considering access to ART in sub-Saharan
Africa in the early 2000s and to date have not materialized.
Revised HIV treatment guidelines have increased the number
of people eligible for ART. With regard to HIV-TB co-infection,
in some parts of Africa, HIV-TB co-infected patients account
for about 70% of patients using TB services. With the
expansion of ART eligibility to these patients, perhaps the
issue of when to start ART will become a less controversial
issue. With increased implementation and expanded cover-
age of HIV testing and linkage to care and treatment, those
with acute HIV infection will contribute a larger proportion of
all new infections. Strategies including laboratory-based
assays for identifying these individuals quickly and interven-
ing early will be central to maintaining reductions in onward
transmission of HIV and gains made from TasP [20].
Conclusions
There remains an urgent need to improve and scale-up HIV
prevention efforts for women, especially in southern Africa.
We have seen that the most effective HIV prevention efforts
have employed a combination approach, customized for the
specific settings and populations. Providing women with a
variety of prevention options will likely lead to the most
effective prevention for the most women in the widest range
of settings. Such a strategy has been effective in addressing
women’s needs for contraception. Over the next decade,
following new WHO guidelines, we will see an increase in the
number of people starting ART at higher CD4 cell counts. This
will lead to decreased HIV transmission; however, there will
continue to be a pressing need for women-controlled
prevention methods as not all male partners will be virally
suppressed. The sobering observations of the challenges in
many settings of achieving high levels of coverage in the
various steps of the HIV prevention and treatment cascade
will require new, more effective methods for HIV-negative
women. Moreover, there continues to be a pressing need to
increase levels of HIV testing to identify HIV-positive persons,
including those with acute infection.
On-going and planned studies of new ARV-based preven-
tion methods hold the promise of offering women highly
effective prevention that can substantially limit HIV transmis-
sion. Studies to date have not identified sex differences in the
levels of HIV protection provided by ARV-based methods; the
overriding factor for both women and men is the level of
adherence to products. It will be important to enhance our
understanding of women’s perceptions of risk and the
complex behavioural dynamics that influence adherence to
complement the development of new biologic products. On-
going and planned PrEP demonstration studies will add
greatly to our understanding of how ARV-based products
will add to our HIV prevention tool kit (avac.org) [47].
The technical advances remain an important first step but
are no magic bullets. We need to enhance our understanding
of the bio-behavioural nexus, and demonstration projects will
help identify appropriate target populations, acceptability
of products, demand creation strategies and product use in
non-trial settings.
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Abstract
Introduction: Constructively engaging male partners in women-centred health programs such as family planning and prevention
of mother-to-child HIV transmission has resulted in both improved health outcomes and stronger relationships. Concerted
efforts to engage men in microbicide use could make it easier for women to access and use microbicides in the future. This paper
synthesizes findings from studies that investigated men’s role in their partners’ microbicide use during clinical trials to inform
recommendations for male engagement in women’s microbicide use.
Methods: We conducted primary and secondary analyses of data from six qualitative studies implemented in conjunction with
microbicide clinical trials in South Africa, Kenya, and Tanzania. The analyses included data from 535 interviews and 107 focus
groups with trial participants, male partners, and community members to answer research questions on partner communication
about microbicides, men’s role in women’s microbicide use, and potential strategies for engaging men in future microbicide
introduction. We synthesized the findings across the studies and developed recommendations.
Results: The majority of women in steady partnerships wanted agreement from their partners to use microbicides. Women used
various strategies to obtain their agreement, including using the product for a while before telling their partners, giving men
information gradually, and continuing to bring up microbicides until resistant partners acquiesced. Among men who were aware
their partners were participating in a trial and using microbicides, involvement ranged from opposition to agreement/non-
interference to active support. Both men and women expressed a desire for men to have access to information about
microbicides and to be able to talk with a healthcare provider about microbicides.
Conclusions: We recommend counselling women on whether and how to involve their partners including strategies for gaining
partner approval; providing couples’ counselling on microbicides so men have the opportunity to talk with providers; and
targeting men with community education and mass media to increase their awareness and acceptance of microbicides. These
strategies should be tested in microbicide trials, open-label studies, and demonstration projects to identify effective male
engagement approaches to include in eventual microbicide introduction. Efforts to engage men must take care not to diminish
women’s agency to decide whether to use the product and inform their partners.
Keywords: Microbicides; HIV; qualitative research; partner communication; gender relations.
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Introduction
Microbicides were originally conceived of as a female-
controlled HIV prevention method [1]. Subsequent research
has found that although many women appreciate a product
they can use without a partner’s knowledge [27], micro-
bicide trial participants typically talked with their steady
partners about the product [3,6,812]. Moreover, male
partners’ awareness and acceptance of product use influenced
trial participants’ product acceptance and self-reported ad-
herence [7,1316]. Male partner influence seems to differ by
partner type, however. In several trials, women reported
better adherence and greater ease using products discretely
with casual, transactional, and non-cohabitating partners
compared to steady partners [11,1618]. Involving male
partners in microbicide use can also affect relationship
quality; some trial participants reported that involving their
partners improved partner communication and increased
shared responsibility for HIV protection [13,16,1921].
After more than two decades of testing microbicides in
clinical trials, the CAPRISA 004 trial of 1% tenofovir gel
provided proof of concept that microbicides can reduce
women’s HIV risk [22]. Ongoing clinical trials, including the
FACTS 001 trial of 1% tenofovir gel and the MTN-020 and IPM
027 trials of the dapivirine ring, could provide sufficient
evidence to support product licensure and introduction.
Male engagement in family planning and prevention of
mother-to-child HIV transmission (PMTCT) has been shown
to improve acceptability, uptake, adherence, and health
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outcomes [2327]. Considering whether and how to engage
male partners at the outset of microbicide introduction could
help maximize the potential for HIV prevention.
This paper synthesizes findings from microbicide studies
that investigated men’s role in their partners’ microbicide use
during clinical trials in sub-Saharan Africa. Clinical trials are a
unique environment, so men’s roles may differ in the context
of ‘‘real world’’ use. Nevertheless, the data provide a starting
point for identifying effective ways to engage male partners
in future research and eventual microbicide introduction.
Methods
In January 2013, FHI 360 convened a meeting of microbicides
experts and male engagement experts to develop the
following research questions to inform recommendations
for engaging male partners in microbicide introduction:
1) What existing gender norms could facilitate or hinder
constructive male engagement in microbicide use?
2) What did women in the trials tell their male partners
about the trial and/or the product, when did they tell
them, and why?
3) How have men been involved in women’s use of
microbicides?
4) What information do men want about microbicides?
5) What are the best ways to engage men in women’s
microbicide use?
6) What are men’s barriers to accompanying their partners
to the clinic for microbicide services?
To answer the research questions, FHI 360 and the Kenya
Medical Research Institute collected qualitative data in
Kisumu, Kenya, where three microbicide trials had been
conducted. FHI 360 also partnered with social scientists who
had previously collected qualitative data about male engage-
ment during microbicide trials.
This paper includes data from six qualitative studies
(described in detail in Table 1). The trials all tested
microbicide gel formulations, except IPM 015, which tested
a microbicide ring. The VOICE trial tested oral pre-exposure
prophylaxis as well as daily 1% tenofovir gel, and the mock
clinical trial tested a proxy gel and proxy oral pill. All studies
received approval from local ethics committees, and in-
formed consent was obtained from each study participant.
Social scientists from each study conducted primary or
secondary analyses of their data and summarized the findings
to answer the research questions, and FHI 360 staff
synthesized the findings across the six studies. In November
2013, the social scientists and additional experts met to
discuss each study’s results and identify central themes and
programmatic implications of the data.
Results
Gender norms
Prevailing gender norms about sexuality and complex
relationship dynamics affected how women addressed their
trial participation and microbicide use with male partners.
Couples were more likely to discuss HIV risk, get tested,
and use condoms at the beginning of a relationship. Such
discussions were considered less acceptable later in a
relationship. For some men, a partner’s use of microbicides
was a sign that she suspected he was unfaithful or that she
had outside partners. Women found ways to work within the
existing patriarchal gender relations, such as negotiating
microbicide use without openly challenging male authority or
voicing suspicions of infidelity. In some cases men and
women implied that men needed a public appearance of
authority, but were more willing to be flexible within the
privacy of their relationships.
Partner communication
Women and men agreed that, ideally, women would discuss
microbicide use with their steady partners. The majority of
women wanted agreement from their steady partners to use
microbicides, though many women and some men thought
it was ultimately the woman’s decision. Trial participants
typically decided whether to discuss microbicide use with
their partners based on: 1) the nature of their relationship, 2)
the partner’s temperament, and 3) evaluation of how the
partner might react if told in advance versus finding out the
product had been used without his knowledge. Though
microbicide use and trial participation are distinct topics,
women usually did not distinguish between the two when
communicating with partners.
Women gave two main reasons for not discussing micro-
bicide use with partners. They either feared a negative
reaction, ranging from mere objection to violence, or thought
their partners did not need to know, particularly in casual
relationships. Women who feared a negative reaction often
thought the benefit of using microbicides was worth the risk of
their partners later discovering their covert use. Contrary to
the widely reported belief that discreet use would cause
problems, some men who were unaware of their partner’s
microbicide use were not upset when they found out about it.
Trial participants who decided to discuss microbicides with
their partners did so for emotional, logistical, and strategic
reasons. Many women said they wanted to promote an
open, trusting relationship or prevent a disagreement or
breakup. Others wanted to gain the partner’s support in case
they later experienced side effects or other problems. Some
felt it was ‘‘the right thing to do,’’ because their partners
would also be exposed to an experimental product, and
others thought it would be difficult to explain the sudden
need to use condoms, frequent visits to the clinic, and (for
gel users) change in lubrication during sex. They also said it
would be challenging to hide the applicators and insert the
gel. Women reported a stronger sense of desire or obligation
to discuss microbicide use in steady relationships than casual
relationships. They also said that the logistics of trial
participation and product use were more difficult to keep
secret from a steady partner.
The vast majority of women inMDP301 andmanywomen in
the other studies told their partners about their microbicide
use early during trial participation. The follow-up study in
Kenya was an exception; one-third of the women interviewed
said they had not told their partners. This may have been
because they used the product for a shorter period of time
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Table 1. Qualitative data included in the analysis
Clinical trial Qualitative data included in analysis
Trial: MDP301 [28]
Phase: III
Product: PRO2000 vaginal gel
Length of product use: 12 months (24 in Uganda)
Years: 20052009
Sites: 13 sites in South Africa, Tanzania, Uganda,
and Zambia
Participants: 9,385 sexually active women, aged
18 years or older (]16 years in Tanzania and
Uganda)
Study name: MDP301 [10,2931]
Main focus: Social science sub-study to assess the accuracy of behavioural and adherence
data, acceptability of the gel and the trial procedures, and understanding of the trial and the
consent procedure
Years: 20052009
Sites: 3 sites in Johannesburg, Durban, rural KwaZulu-Natal, South Africa
Ethics approvals:
Witwatersrand University Human Research Ethics Committee; University of KwaZulu-Natal
Biomedical Research Ethics Committee; The Medicines Control Council of South Africa
Participants:
 154 individual in-depth interviews (IDIs) with 90 men and women (45 couples). These
women shared information about the trial and involved their partners from early on
 60 IDIs with 30 women who did not immediately inform their partners
 31 focus group discussions (FGDs) with trial participants, 18 FGDs with women in the
community and 18 FGDs with men in the community
Methods for secondary analysis: NVivo software was used to re-analyse IDIs and FGDs,
through additional coding and extraction of themes relevant to male engagement
Trial: Carraguard Phase 3 Trial [32]
Phase: III
Product: Carraguard vaginal gel
Length of product use: 924 months
Years: 20042007
Sites: 3 sites in South Africa (Gugulethu,
Soshanguve and Isipingo)
Participants: 6,202 women, aged 16 and older
Study name: Evaluation of the Informed Consent Process in the Phase 3 Study of the Efficacy
and Safety of the Microbicide Carraguard† in Preventing HIV Seroconversion in Women
[3337]
Main focus: Informed consent
Years: 20062007
Sites: Gugulethu and Soshanguve, South Africa
Ethics approvals: Population Council Institutional Review Board; Ethics Committee of the
University of Cape Town; the Research Ethics and Publication Committee of the University of
Limpopo, Medunsa Campus
Participants:
 103 IDIs with trial participants
 5 FGDs with trial participants (n29)
 1 mixed gender FGD (n3 trial participants, 2 male partners)
 2 FGDs with male partners (n8)
Study name: Microbicides Acceptability: A Qualitative Study to Explore Social and Cultural
Norms, Interpersonal Relations and Product Attributes [38,39]
Main focus: Sexual norms and gender roles affecting microbicide acceptability
Years: 20062007
Sites: all three sites
Ethics approvals: Population Council Institutional Review Board; Ethics Committee of the
University of Cape Town; the Research Ethics and Publication Committee of the University of
Limpopo, Medunsa Campus; the Biomedical Research Ethics Committee, University of Kwa-
Zulu Natal
Participants:
 62 IDIs with trial participants
 14 FGDs with trial participants (n97)
 2 FGDs with male partners (n13)
 3 IDIs with male partners
Methods for secondary analysis: Thematic analysis of the previously coded data was
conducted for codes most pertinent to the research questions
Trial: MTN-003 ‘‘VOICE’’ [40]
Phase: IIb
Product: Vaginal 1% tenofovir gel, oral tenofovir,
oral tenofovir/emtricitabine
Study name: MTN-003C ‘‘VOICE-C’’ [41]
Main focus: Household and community-level factors associated with study product
adherence in VOICE
Years: 20102012
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Table 1 (Continued )
Clinical trial Qualitative data included in analysis
Length of product use: Up to 36 months
Years: 20082012
Sites: South Africa (3 sites), Zimbabwe, and
Uganda
Participants: 5029 women, half were aged 1824
Site: Johannesburg, South Africa
Ethics approvals: Office of Research Protection Institutional Review Board, RTI International;
Human Research Ethics Committee of the University of the Witwatersrand
Participants:
 22 male partners in 14 IDIs and 2 FGDs (n8)
 102 randomly-selected female VOICE participants in IDIs (n41), ethnographic
interviews (n21) and 7 FGDs (n40)
Methods for secondary analysis: Thematic analysis of coded transcripts from all IDI, EI and
FGD data from male partners and female study participants described above
Trial: IPM 014A
Phase: I/II
Product: Dapivirine vaginal gel 4759, 0.05% 2.5G
Length of product use: 6 weeks
Years: 2009
Sites: Kenya, Malawi, Rwanda and South Africa




Product: Dapivirine vaginal ring
Length of product use: 12 weeks
Years: 2010
Sites: Kenya, Malawi, Rwanda, South Africa
and Tanzania
Participants: Approximately 280 women, aged
1840
Study name: Male Engagement in Microbicides
Main focus: Identifying strategies for engaging men in future trials, open-label studies,
demonstration projects, and microbicide introduction so they will support their female
partners in using microbicide products for HIV prevention or, at least, to minimize men’s
interference in women’s microbicide use
Years: 2013
Site: Kisumu, Kenya
Ethics approvals: Kenya Medical Research Institute Ethical Review Committee; FHI 360’s
Protection of Human Subjects Committee
Participants:
 30 IDIs with former female trial participants
 25 IDIs with women who were not trial participants
 14 IDIs with men who were partners of trial participants at the time of the trial
 29 IDIs with men who were not partners of trial participants
Methods for analysis: Thematic analysis of IDIs using NVivo 9 software. The saliency of
themes was assessed via frequencies, degrees of emphasis and elaboration, co-occurrences,
and contrasts of themes across interviews, and compared between participant groups
Trial: MTN-004/ VivaGel [42]
Phase: I
Products: VivaGel† (SPL7013 gel) vaginal gel
Length of product use: 14 days
Years: 20062007
Sites: United States, Kenya
Participants: 54 sexually active women,
aged 18 to 24
Trial: Adolescents and Microbicide Clinical Trials:
Assessing the Opportunities and Challenges of
Participation [4346]
Phase: Mock clinical trial
Product: Proxy vaginal gel (Pre-Seed lubricant)
and proxy oral pill (Vitacap multivitamin)
Length of product use: optional 02 months
Years: 20112013
Sites: Tanzania
Participants: 135 sexually active adolescents and
young women, aged 1521
Study name: Adolescents and Microbicide Clinical Trials: Assessing the Opportunities and
Challenges of Participation [45,4749]
Main focus: Socio-cultural factors that hinder young women’s participation in topical or oral
microbicide trials
Years: 20102011
Site: Dar es Salaam, Tanzania
Ethics approvals: Muhimbili University of Health and Allied Sciences; National Institute for
Medical Research (Tanzania); FHI 360’s Protection of Human Subjects Committee
Participants:
 3 FGDs with mothers of adolescents in the community (n25)
 2 FGDs with fathers of adolescents in the community (n18)
 2 FGDs with unmarried male partners of adolescents in the community (n14)
Methods for secondary analysis: Thematic analysis of coded excerpts from all FGD data from
male partners, fathers, and mothers of adolescent girls
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compared to women in the other studies, making it less
necessary to inform their partners.
When male partners were initially resistant to using
microbicides, women used a number of strategies to obtain
their agreement. Some women used the product for a while
before telling their partners about it. If a partner objected, the
woman reminded him that he had not noticed a difference, or
in some cases that he had noticed but was enjoying their
sexual experience. This was particularly the case with micro-
bicide gels; many couples found the lubrication from the gel
increased pleasure or at least decreased pain. Other women
gave their partners incomplete information (e.g. not mention-
ing that the microbicide contained an antiretroviral drug) or
misinformation (e.g. saying it was a family planning method).
Other strategies included giving men information gradually or
continuing to bring up microbicides until resistant partners
acquiesced. Some women made their partners feel that they
were making the decision, playing into the gender norm that
men dominate decision-making. When partners did not agree
on microbicide use, some women succeeded in using without
their knowledge. See Table 2 for illustrative quotes about
partner communication.
Men’s roles
Among men who knew about their partner’s participation in
a trial and use of microbicides, involvement ranged from
opposition to agreement/non-interference to active support
(See Figure 1, Table 2). Most men fell in the ‘‘agreement/non-
interference’’ part of the continuum. This may not be
representative of all trial participants’ experiences, because
women who encountered opposition from their partners
may have discontinued trial participation or elected not to
participate in interviews.
Opposition
Some men were opposed to their partners participating in
the trial and/or using microbicides because they had
concerns about product safety, potential partner infidelity,
and the researchers’ intent. Some men were resistant
because they lacked knowledge about the product or trial,
and some did not want their partners participating in
something beyond their control or understanding. Their
opposition ranged from voicing unease or uncertainty to
outright refusal.
Agreement/non-interference
Some men gave their partners permission to use micro-
bicides. In other cases, male partners’ ‘‘agreement’’ was tacit;
they did not give express permission, but knew their partners
were using microbicides and did not interfere.
Active support
Some men provided their partners with instrumental or
emotional support to participate in a trial and use micro-
bicides. They reminded their partners to use the gel or in
some cases inserted it for them as part of foreplay. They
helped their partners attend clinic visits by reminding them
of their appointments, occasionally accompanying them, or
giving them transport money. The studies did not quantify
the proportion of men who provided these more active
forms of support, though it seems they were in the minority.
A larger number of men were reported to have adapted their
sexual practices to meet the trial requirements of regular
condom and microbicide use.
Men’s involvement often varied over time. For example,
some men were opposed to microbicide use at first, but after
their partners convinced them to try it, they liked it and
agreed to the product’s use. Other men were generally
supportive of microbicide use but occasionally suggested sex
without the gel.
Other considerations for engaging male partners
Periodic HIV counselling and testing (HCT) is required during
trial participation and will be part of the service delivery
package for any antiretroviral-based microbicide introduced
in the public sector. Trial participation gave women a reason
to discuss HIV testing and results with their partners. Indeed,
men equated clinical trials with access to HIV testing and
results, which elicited two common responses. A number of
men were pleased their partners were getting tested
regularly and being found to be HIV negative. Particularly
in the studies in South Africa, men were generally unwilling
to get tested themselves and used their partner’s HIV-
negative status as a proxy for their own status. Men in the
study in Kenya were generally more open to HIV testing. The
second common reaction was fear. Some men did not want
to go to the trial clinic with their partners because they
feared being forced to get tested.
Men and women expressed a desire for men to have
access to information about microbicides. Men wanted to
know about the safety and side effects of the product,
whether microbicides prevent pregnancy, whether microbi-
cides protect men from HIV, and whether they affect fertility
or the sexual experience. Some also had questions (and
suspicions) about the clinical trial process, including why it
was being tested by ‘‘whites’’ or ‘‘foreigners’’ on African
women.
Some women and men said it would be helpful if male
partners could talk directly with a healthcare provider about
microbicides, because providers carry authority and could
legitimize the product and the research. Some felt their own
ability to convey information in the most accurate and
persuasive way was limited and wanted assistance from
providers.
Several of the studies experienced challenges recruiting
men for interviews and focus groups. Men were often
unavailable because they were working. Others were hesitant
to go to the study clinic because they were afraid it would
involve HIV testing or thought ‘‘the clinic was meant for
women only.’’ Some studies had more success recruiting men
if they conducted interviews and focus groups outside of the
clinic.
Discussion
Findings from these six qualitative studies confirm that male
partners play an important role in women’s microbicide use
and provide insights for engaging men in future microbicide
studies and product introduction. Promoting women’s
agency to decide whether to use microbicides and inform
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Table 2. Select themes and illustrative quotes
Theme Illustrative quotes
Reasons women discussed microbicides with their partners
To promote an open, trusting relationship or to prevent a
disagreement or breakup
If we did not have an agreement before I started participating in
the study, [. . .] maybe we would have fought and I would have decided to
quit the study. So I tell him about a lot of things before they happen
because I don’t like keeping secrets. (VOICE participant, Johannesburg,
South Africa)
To gain their partner’s support in case they later experienced
problems
I thought I should tell them [partner and a friend] because maybe if I tell
them [. . .] and there are problems while I am participating at least they
will know that I am in the trial. [. . .] They can give me support. (Carraguard
participant, Soshanguve, South Africa)
Would be difficult to hide trial participation and microbicide use I had to because it was going to be difficult to do anything without telling
him. He was going to be surprised if I start applying the gel and he does
not know about it, it was not going to be possible. (Carraguard participant,
Soshanguve, South Africa)
Reasons women did not discuss microbicides with their partners
Feared a negative reaction My partner is a difficult guy to deal with . . .. He’s noisy, violent, and
anything you tell him he disapproves; even if I left the house for a few
minutes he would think that I’ve gone to see other men . . .. He would have
beaten me up or chased me away . . .. I think it should be a secret. (IPM
014A participant, Kisumu, Kenya)
Thought their partners did not need to know It just did not come to my mind to tell him because I think it is too early in
our relationship. I will tell him later. (VOICE participant, Johannesburg,
South Africa)
Strategies used with reluctant partners
Used the product for a while and then told partner about it I told him about it and he refused to allow me to use the gel. [. . .] I said to
him, ‘it’s fine’ . . . [but] I used the gel without telling him and we had
sex all the time. [. . .] He did not feel it. And after two months using it in
secret I talked to him again about it. But I did not tell him I was using
it in secret. Then he said that if I used the gel he would not have sex with
me. I asked him why. He said that he did not know if sex was going
to be the same or not. Then I asked him how he felt about our sex and he
said that it was okay. I then told him I had been using the gel,
and he said that I could continue to use it. (MDP301 participant,
South Africa)
Gave partners incomplete information or misinformation I just told him that I was participating in a study. (IPM 015 participant,
Kisumu, Kenya)
I just told him we were studying something on family planning. (IPM 015
participant, Kisumu, Kenya)
Gave partner information gradually or continuing to bring up
microbicides with their resistant partner until they acquiesced
I told my husband that at Empilisweni [study clinic] it is said there
is a gel that is being used that helps prevent HIV; my husband refused that
I come here . . .. When I came home I told him that I had been here and I
watched a video and I’m going to come again, and he wasn’t
agreeable, resisting, and I came again . . .. and then on another
day he gave me permission. (Carraguard participant, Gugulethu,
South Africa)
Continuum of male engagement in women’s microbicide use
Opposition Personally if you ask me I will not allow her because of one reason, I think
she can be like a slave; every end of month she will be attending clinic.
Also, she will not be allowed to carry pregnancy; it means we will postpone
getting children because of that study. (Male partner of adolescent
woman, Dar es Salaam, Tanzania)
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their partners is of paramount importance [50]. Not only is
each woman best equipped to understand whether it is safe
and/or will be productive to discuss microbicide use with her
partner, she is also likely to be most skilled in introducing the
subject and ultimately gaining his support. Enabling women
to make decisions about microbicide use and providing the
skills and enabling environment to act on them will help
ensure that microbicides, if effective, are the game-changer
for women’s HIV prevention they were intended to be.
We recommend the primary goal of male engagement in
women’s microbicide use be to promote women’s ability to
access and use the product. To accomplish the primary goal,
we recommend 1) providing support to women through
counselling to decide whether and how to involve their
partners and 2) sharing basic information about microbicides
with men through couples’ counselling, community educa-
tion, and mass media to increase their awareness and
acceptance of the product (see Table 3).
Some of these male engagement strategies  including
counselling women, inviting male partners to the study clinic,
offering couples counselling and informational materials, and
doing community outreach to men  are currently being
implemented at some microbicide trial sites to improve
participant recruitment, retention, and adherence. However,
the positive and negative effects of these approaches have
not been rigorously evaluated. Consistent product use, which
Table 2 (Continued )
Theme Illustrative quotes
Agreement/non-interference . . . he had the option of stopping me from using the product. He will tell
me not to participate in anything that he doesn’t like. I went to the clinic
and he knew about it. He never stopped me. That means he supported my
decision. (IPM 015 participant, Kisumu, Kenya)
When she comes here she tells me that she is coming here [study clinic], I
do not have a problem and I allow her to come here. (Male partner of
VOICE participant, Johannesburg, South Africa)
I have told her one thing ‘if you are happy and it is treating you well [not
reacting negatively to you], I do not have a problem, and I will not follow
you or accompany you when you go to the study because to a certain
extent [if I do that] you may think that I do not trust you.’ (Male partner of
VOICE participant, Johannesburg, South Africa)
Active support [My partner] was very receptive. He even accompanied me to the clinic
when he was off duty. Sometimes he even ask me before we have sex that
‘are you not applying the gel, please don’t forget it.’ (Carraguard
participant, Soshanguve, South Africa)
I used to give her money for clinic visits and took care of our children when
















did not interfere with microbicide
use; implicit or explicit
agreement to use 
active support
supported partner to use
product (e.g., provided
transport to clinic, reminded
her to insert gel)   
after partner refused, woman
used without his knowledge
Figure 1. Continuum of male partner involvement in microbicide use.
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Table 3. Recommended strategies for engaging male partners
Goal Objectives Strategies Rationale Considerations
Increase women’s ability
to access and use
microbicides
Support women to decide
whether/how to talk with partner
about microbicides
Counselling for women Context of trial participation provided
women supportive environment for
communicating with partner; women will need
support in real world introduction
Include:
 Women’s right to decide whether to talk with her
partner
 Strategies for communicating with partner to gain
his approval
 Strategies for using microbicides without partner’s
knowledge
 Written materials women can share with partner
Increase men’s awareness and
acceptance of microbicides to
create an enabling environment




Women and men expressed
a desire for men to be able to
talk with health providers
Men hesitant to attend clinics because:
 Feared HIV testing
 Some clinics viewed as women’s spaces
 Scheduling conflicts
To address these barriers:
 Consider offering microbicides at clinics with
services for men and women
 Providers offer to call partners or visit homes
Community education May be more effective than
reaching men through clinics
 Provide general information on benefits, safety
 Target spaces where men congregate
Mass media May be more effective than
reaching men through clinics
 Feature health providers, who are viewed as
reliable sources of information
 Promote benefits, safety





































































































is crucial to effectiveness, has been lower than anticipated in
trials [22,32,51], and may be improved through strategies to
increase or improve positive male engagement. The male
engagement strategies we recommend should be tested as
part of a multi-pronged adherence support program. Their
effect on partner communication, relationship quality and
intimate partner violence should also be measured.
Limitations
There are several limitations to our synthesis. Women
participating in clinical trials may differ from women in the
general population; they may be more empowered or more
motivated to prevent HIV or may have partners who are
more open to their participation, among other differences.
Moreover, some of the qualitative studies experienced
difficulty recruiting men; those who agreed were likely
more supportive partners and therefore not representative
of all male partners of trial participants. It is likely that some
women did not participate in microbicide trials because of
partner opposition, so such couples would not be repre-
sented in the studies. Clinical trials also provide a supportive
context for women to discuss microbicides with their
partners. Specifically, trial requirements give women leverage
to negotiate condom and microbicide use with partners. In
addition, women receive intensive counselling and support
from trial staff. These conditions may be difficult to replicate
in real world microbicide introduction, where providers have
less time and fewer resources. Partner engagement may
differ outside of clinical trials; women may be more or less
likely to talk with their partners when they are using a
product with known effectiveness and when condom use is
recommended but not required.
Most of the studies focused on microbicide gels. Partner
interaction may differ somewhat for other microbicide
formulations, such as rings, films, suppositories, and inject-
ables. For example, women using a gel may be more likely to
tell their partners about their microbicide use compared to
women using a ring, because they anticipate the increased
lubrication caused by the gel will be noticed by partners or
that it will be difficult to insert gel regularly without a
partner’s knowledge. Also, women may find it easier to talk
with partners about use of a multipurpose microbicide
product that protects against both HIV and pregnancy,
because contraceptive use may be more acceptable than
using HIV prevention methods in steady relationships.
Although our findings are not necessarily generalizable to
microbicide use outside of the trial context or to different
microbicide formulations, this is the first study to synthesize
data on partner interactions in multiple clinical trials, and our
recommendations provide a starting point for future male
engagement efforts in microbicide research and programs.
Conclusions
Microbicides by themselves will not alter the underlying
gender norms that put women at risk of HIV. If proven
effective, they may give women some level of increased
control over HIV prevention, but many women  particularly
those in steady relationships  may find it easier to access
and adhere to a microbicide product if their male partners
are supportive of its use. The strategies we recommend 
based on data from multiple sites in three countries  could
increase men’s awareness and acceptance of microbicides,
thereby potentially enhancing women’s ability to access and
use microbicides.While the strategies will need to be tailored
to individual communities and specific microbicide formula-
tions, they must consistently preserve women’s agency to
decide whether to use the product and inform their partners.
They should be tested in microbicide trials, open-label
studies, and demonstration projects to determine their
impact on women’s microbicide use and gender relations
and identify effective male engagement strategies to include
in eventual microbicide introduction.
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Abstract
Introduction: Product adherence and its measurement have emerged as a critical challenge in the evaluation of new HIV
prevention technologies. Long-acting ARV-based vaginal rings may simplify use instructions and require less user behaviour,
thereby facilitating adherence. One ARV-based ring is in efficacy trials and others, including multipurpose rings, are in the
pipeline. Participant motivations, counselling support and measurement challenges during ring trials must still be addressed. In
previous HIV prevention trials, this has been done largely using descriptive and post-hoc methods that are highly variable and
minimally evaluated. We outline an interdisciplinary framework for systematically investigating promising strategies to support
product uptake and adherence, and to measure adherence in the context of randomized, blinded clinical trials.
Discussion: The interdisciplinary framework highlights the dual use of adherence measurement (i.e. to provide feedback during
trial implementation and to inform interpretation of trial findings) and underscores the complex pathways that connect
measurement, adherence support and enacted adherence behaviour. Three inter-related approaches are highlighted: 1)
adherence support  sequential efforts to define motivators of study product adherence and to develop, test, refine and
evaluate adherence support messages; 2) self-reported psychometric measures  creation of valid and generalizable measures
based in easily administered scales that capture vaginal ring use with improved predictive ability at screening, baseline and
follow-up that better engage participants in reporting adherence; and 3) more objective measurement of adherence  real-time
adherence monitoring and cumulative measurement to correlate adherence with overall product effectiveness through
innovative designs, models and prototypes using electronic and biometric technologies to detect ring insertion and/or removal
or expulsion. Coordinating research along these three pathways will result in a comprehensive approach to product adherence
within clinical trials.
Conclusions: Better measurement of adherence will not, by itself, ensure that future effectiveness trials will be able to address
the most basic question: if the product is used per instructions, will it prevent HIV transmission? The challenges to adherence
measurement must be addressed as one component of a more integrated system that has as its central focus adherence as a
behaviour emerging from the social context of the user.
Keywords: vaginal ring; acceptability; adherence; clinical trial research; HIV prevention; measurement.
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Introduction
In July 2010, the CAPRISA 004 clinical trial of tenofovir 1% gel
demonstrated that an ARV-based vaginal gel could prevent
acquisition of HIV [1]. Subsequently, results from the iPrEX,
Partners PrEP, TDF2 and Bangkok Tenofovir trials of oral ARV
dosing further bolstered confidence in ARV-based prevention
[25]. In each of these trials, sub-analyses indicated that poor
adherence to the prescribed dosing regimen reduced efficacy.
The importance of adherence to product use instructions
was underscored by results from the VOICE and FEM-PrEP
trials, where poor adherence to vaginal (VOICE) and oral
(VOICE and FEM-PrEP) dosing regimens resulted in an inability
to determine effectiveness [6,7].
The delivery of microbicides through vaginal rings is
perceived by some as a way to achieve better adherence,
in part because rings have the potential to simplify the
behavioural requirements for use. A number of long-acting
ARV-based and multi-purpose prevention rings are in devel-
opment.Two phase 3 clinical trials are now underway to assess
the efficacy of a 28-day vaginal ring containing the antire-
troviral drug dapivirine to reduce HIV transmission among
African women [8]. Other rings in development include
CONRAD’s 90-day ring that contains both tenofovir and
a contraceptive; the International Program for Microbicide’s
(IPM) dapivirine ring with or without a contraceptive added
that would be effective for 30 days and potentially up to 6090
days; the Population Council’s 90-day ring containingMIV-150,
zinc acetate and carrageenan, with or without a contraceptive,
designed to protect against HIV, herpes simplex virus type-2
and human papillomavirus (Barbara Friedland, personal
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communication, 2014); and Merck’s project to develop their
ethylene vinyl acetate copolymer contraceptive ring as a
method for also delivering ARVs. It is anticipated that over
the next three years, multiple products will move from
preclinical to clinical testing of safety and pharmacokinetics
during use ranging from 30 days to 12 months.
Social science research with participants in trials of micro-
bicides and PrEP indicate that a wide array of factors may
potentially influence adherence. For example, lack of under-
standing about clinical research practices (e.g. how biological
specimens will be used) [9], concerns about product safety
[10] and distrust of the motivations of researchers and trial
sponsors (e.g. motivated by negative values such as greed and
racism) [9,11,12] are frequently described for HIV prevention
research participants and communities. For women, decisions
about whether and what to disclose to male partners about
product use and research participation reflect culturally
regulated gender dynamics that can either generate support
or create obstacles for a woman’s decision to participate in
a trial and adhere to product use [10,1317]. There is also
increasing recognition of the fact that the on-going and
intensive level of interaction among participants in the
research clinic waiting room and between participants and
research staff foster the emergence of a research culture that
may exacerbate or mitigate these other challenges [10].
Research conducted by IPM in preparation for phase 3 trials
of the 30-day dapivirine ring found that women reported
removal or expulsion of the ring between study visits at fre-
quencies ranging from 4 to 18% of participants over varying
time frames [18,19]. The most common reasons cited for ring
removal were menses, periodic cleaning and expulsion during
urination or defecation. Currently, self-report is the primary
method for estimating the number of hours or days that a
removed or expelled ring remains outside the vagina before it
(or a new ring) is inserted. Although self-reported adherence
has been shown to over-estimate product use to varying
degrees in ARV-based HIV prevention trials, collecting infor-
mation on reasons for non-adherence and participants’ ex-
periences with product use more generally is essential to
providing effective counselling and support for proper use
of all such products, including vaginal rings. Recognition of
adherence challenges is necessary but not sufficient to ensure
that participants receive adequate support for adherence at
the level needed to evaluate product effectiveness. Also
important are motivations for adherence within the context
of a clinical trial. Most research on adherence outcomes has
focused on the treatment context, where the goal is to
maximize health benefits for clients. In the trial context, the
health benefits of product use are unclear and may be non-
existent, especially if there is randomization to a placebo arm.
There is also greater ambiguity about the potential risks than is
normally the case with approved medications. These unique
clinical trial elements must be considered in optimizing clinical
trial adherence to ring use. Additional consideration must be
given to how the clinical trial elements are situated relative
to the social context of the trial participants, for example,
how the motivations of researchers are understood in the
community.
Because vaginal rings can be inserted and removed by the
user, direct observation of enacted adherence, that is, the
actual act of using the product over time, is not feasible. In
this regard, the adherence measurement challenges for rings
are similar to those faced in identifying a valid, reliable and
accurate measure of microbicide adherence with respect to
other drug delivery systems, which has been elusive [20].
Proxy measures of adherence for microbicides specifically,
and for PrEP more generally, have ranged from self-reported
counts of use/non-use to measurement of drug concentra-
tion in the blood and vaginal fluids. All proxy measures have
strengths and weaknesses [21]. For example, in the case of
vaginal rings, the wide intra-individual variability in drug
blood levels during use creates challenges for accurately as-
sessing how long an ARV-based ring has been inserted or if it
has been removed or expelled and reinserted [22]. Efforts are
underway to identify biomarkers of adherence, for example,
measurement of residual drug in rings, the quantification of
biofilm on the surface of vaginal rings to assess duration of
insertion and assessment of plasma drug levels aggregated by
site. Nonetheless, adherence measurement remains depen-
dent, at least in part, on self-report, which is known to be
affected by social desirability biases and cognitive limits on
recall [23,24].
No single approach to measuring ring adherence will be
adequate to provide the level of detail needed to 1) monitor
adherence in real time to target participants for focused dis-
cussions around product use, 2) allow for statistical inferences
about effectiveness while controlling for adherence and
3) inform planning for adherence assessments during pro-
grammatic implementation of effective products. Increasingly,
researchers are advocating for use of several adherence
measures that can be triangulated [25,26].
While considerable innovation is emerging to provide
adherence support and develop more objective measures,
approaches have been largely specific to a particular study or
study-site. Furthermore, the adherence support procedures
used to date in microbicide or PrEP trials have been derived
from theory and practice established mainly in the treatment
context, with no evaluative piloting for the experimental
prevention research context. In the CAPRISA 004, iPrEX and
VOICE trials adherence support procedures underwent mod-
ification after trials were well underway [27,28]. Empirical
data on the fidelity of research teams to adherence support
guidelines is limited, further undermining efforts to under-
stand the effectiveness of a given adherence support
approach. Biometric measures such as drug levels have simi-
larly undergone continual refinement in the context of the
very trials where those measures have been used to evaluate
adherence. Innovative approaches sometimes have difficulty
getting traction in clinical trials, due to concerns about their
impact on trial implementation in the absence of pilot data.
Discussion
Developing an interdisciplinary framework
An interdisciplinary framework is needed to move past the
current ad hoc approach and integrate the various dimensions
of adherence assessments without burdening or detracting
from on-going product development or trial implementation.
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Figure 1 describes the key components of such a framework
for understanding, measuring and supporting ring adherence.
This framework highlights the dual use of adherence mea-
surement (i.e. to provide feedback during trial implementa-
tion and to inform interpretation of trial findings) and
underscores the complex pathways that connect measure-
ment, adherence support and enacted adherence behaviour.
Adherence support process
Secondary analysis of data from the CAPRISA 004 trial suggests
that use of a theory-driven approach to support adherence
to product use instructions can be effective. Midway through
the CAPRISA 004 trial the investigators revised their adher-
ence support approach to a counselling package based on
motivational interviewing, referred to as Adherence Support
Program (ASP). Findings indicate that implementation of ASP
was associated with an increase in the proportion of women
reporting high adherence, an increase in detectable tenofovir
levels and an increase in the estimate of product effectiveness
[29]. Similarly, the Uganda Partners PrEP site conducted an
ancillary adherence counselling intervention study with a
subset of participants. The intervention was adapted from an
evidence-based HIV treatment adherence intervention called
Lifesteps [30] that included cognitive-behavioural, motiva-
tional interviewing, and problem-solving techniques and
significantly increased adherence as measured by unan-
nounced pill counts [31].
In the iPrEX PrEP trial among MSM, which also demon-
strated product effectiveness, a different but somewhat
related approach was developed called next step counselling
(NSC). NSC was designed to promote open discussions about
product use and to build motivation and positive regard for
the use of an unproven product (or potentially a placebo
product) within a clinical trial [32]. In conjunction with NSC,
a neutral assessment (NA) approach was also implemented
where rates of product use were collected by non-counselling
team members who were trained to intentionally remove
judgment and negative consequences (e.g. extensive follow-
up, probing or additional procedures) for reporting product
non-use. The combined NSC/NA approach subsequently formed
the basis for adherence support procedures called VASP
(VOICE adherence strengthening program) used in the latter
half of the VOICE trial. Neither trial had a comparison arm by
which to evaluate the combined approach. However, unlike
the CAPRISA 004 and Uganda Partners PrEP findings, mid-trial
adoption of VASP did not appear to increase adherence when
individual adherence was examined pre- and post-VASP im-
plementation. A NSC/NA type of approach was used in the
early part of FACTS 001 (an on-going follow-on phase 3 trial
to replicate CAPRISA 004), which was subsequently switched
to using the ASP approach. The IPM and MTN trials currently
Figure 1. An integrated framework for adherence support and measurement in clinical trials of ARV-based vaginal rings for HIV
prevention.
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assessing IPM’s 28-day dapivirine vaginal ring draw on a
variety of adherence support strategies. The MTN study uses
a VASP-style approach, called Adherence Counseling Educa-
tion (ACE) and a number of small group-focused discussions
and activities. Common elements across all of the ARV-based
trials described above include aspects of motivational in-
terviewing and client centred models originally developed
outside the research context; some also include use of
product returns, self-report or biomarker (drug level) mea-
sures of product non-use to target adherence counselling
with participants.
While current efforts to address the adherence support
challenges in real-time with on-going clinical trials are theory-
based and draw on behavioural science methods, none of the
approaches used in blinded biomedical randomized con-
trolled trials of HIV prevention have been evaluated rigor-
ously for that context. The motivational interviewing and
client-centred counselling approaches used in these trials
were derived from models largely developed with U.S. pop-
ulations and focused on counselling intended to engage
clients in the dynamics of change, that is, moving from a
behaviour or set of behaviours that are recognized as costly/
unhealthy to ones that are beneficial/healthy [33]. Counsel-
lors sought to promote investment in change, avoiding overt
instruction or persuasion about what clients ‘‘should’’ do.
Instead, counsellors respected clients’ reasons not to change,
provided a safe place for full expression of this resistance to
change, and facilitated genuine development of an apprecia-
tion and desire for an alternative to current behaviour that
maximized values and perceived benefits from a client’s
perspective.
The reality of clinical trial research limits implementation
of full motivational interviewing principles. For example,
while participants in randomized controlled trials have auto-
nomy with regard to deciding whether to enrol or whether
to comply with all study requirements, they lack autonomy
to actively choose the intervention to be administered 
a component of choice that is core to the MI approach.
Similarly, given the critical importance of protocol compliance
for successful trial implementation, it is unlikely that research
staff can maintain genuine appreciation for a participant’s
right not to adopt the trial-desired behaviour. Finally, the
primary motivational basis behind MI is undermined by the
potential lack of a direct (or any) health benefit accruing to
the participant as a result of adopting the clinically-desired
adherence behaviour.
In contrast to motivational interviewing-based approaches,
compliance-oriented approaches rely on overt persuasion,
use of external reinforcements or the threat of negative con-
sequences to encourage clients to adopt a behaviour judged
by an external expert to be ‘‘better for you.’’ However, the use
of pure persuasion can be alienating and could create negative
feelings towards product use and trial participation, which
could further deteriorate motivation to report on product
non-use in the clinical research setting. The use of motiva-
tional interviewing-based engagement with participants, with
its valuing of genuine discourse and attempt to balance power
between researchers and participants is arguably a better fit
with the participatory kinds of engagement reflective of
current standards for HIV prevention research practice [34].
Effective support for study product use in blinded HIV
prevention trials requires a theory-based, informed approach
that meets the specific needs of both trial participants and
the trial itself. Such a participant-centred approach would
leverage respect for autonomy, as classically defined for
human research protections [35,36], while opening a dialog
to identify, develop and foster personal investment in the
objectives of the prevention trial. It would acknowledge, and
then work with the uncertainty of a direct health benefit and
the unknown health risks accruing to the participant as a
result of adherence in the experimental context of a pre-
vention trial. It would also explicitly recognize the cultural
and social dynamics that enter into a person’s motivations
to enrol in a trial, continue active engagement, take up
product use as assigned and adhere to study requirements
as requested. Unique to a participant-centred approach, the
intervention focus would be the participants’ motivation
towards and skills in achieving full engagement with the re-
search goals of the study rather than specifically on product
use, per se. Persistent, as-recommended product use would
be one of several desired outcomes of personal engagement
in the study.
Adherence support fidelity
Anecdotal evidence suggests that fidelity to adherence
support protocols by trial staff may be a significant but un-
measured factor in participant adherence to instructions for
product use. The importance of fidelity was underscored in a
recent assessment of MI to support ARV treatment adherence
in South Africa [37]. Yet fidelity measures are rarely included
in HIV prevention trials. Considerable attention has been
placed on the failure of women to follow product use
instructions in the FEM-PrEP and VOICE trials but very little
has been focused on whether those providing the instructions
and adherence support were doing so in compliance with
the standards and procedures developed for the trials. In the
absence of fidelity measures it is impossible to determine the
relative contributions of participant motivation, adherence
support system design and provider implementation. An
effective adherence support process will not ensure adequate
levels of adherence if it is poorly implemented.
Adherence psychometrics
Despite shortcomings, the assessment of self-reported ad-
herence remains a standard component of trials because it is
inexpensive, relatively non-invasive and allows for immediate
feedback [21]. Methods to improve validity and reliability of
self-reported adherence measures have largely focused on
mode of data collection (e.g. use of ACASI). However, there
has been a lack of support for development of psychometric
measures similar to those long used to assess treatment non-
compliance [38,39]. Psychometrically validated scales are
composed of multiple items in the form of questions or
statements that, when combined, measure a more complex
concept that may not be directly observable [4042]. As such,
they may better assess the multiple factors likely to contribute
to non-adherence.
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Drawing on behavioural theory and existing social and
behavioural research on acceptability and adherence, it
should be feasible to identify a multidimensional set of items
that assess adherence to products in the HIV prevention
pipeline. The process for developing such psychometric
measures is fairly straightforward. The first step is to identify
relevant conceptual domains that influence ring adherence,
developing specific items that adequately represent each
domain. Both the published literature and unpublished
qualitative data may be consulted to determine potential
domains, such as product-related attitudes (i.e. perceived
benefits and barriers to ring use), motivations for product use
within a clinical trial setting and perceived self-efficacy to use
a ring as instructed, as well as barriers potentially associated
with non-adherence (i.e. low levels of knowledge, social
stigma associated with product use, male partner concerns,
domestic violence, lack of mobility.) Content validity  the
degree to which the domains and draft items represent the
underlying dimensions of vaginal ring adherence behaviour
within a clinical trial context  would be assessed in part
through review and feedback by a panel of behavioural and
social researchers, cultural experts and/or clinicians with
expertise in HIV prevention adherence. Both the content,
sequence and wording of draft items, as well as the overall
framing and instructions for scale administration, must then
be evaluated in a small number of culturally diverse sites,
using standard cognitive interviewing techniques and/or focus
group discussions, to verify that the draft measure includes
relevant content and that individual items are salient, well
understood and easily rated by participants similar to those
who might take part in vaginal ring trials.
After the draft scale items are refined, they are incorpo-
rated into a survey that also includes measures of behavi-
ours or attitudes that are hypothesized to predict or affect
adherence directly or indirectly. The survey is administered to
women in one or more cultural settings who are current or
former trial product users. Exploratory and confirmatory
factor analysis techniques are applied to determine the final
structure and content of the adherence scale, and the the-
oretical associations between adherence as measured by
the scale and other factors/variables are explored. Once the
psychometric properties of the scale measure is confirmed,
opportunities to assess the predictive value of the adherence
scale can then be sought, for example, by examining how
well the scale score correlates with biometric indicators of
product use.
A validated scale of vaginal ring adherence would poten-
tially have multiple applications within the context of HIV
prevention clinical research. It could support the trial’s eval-
uation of vaginal ring efficacy by providing complementary
evidence on adherence, particularly when biomarker adher-
ence data may be missing or incomplete for some trial par-
ticipants. The use of a composite biomarker-plus-adherence
scale approach was shown to correlate better with viral load
than use of biomarker data alone in one study on HAART
effectiveness [43]. Additionally, given the multidimensional
composition of a vaginal ring adherence scale, it could alert
staff to a participant’s potential issues around adherence at
baseline (if, for example, commitment to correct and con-
tinuous product use ranked low among an individual’s
motivations for trial participation) and/or provide real-time
feedback on barriers or facilitators of use to adherence
support staff over the course of the trial. While the process
of developing adherence psychometrics requires an upfront
investment of time and resources, once a scale is validated it
is a cost-effective tool to adapt and implement across the
applications described above.
Adherence biometrics
There has been considerable attention given to the develop-
ment of biomarkers and biometric measures that rely less on
verbal self-report by participants and provide more direct
measures of events or adherence. Examples include electronic
devices such as MemsCap and WisePill devices for pill storage
and Wisebag for microbicide applicator storage, which allow
electronic tracking of when the storage devices are opened,
ostensibly for use (or, in the case of rings, for storage) of
the product [44,45]. Some biometric approaches may indi-
cate a point-in-time when the product is used, while other
approaches may indicate more cumulative use patterns. For
example, two approaches currently under investigation with
the potential to measure varying durations of ring use include
quantification of ring biofilm (which should increase with
duration of insertion) and of residual drug (which should
decrease with duration of insertion). Other biometric methods
have the potential to indicate ring insertion at a given point
in time. One such approach is the adaptation of an esther
taggant previously tested in vaginal gel to ring technologies
[46]. Another approach with some potential is the use of an
RFID tag that would allow random non-intrusive scanning for
ring insertion. Rather than measuring ring insertion, some
biometric approaches might indicate current or cumulative
ring removal. For example, it might be possible to develop a
cumulative measure of ring exposure to air that could indicate
the proportion of time the ring was removed, or exposure to
water that might indicate removal and washing.
Adherence analytics
To address vaginal ring adherence in the comprehensive way
described above, we need to consider the analytical integra-
tion of the various approaches. As illustrated in Figure 1,
analytic findings from each framework component may
inform other components as well as ensuring that the best
science is used within each component.
Individual elements of comprehensive adherence support
processes should minimally be pretested through use of
cognitive interviewing techniques and piloted using compre-
hension assessments on the part of participants and fidelity
assessments with regard to implementation by research staff
prior to their use in effectiveness trials. Experimental or quasi-
experimental assessments of the comparative effectiveness of
different adherence support system designs would be ideal.
Formative research to develop adherence support can also
inform development of the psychometric measures and
determine acceptability of various biometric measurement
approaches in specific cultural contexts.
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Examples of fidelity measures that should be included in
ARV-based HIV prevention trials include the quality and extent
of staff training in the method, quality and consistency in
implementation, organizational support for implementation,
documentation of practices and adaptation to local and
emergent needs. Use of mobile phones or other technology
may also be helpful in monitoring fidelity as well as adherence
on the part of participants. Here again, formative research
findings will be critical for developing and adapting measures
to specific trials and contexts.
Points of potential interface between psychometric and
biometric measurement and adherence support should be
identified and consciously and overtly considered when de-
signing measures, support strategies and guidelines for
administering each.
Conclusions
After more than two decades of biomedical HIV prevention
effectiveness trials, it is now clear that randomization, blinding
and use of placebo controls cannot mitigate any behavioural
or sociocultural context-specific issues that might arise during
the course of a trial. Rather, behaviours and contexts that drive
adherence are at issue for evaluating effectiveness. Increas-
ingly, researchers are advocating for use of several adherence
measures that can be triangulated [19,38]. Coordinated
research is needed along three pathways to generate com-
plementary measures that can then be triangulated for a
comprehensive picture: 1) psychometrics to improve self-
report measures reflective of behaviour; 2) electronic dispen-
sing or storage options to capture events corresponding to
intended product use or non-use; and 3) biometrics to capture
indications of product ingestion or insertion, as well as fre-
quency or duration of same. Better measurement of adher-
ence will not, by itself, ensure that future effectiveness trials
will be able to address the most basic question: does the
product prevent HIV transmission? The challenges to adher-
ence measurement must be addressed as one component of a
more integrated system that has as its central focus adherence
as a context-driven behaviour.
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Abstract
Introduction: Despite the disproportionate impact of HIV on women, and adolescents in particular, those below age 18 years are
underrepresented in HIV prevention trials due to ethical, safety and logistical concerns. This study examined and compared the
sexual risk contexts of adolescent women aged 1517 to young adult women aged 1821 to determine whether adolescents
exhibited similar risk profiles and the implications for their inclusion in future trials.
Methods: We conducted a two-phase, mixed-method study to assess the opportunities and challenges of recruiting and
retaining adolescents (aged 1517) versus young women (1821) in Tanzania. Phase I, community formative research (CFR),
used serial in-depth interviews with 11 adolescent and 12 young adult women from a range of sexual risk contexts in
preparation for a mock clinical trial (MCT). For Phase II, 135 HIV-negative, non-pregnant adolescents and young women were
enrolled into a six-month MCT to assess and compare differences in sexual and reproductive health (SRH) outcomes, including
risky sexual behaviour, incident pregnancy, sexually transmitted infections (STIs), reproductive tract infections (RTIs) and HIV.
Results: In both research phases, adolescents appeared to be at similar, if not higher, risk than their young adult counterparts.
Adolescents reported earlier sexual debut, and similar numbers of lifetime partners, pregnancy and STI/RTI rates, yet had lower
perceived risk. Married women in the CFR appeared at particular risk but were less represented in the MCT. In addition,
adolescents were less likely than their older counterparts to have accessed HIV testing, obtained gynaecological exams or used
protective technologies.
Conclusions: Adolescent women under 18 are at risk of multiple negative SRH outcomes and they underuse preventive services.
Their access to new technologies such as vaginal microbicides or pre-exposure prophylaxis (PrEP) may similarly be compromised
unless greater effort is made to include them in clinical trial research.
Keywords: adolescents; clinical trials research; sexual and reproductive health; HIV prevention; Tanzania.
Received 20 March 2014; Revised 7 July 2014; Accepted 22 July 2014; Published 8 September 2014
Copyright:– 2014 Tolley EE et al; licensee International AIDS Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution
3.0 Unported (CC BY 3.0) License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.
Introduction
In 2010, 34 million people were living with HIV and
approximately half of the adult cases were among women
[1]. Although estimates of HIV incidence have begun to decline
in general populations, young African women aged 1524
continue to bear a high burden of the disease [1,2]. Indeed,
in Tanzania, HIV prevalence in young women is approxi-
mately 3%, three-fold higher than in men of the same age
group [3]. As elsewhere, Tanzanian young women’s risk of
HIV has been attributed to early sexual debut [4] and fuelled
by poverty and socio-cultural conditions that undermine
the use of currently available HIV prevention methods, such
as condoms [510].
Despite the disproportionate impact of HIV on young
women, they are markedly underrepresented in clinical trials
of new HIV prevention methods. Although a number of
potential prevention approaches, including antiretroviral-
based vaginal and oral products, have been evaluated in
women aged 18 and older, only two trials to date have enrolled
women below the age of 18 [1113].
There is some recent evidence that younger adults in PrEP
trials have poorer product adherence and trial retention,
thus undermining our ability to show product effectiveness
[14]; however, many have argued that adolescents’ inclusion
in clinical microbicide trials is a matter of social justice,
providing important opportunities to assess the safety,
acceptability and effectiveness of new prevention products
within a high-risk population who might differ from their
young adult counterparts in important ways [11,1517].
The social justice argument may well supersede the logisti-
cal needs of trials, or rather, further highlight the special
attention and work required to adequately include adoles-
cents in trials. Furthermore, because regulatory bodies such
as the United States Food and Drug Administration and
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the South African Medicines Control Council are unlikely
to allow microbicides to be marketed to adolescents with-
out data demonstrating that these products are safe and
effective for the adolescent population [18], their exclusion
is likely to delay or even limit adolescent access to new HIV
prevention products.
Nevertheless, multiple barriers exist to the recruitment of
adolescent women, including ethical concerns about younger
women’s biological safety and their cognitive ability to give
informed consent for trial participation, as well as the legal
and social challenges of recruiting young, sexually active
minors [15,16,18]. In addition, although epidemiological re-
search clearly identifies young women as a high-risk group
for HIV, little research has been conducted to distinguish
the risk behaviours and cultural contexts that put specific
adolescents at risk [19]; without more information on ado-
lescent sexual behaviour, it is uncertain whether younger
women’s patterns of sexual risk behaviours would even make
them good candidates for trial participation.
In order to assess the opportunities and challenges of
recruiting adolescent women into HIV prevention clinical
trials, we conducted a mixed-method study in Dar es Salaam,
Tanzania that included community formative research (CFR)
and a six-month mock clinical trial (MCT). The specific
objectives of the CFR were manifold but included gathering
more in-depth information from socio-demographically di-
verse adolescents and young adult women representative of
the types of participants we anticipated being recruited into
the MCT in order to finalize study procedures and measures
for the MCT. For this paper, we use data from both the CFR
and the MCT to identify and compare the sexual relation-
ship patterns, HIV risk perception, HIV risk reduction be-
haviours and incident sexual and reproductive health (SRH)
outcomes of adolescents aged 1517 with those of young
women aged 1821 to determine whether they face similar
or unique risks and to determine how such risks might affect
trial participation.
Methods
This study comprised two research phases  the CFR and
the MCT. During the CFR phase, we conducted a total of
64 in-depth interviews (IDI)  for up to three IDIs each with
23 sexually active young women aged 1521 from different
sexual risk contexts: married adolescents, married young
women, single in-school and single out-of-school adolescents
and young women, of whom some were currently or
previously engaged in sex work. [Note: two participants
completed only the first IDI and one participant completed
the first and second interview, but not the third.] The study
team worked with representatives from community-based
organizations and schools, community and government
leaders and members of a ‘‘Youth Interactive Group’’ (YIG)
to identify and recruit participants from 14 very-low-income
residential locations with high concentrations of bars,
brothels and retail alcohol outlets. Interviews were con-
ducted in Swahili by trained female interviewers, audio-
recorded, transcribed and uploaded into NVivo8, a software
programme that assists with qualitative data management
and analysis. The first and second interviews explored
participants’ home life, school or work situation, first and
current sexual relationships, reproductive and sexual health
knowledge and use of protective behaviours. The third
interview focused on their attitudes towards pre-exposure
prophylaxis (PrEP), microbicides and participation in HIV
prevention clinical research.
During the second research phase, we enrolled 135
sexually active, HIV-negative, non-pregnant adolescents and
young women aged 1521 into a MCT with interviews at
baseline, two, four and six months. Research staff conducted
informational meetings in communities identified during
the CFR and worked with community representatives and
YIG members to recruit participants for the MCT. The study
was conducted at the Infectious Disease Clinic (IDC) in Dar es
Salaam, which offers youth-friendly services. During the
study, participants received urine pregnancy tests at each
visit and were tested for HIV, bacterial vaginosis (BV) (via
gram stain test) and trichomoniasis (via microscopy), at
baseline and month four. Those who tested positive were
called and offered treatment. They also received behavioural
assessments at every visit, with more extensive assessments
at baseline and six months.
Qualitative CFR data were analysed thematically follow-
ing a process of reading, coding and the development of
analytic memos and data reduction matrices [20]. Initial
codes were proposed and discussed by the US and the
Tanzanian research team after reading the first transcripts
from interview 1. The codebook was updated after each
round and coding took place in parallel to data collection.
Memos identified and described dimensions of coded
themes (i.e. identifying common contexts within the HIV
Risk Perception code in which participants did or did
not express concern about HIV risk). Important themes/
sub-themes were quantified and typed into Excel matrices
to identify patterns across age groups and/or risk contexts.
For the MCT, we conducted chi-square tests or Fisher’s
exact tests, as appropriate depending on cell size, to exam-
ine bivariate associations of socio-demographic, sexual risk
behaviour and SRH risk outcomes. Given our small sample
size, we did not further develop multivariable models to
assess differences in adolescent versus young women’s risk
profiles.
Ethical approvals were received from Muhimbili University
of Health and Allied Services, the National Institute for Medi-
cal Research and FHI 360’s Protection of Human Subjects
Committee. Participants aged 16 or older gave written
informed consent; for 15-year-old participants, a parent/
guardian and the participant gave written consent.
Results
CFR phase
A total of 23 adolescents and young women participated
in the CFR phase. Our analysis of sexual relationships, risk
reduction behaviours and risk perception revealed few
differences by age group, but many more by risk context
(Table 1). More than two-thirds of CFR participants had
fractured family lives in which one or both parents had died
or were divorced. In many cases  but especially among five
young women engaged in sex work  these precarious
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beginnings appeared to enhance their vulnerability. Each of
these young women described a scenario in which the death
or divorce of parents and the inability or unwillingness of
other relatives to help care for their needs led to their entry
into sex work. All but one lived on their own, in a brothel
or with a friend. This is in contrast to in-school youth, all of
whom were living with one or both parents.
Sexual relationship patterns
Sexual debut ranged from 13 to 18 years and was almost two
years earlier, on average, for adolescents (14.8 years) than
young women (16.6 years). For seven of the eight married
participants, the first sexual partner was their husband,
although sex often occurred before marriage. Regardless of
risk context, first partners tended to be older (36 years)
than participants, with several husbands older by as much
as 1117 years. No first sexual encounters were reported as
physically forced  however, several participants felt they
were tricked into having sex the first time.
Participants’ accounts of their current sexual relationships
did not appear to vary by age, but did vary by sexual context.
Only two of the eight participants who were or had been
married described their husbands in positive terms. More
commonly, they used terms such as ‘‘cruel’’ or ‘‘harsh,’’
or described husbands as prone to humiliate or insult them.
All four of the married adolescents described being con-
trolled and sometimes beaten by their husband. A 17-year-
old who was currently staying at her mother’s house
admitted that ‘‘there was too much humiliation . . . A small
mistake and he beats me.’’
In contrast, sex workers and in-school youth tended to
describe their relationships in more positive terms than the
other participants. For example, an 18-year-old sex worker
described her boyfriend as ‘‘not very capable’’ of much
financial support but able to satisfy her sexually. She added
‘‘I am enjoying (sex) to a large extent; that is why we love
each other.’’ A 21-year-old single university student described
the emotional and material support she derived from her
current partner, a non-Tanzanian businessman: ‘‘He is so
caring; when I fall sick he takes me to the hospital; when
I am hungry he cooks for me. So, he somehow treats me like
a baby. . . . He gives me daily company.’’
The word ‘‘trust’’ was often used to describe participants’
current relationships. The term, however, conferred multiple
and sometimes contradictory meanings, including emotional
and material support, and sexual discretion but rarely sexual
exclusivity. A 20-year-old, who reported being married from
the age of 13 or 14, was both doubtful and trustful of her
husband’s behaviour, ‘‘I trust my husband; if he has women
outside, he will use a condom . . . fidelity is so important
to me, because I trust someone  because he is not a player.
He doesn’t do dirty things . . . he is not just having sex with
women. That is why I trust him.’’
Risk reduction behaviours
About half of the CFR participants (similar proportions of
adolescents and young women) reported currently using
condoms, although this varied widely by risk context. Only
two of the eight married women used condoms with their
husbands and about half of the unmarried in-school and out-
of-school participants used them with one or more partners;


















N (%) N (%) N (%) N (%) N (%) N (%)
Mean age 17.2 18.4 18.0 18.4 16.4 19.6
Mean years of education 8.4 6.9 8.3 10.2 7.2 9.3
Living with one or both parents 1 (20) 1 (13) 1 (20) 5 (100) 4 (36) 4 (33)
Living with husband or partner 0 (0) 7 (87) 0 (0) 0 (0) 3 (27) 4 (33)
Living with relative 0 (0) 0 (0) 3 (60) 0 (0) 3 (27) 0 (0)
Living on own (brothel/with friend) 4 (80) 0 (0) 1 (20) 0 (0) 1 (9) 4 (33)
Parents separated/divorced 2 (40) 1 (13) 3 (60) 2 (40) 4 (36) 4 (33)
One or both parents deceased 3 (60) 6 (75) 2 (40) 0 (0) 5 (45) 6 (50)
Currently employed 5 (100) 4 (50) 3 (60) 1 (20) 5 (45) 8 (67)
Two or more lifetime sex partners 3 (100)a 6 (75) 5 (100) 5 (100) 8 (72) 8 (67)
Ever described partner abuse 0 (0) 7 (87) 2 (40) 0 (0) 4 (36) 5 (42)
Ever tested for HIV 3 (75)a 7 (87) 2 (40) 3 (60) 7 (64) 8 (67)
Ever RTI symptoms 2 (40) 3 (37) 2 (40) 3 (60) 2 (18) 8 (67)
Ever pregnant 1 (20) 7 (87) 2 (40) 4 (80) 6 (54) 8 (67)
Currently using condoms 5 (100) 2 (25) 3 (60) 2 (40) 6 (54) 6 (50)
Ever used hormonal contraception 2 (40) 2 (25) 2 (40) 0 (0) 1 (9) 5 (42)
aSome missing information due to lack of second or third interviews.
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most described using condoms to avoid pregnancy as well
as disease. In contrast, all of the participants engaged in sex
work described consistently using condoms, mostly to avoid
HIV/STIs.
Adolescents and young adult women suggested that
condom use was acceptable or even expected at the beginning
of a new relationship. However, most participants described
having stopped condom use within their own relationships
as ‘‘trust’’ had been established. Several participants sug-
gested that trust was more firmly established after both had
tested negative for HIV. The majority of participants who had
ever tested for HIV did so within the context of pregnancy
or because of illness, although two students and two sex
workers described more routine testing behaviour. Five
married participants and one out-of-school participant said
their partners refused testing.
Among those who were not sex workers, more-consistent
condom use appeared to be for the purpose of preventing
pregnancy. Only four participants reported currently using a
modern, non-barrier method, including two injectable users
and one participant each using oral pills and an implant.
Several others reported having used or considered using an
injectable previously, but stopped or did not initiate use out
of fear of side effects.
Risk perception
Most participants recognized they were at some risk of HIV,
but about half appeared reluctant to attribute that risk
directly to their own or their partner’s behaviours. A 17-
year-old married adolescent both trusted and did not trust
her 20-year-old husband: ‘‘I think I can get HIV if my husband
goes outside marriage, if he has sex with a person that is
HIV positive, because I don’t use protection . . . I don’t use
protection because I trust my husband.’’ To protect herself,
she said that it was important ‘‘to be settled with my
husband and not to have many men. Myself  I can settle,
but I don’t know about my partner.’’
A few participants were more direct in their acknowl-
edgement of risk. A 21-year-old university student admitted
that, ‘‘Most of us young ladies get HIV because of having
relationships for money or other material things, so that drives
you to have reckless sex. For example, I can’t face somebody
and tell him ‘Let’s go and test.’ I can’t, I will just test myself,
so that lack of confidence . . . leads to acquiring HIV.’’ Similarly,
a sex worker stated, ‘‘I have told you my business; worrying is
inevitable.’’ Several participants assessed their risk as minimal,
because they took precautions. For example, a 20-year-old
university student agreed that she was ‘‘of course concerned
about AIDS, but not too concerned about other disease . . .
because I protect myself . . .. Also, (I use) condoms and then
I don’t mix people. If I have one (partner), it’s just him. Maybe
if we breakup, that’s when I go to another person.’’
SRH outcomes
Participants’ knowledge about sexually transmitted infections
(STIs) was variable. Almost half of participants described
having ever experienced reproductive tract symptoms, includ-
ing itching, ‘‘fungus,’’ unusual vaginal discharge or painful
intercourse. A few women appeared to use home remedies
such as ‘‘Dettol’’ (an antiseptic liquid soap), although most
sought treatment from a health facility. However, while
participants described being provided medications for treat-
ment, they rarely described being counselled about the source
of infection or about ways to reduce sexual risk.
Unprotected sex and unplanned pregnancy were common
among the CFR participants. More than half (14 of 23) had ever
been pregnant  almost equally divided by age group. Only
7 of the 14 ever-pregnant participants had living children
and two adolescent participants became pregnant during the
CFR. Four participants, two in each age group, reported having
aborted at least once.
MCT phase
Adolescents and young adult women who participated in our
MCT differed from the CFR qualitative sample in several
important ways. First, they appeared to come from more
stable homes, given that themajority ofMCTparticipants (83%
of adolescents and 58% of young adult women) were living
with one or both parents. In addition, we enrolled fewmarried
women into the MCT. However, there were also striking
similarities between the CFR and the MCT phases, especially
in terms of sexual debut, patterns of sexual risk and risk
reduction behaviours. Below, we describe the MCT partici-
pants and patterns of sexual risk, with a focus on whether
and/or how adolescents differed from their adult counter-
parts. Table 2 describes the socio-demographic, sexual risk
and protective factors by age group.
Socio-demographics
Overall, the MCT sample of 135 participants was more similar
to the group of single out-of-school CFR participants than to
other risk contexts. They had similar years of education and
work. About half of the participants were neither in school
nor employed. Almost all adolescents (98%) and most young
adult women (80%) were single, but had a regular partner.
Sexual relationship patterns
As in the CFR, adolescents who joined the MCT reported
similar or higher risks than their young adult counterparts.
On average, adolescents initiated sex about six months earlier
than did young adult participants (at 15.2 versus 16.3 years
of age.) More than a third of participants, with similar
proportions of adolescents and young adult women, reported
their first sexual encounter to be coerced or forced. About
10% of participants’ first sexual partners were five or more
years older than themselves.
At baseline, adolescents reported fewer sex partners over
their lifetime (range, 15) than young adult women (range,
110). However, mean number of sexual partners was similar
when adjusted for years of sexual exposure. About 14% of
participants reported ever exchanging sex for money or
goods, with no differences by age. There were no statistically
significant differences in current sexual or substance use risks
across age categories. Half of the participants in each age
group had engaged in sex during the week prior to enrolment
and about half reported using a condom at last sex. About
10% of participants reported using alcohol during their last
sexual encounter; 4.9% of adolescents and 8.5% of adult
participants reported that their last sexual encounter was
coerced or forced.
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Risk reduction behaviours and risk perceptions
The rate of having ever used contraception was low; no
adolescents and fewer than 15% of young women were
currently using a modern contraceptive method. Condom use
at last sex was similar between age groups. Although the
difference was not statistically significant, fewer adolescents
(about half) than young women (nearly two-thirds) reported
any condom use in the past four weeks (data not shown).







Age (mean) 16.4 19.3
Years of education (mean) 8.4 8.9 0.18
Relationship status % %
Married or cohabitating 2.4 9.6
Regular partner, not cohabitating 97.6 79.8 0.02a
Single 0.0 10.6





Occupation % % 0.13
Paid employment 22.0 30.9
Student 29.2 14.9
Unemployed, not in school 48.8 54.2
Religion % %
Muslim 56.1 52.1 0.36a
Catholic 39.0 34.0
Other 4.8 13.8
Mean age at sexual debut 15.2 16.3
Range (1117) (1020) 0.0002
First sexual encounter coerced/forced 34.2% 45.7% 0.21
First sexual partner 5 years older (N36) (N87) 1.00a
8.3% 10.3%
Mean number of lifetime sex partners 1.7 2.6
Range (15) (110) 0.002
Mean number of sexual partners per year of sexual exposure 1.24 1.06 0.24
Two or more partners in lifetime 39.0% 72.3% B0.001
Ever concurrent partners 19.5% 16.0% 0.61
Ever exchanged sex for money or gifts 14.6% 13.8% 0.09
Ever tested for HIV 47.5% 75.0% 0.002
Ever had a pelvic exam 5.1% 15.7% 0.14a
Ever used modern contraceptives 2.4% 21.3% 0.004a
Current contraceptive use (non-condom) 0.0 14.9 0.006a
Had sex in last week (N41) 51.2% (N93) 49.5% 0.85
Condom at last sex 43.9% 50.0% 0.51
Alcohol at last sex 12.2% 8.5% 0.53a
Forced/coerced last sex 4.9% 8.5% 0.72a
(N41) (N93) 0.005a
Perceptions of HIV risk % %
No perceived HIV risk 36.6 15.1
Perceived a little HIV risk 58.5 64.5
Perceived a lot of HIV risk 4.9 20.4
Any incident SRH outcomeb (N35) 22.9% (N69) 14.5% 0.29
Incident pregnancy 17.1% 10.1% 0.31
Diagnosis of bacterial vaginosis or trichomoniasis after baselineb (N22) 9.1% (N55) 5.5% 0.62a
aFisher’s exact test used for any cells with values of 5 or less; bsubsample includes only those who had a month 4 clinic visit, during which pelvic
and lab tests were conducted. RTIreproductive tract infection; SRHsexual and reproductive health; STIsexually transmitted infection.
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Despite early sexual debut and some similarities in
patterns of sexual risk, over a third of adolescents (36.6%)
perceived themselves to be at no risk of HIV, compared to
15.1% of their counterparts.
SRH outcomes
Over the six-month study period, there were 13 incident
pregnancies (six in adolescents and seven in young women)
among the 104 participants who had at least one follow-up
visit and five confirmed cases of incident RTIs/STIs (three
cases of BV and two cases of trichomoniasis) among the
78 participants who attended the four-month visit and
completed lab tests. In addition, three cases of BV and five
cases of trichomoniasis were identified and treated at
enrolment. No participant was diagnosed more than once
with an RTI/STI. Four young women and one adoles-
cent were not enrolled in the MCT due to a positive HIV
diagnosis at screening (data not shown). However, no inci-
dent HIV infections were detected post-enrolment. Although
not statistically different, almost 20% of adolescents and
10% of young adult women became pregnant during this
six-month study.
Discussion
The findings from this study have several implications when
considering adolescent participation in HIV prevention trials.
First, sexually active adolescents in this study reported
behaviours that put them at similar risk of HIV and other
STIs as their adult counterparts. Adolescents in both phases
initiated sex earlier than young adult women; had similar
numbers of lifetime partners; and similar patterns of sexual
concurrency, transactional sexual behaviour and alcohol use.
Despite high levels of pregnancy and moderate levels of
RTIs/STIs, use of condoms and other contraceptive methods
was low or inconsistent for half or more of the participants,
regardless of age. Given their sexual risk and barriers to using
available risk reduction methods, it is important to determine
whether new HIV prevention technologies would be safe,
efficacious and acceptable to this population.
Nevertheless, adherence problems identified in two recent
trials that aimed to evaluate the efficacy of new vaginal and/or
oral HIV prevention methods in African women have raised
concern about recruiting young women. Both the FEM-PrEP
and the VOICE trials failed to produce evidence of effective-
ness for products that were shown to be effective in other
populations. Although neither trial recruited women below
the age of 18, in the VOICE trial, young, single participants
aged 1824 were much more likely to contract HIV and much
less likely to adhere to their study product than married
women aged 25 and above [14]. In the FEM-PrEP trial, low
adherence was attributed in part to women’s low perception
of HIV risk [21].
Indeed, the majority of young women  but especially
adolescents who participated in our MCT perceived them-
selves to be at little or no risk of HIV. In that respect, those
who joined our clinical study differed from the CFR sample.
In particular, young married women and single, out-of-school
women appeared particularly vulnerable. Most described
sexual partners who were at times controlling or even
abusive. They expressed concern about HIV risk, but had
difficulty articulating actions they could take on their own to
reduce that risk. Despite young married women’s apparent
need for new, women-initiated HIV prevention methods,
the small number of married participants who enrolled in
our study suggests additional challenges in recruiting this
population.
This paper does not address issues related to the feasi-
bility of adolescent recruitment and retention in HIV preven-
tion trials, or their adherence to products. However, several
South African studies examining the feasibility of recruiting
adolescents into HIV biomedical and/or vaccine clinical trials
found similar rates of incident pregnancy, STIs and HIV among
adolescents below the age of 18 and adult women [11,22].
While adolescents comprised a much smaller proportion of
the overall sample in both studies (less than 20%), there were
no differences in retention by age groups. A third South African
study followed 100 HIV-negative adolescent women and
men aged 1417 over 12 months in preparation for HIV
vaccine trials. Follow-up at one year was high (82%), but while
incident pregnancy occurred among 7% of female participants,
no incident HIV infections were diagnosed [23]. Finally, in
a recent analysis of adolescent data from the Carraguard
microbicide trial, young women aged 1617 were no more
likely than those aged 1819 to miss visits, report missed
doses or be lost to follow-up. However, they acknowledge
that adolescent inclusion in clinical trials may require some
modifications to trial design or implementation (i.e. training
in youth-friendly counselling and further consideration of
informed consent and compensation issues) to support their
participation [24].
The study had several limitations. Originally, we aimed to
conduct this study in two culturally diverse research sites,
with an intended MCT sample size of 300 for subsequent
regression analyses: 150 participants each from Pune, India,
and Dar es Salaam, Tanzania. Unfortunately, the Indian site
was closed after the CFR phase, largely due to difficulties
obtaining approval from the local ethics committee (EC) for
the MCT. The Indian EC restricted adolescent recruitment
to married women only, with husband and/or parental
consent required if below the age of 18. The Indian EC’s
stance further highlights the cultural dimensions that shape
young women’s sexual risk and their ability or inability to
reduce risk by accessing HIV prevention information, pro-
ducts, services  and even clinical trials. Furthermore,
observed differences across age groups on those sexual
behaviour measures that summarize a participant’s entire
sexual history have ambiguous interpretations. For example,
while older participants were more likely to report ‘‘ever’’
being tested for HIV, this difference might be expected since
they are likely to have been sexually active for a longer
period of time and also more likely to have become pregnant
and tested within the context of antenatal care. And, since
we did not collect data on the timing of these behaviours,
we are unable to adjust for the unequal periods of risk across
the two age groups. However, this limitation does not apply
to the reported number of sex partners per year, questions
relating to the first sexual experience, or to measures that
refer to a behaviour within a specified time frame (e.g. sex in
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the past week or incident pregnancy). Finally, while the
qualitative data from our CFR participants provide a richer
understanding about the contexts within which young
women experience risk, these data cannot be linked directly
to MCT participants  who were recruited from the same
venues, but through different approaches.
Conclusions
Adolescents under age 18 are at risk of negative SRH
outcomes, including pregnancy, STIs, RTIs and HIV. They are
less likely than their older counterparts to report accessing
HIV testing, obtaining gynaecological exams or using protec-
tive technologies such as contraception. With adolescents
at similar, if not higher risk, than their young adult counter-
parts, combined with their underuse of current preventive
services, their inclusion in clinical trials for new preventa-
tive technologies is clearly warranted  but additional support
for recruitment, retention and product adherence may be
required. Their access to new technologies such as vaginal
microbicides or PrEP may be compromised unless research is
undertaken to assess the safety, acceptability and effective-
ness of these products in this age group. Adolescent exclusion
from HIV prevention trials may hinder access to new HIV
prevention technologies, once available.
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Abstract
Introduction: Current HIV prevention options are unrealistic for most women; however, HIV prevention research has made
important strides, including on-going development of antiretroviral-based vaginal microbicide gels. Nevertheless, social-
behavioural research suggests that women’s ability to access and use new HIV prevention technologies will be strongly influenced
by a range of socio-cultural, gender and structural factors which should be addressed by communications and marketing
strategies, so that these products can be positioned in ways that women can use them.
Methods: Based on an extensive literature review and in-country policy consultation, consisting of approximately 43 stakeholders,
we describe barriers and facilitators to HIV prevention, including potential microbicide use, for four priority audiences of Kenyan
women (female sex workers [FSWs], women in stable and discordant relationships, and sexually active single young women).
We then describe how messages that position microbicides might be tailored for each audience of women.
Results: We reviewed 103 peer-reviewed articles and reports. In Kenya, structural factors and gender inequality greatly influence
HIV prevention for women. HIV risk perception and the ability to consistently use condoms and other prevention products often
vary by partner type.Women in stable relationships find condom use challenging because they connote a lack of trust. However,
women in other contexts are often able to negotiate condom use, though they may face challenges with consistent use.
These women include FSWs who regularly use condoms with their casual clients, young women in the initial stages of a sexual
relationship and discordant couples. Thus, we consider two approaches to framing messages aimed at increasing general
awareness of microbicides  messages that focus strictly on HIV prevention and ones that focus on other benefits of microbicides
such as increased pleasure, intimacy or sexual empowerment, in addition to HIV prevention.
Conclusions: If carefully tailored, microbicide communication materials may facilitate product use by women who do not
currently use any HIV prevention method. Conversely, message tailoring for women with high-risk perception will help ensure
that microbicides are used as additional protection, together with condoms.
Keywords: microbicide; communication; women; HIV prevention; messages; Kenya.
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Introduction
In Kenya, HIV prevalence has fallen from 7.2% in 2007 to 5.6%
in 2012 among adults aged 1564 [1,2]. However, women
continue to be disproportionally affected by HIV; prevalence
rates were 6.9% among women, compared to 4.4% among
men [1]. In addition, approximately 40% of new infections
have occurred within stable couples [1]. Women’s need for
new HIV prevention technologies remains a priority.
Recent trials have demonstrated the effectiveness of new
antiretroviral (ARV)-based HIV prevention products. Oral pre-
exposure prophylactic (PrEP) use of tenofovir or Truvada (teno-
fovir and emtricitibine) was shown to reduce HIV transmission
in heterosexual discordant couples (by 62% for tenofovir-only
and 73% for Truvada) [35]. Additionally, the CAPRISA 004
clinical trial in South Africa produced a proof of concept for
peri-coital vaginal use of 1% tenofovir gel in reducing HIV
transmission to heterosexual women [6].
While oral PrEP has been approved for use in high-risk
populations in the United States [7], decisions about vaginal
microbicide gel may still be several years away as regula-
tors await confirmatory results from the FACTS 001 trial.
Furthermore, despite commonalities between oral and vaginal
ARV-based products for HIV prevention, their introduction
strategies may require different approaches.
The need for tailored introduction strategies
Social-behaviour research conducted alongside microbicide
clinical trials suggests women’s acceptability of new HIV pre-
vention technologies, and their ability to access and use them,
will be strongly influenced by the way products are positioned
by communication and marketing strategies [8]. For messages
to be effective, they must be tailored; different audiences
will perceive different sources of risk, outcome expectations
and barriers to action. For example, previous research
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suggests women’s ability to identify their HIV risk varies
considerably by geographic and sexual relationship context
[912]. Research globally has associated low rates of condom
use, especially among women in stable relationships, with
the perception that condoms are primarily for HIV prevention.
And, because HIV is associated with high-risk sexual behav-
iour, the request for condom use within a stable relationship
connotes unfaithfulness. Female condom programmes have
worked to reverse such connotations by emphasizing the use
of female condoms for contraception and by promoting their
use in loving relationships [13]. It will be equally important
to develop and test potential ways to position microbicide use
to avoid stigmatization.
Some researchers and advocates have suggested that
vaginal microbicide gel might be less stigmatized if it is
positioned as a sexual lubricant [14]. However, although the
notion that gel use increases sexual pleasure could be posi-
tively perceived by some, it may be negatively perceived by
others. Similarly, if gel is promoted for use among audiences
in which condom use is a norm, communication strategies
should model dual use of gel and condoms to avoid the sub-
stitution of more efficacious condoms with less efficacious
microbicide products. Therefore, introduction strategies, in-
cluding the content and framing of messages, will need to be
tailored to various audiences if new technologies are to be
widely accessed and used.
Communicating about Microbicides with Women in Mind
is a three-phase project to assist Kenyan policymakers, pro-
gramme implementers and advocacy groups in planning for
future introduction of ARV-based vaginal microbicide gel,
once proven effective. Specifically, the project aims to de-
velop a suite of communication materials tailored to the
needs of potential users and to assess the effects of message
framing on interest in microbicide use, negative attitudes
towards microbicides and potential condom migration.
In this paper, we draw on an extensive literature review
and in-country policy consultation, conducted during the first
project phase, to describe four potential audiences who might
benefit from microbicide use. We also discuss how commu-
nication materials might require tailoring for each audience.
Methods
Literature search strategy
During the first phase, we systematically searched peer-
reviewed articles, from January to July 2012, using PubMed
and Google Scholar. We sought peer-reviewed articles of
academic quality that identified barriers and facilitators to
HIV prevention among four potential end-user audiences
representing different sexual relationship contexts: female
sex workers (FSWs), women in stable relationships, women
in discordant relationships, and sexually active, single young
women.These priority audiences were selected based on their
high HIV prevalence rates and previous research of key
populations who might benefit from vaginal microbicide use
[6,9,10]. Other data sources included national surveillance
system data reports, such as the AIDS indicator surveys and
demographic health surveys.
The search includedmedical subject headings (MeSH) terms
for HIV and AIDS, terms associated with each of the four
priority audiences (‘‘sex work,’’ ‘‘FSWs,’’ ‘‘couples,’’ ‘‘serodis-
cordant couples,’’ ‘‘young women,’’ ‘‘women,’’ ‘‘youth,’’ and
‘‘adolescents’’), and key terms associated with HIV prevention
(‘‘HIV testing,’’ ‘‘condoms,’’ ‘‘microbicides,’’ ‘‘PrEP,’’ ‘‘sexual
relationships,’’ ‘‘communication,’’ ‘‘discussion,’’ ‘‘negotiation,’’
‘‘HIV risk perception,’’ ‘‘sexual pleasure,’’ ‘‘sexual practices,’’
‘‘sexual power,’’ ‘‘gender-based violence/coercion,’’ ‘‘stigma,’’
‘‘education,’’ ‘‘social support,’’ ‘‘money,’’ ‘‘substance use,’’ and
‘‘alcohol use’’).
Inclusion and exclusion criteria
Studies of any design were eligible for inclusion if they
addressed HIV prevention among one or more of the specified
audiences and if they were published between 1990 and 2012.
Articles were also included in the analysis if they reported
findings from Kenya or neighbouring countries, including
Uganda, Rwanda and Tanzania. Several multi-site studies in
sub-Saharan African were also included when Kenya was one
of the prioritized countries. All surveillance reports specific
to Kenya were included in the analysis. Articles and reports
were excluded if they did not focus on any of the priority
audiences, HIV prevention, or Kenya and its neighbouring
countries (Figure 1).
Analysis
The search yielded 103 unique articles and reports (Table 1),
96 of which were specific to Kenya; the remaining pertained
to neighbouring sub-Saharan African countries. Several arti-
cles (n27) included information on men and young boys;
they were retained because they contained information
relevant to the priority audiences.
Articles and reports were uploaded into NVivo 9.2, read for
content and coded to identify 26 broad themes, including risk
perception, sexual practices, communication and condom
use as well as priority audiences. Articles and reports were
categorized and analysed by audiences based on specific
themes; those containing data on multiple audiences were
coded for each relevant audience. Data pertaining to multiple
audiences or themes were also double coded. For each main
theme, we created an Excel matrix organized by article, with
up to three illustrative excerpts across the columns, and
colour-coded by audience group. These thematic matrices
helped identify similarities and differences among audiences
in terms of HIV prevention needs and challenges.
Data were presented and discussed during a two-day
national policy consultation, conducted in Naivasha, Kenya,
in collaboration with the National AIDS and STI Control
Programme and the Kenya Medical Research Institute. Par-
ticipants included 43 stakeholders comprising Kenyan policy-
makers, programme managers and civil society advocates, as
well as representatives from international non-governmental
organizations (NGOs) and funding agencies. The potential
introduction of ARV-based HIV prevention in Kenya, including




The varying social contexts within which women and their
partners live, work and love create unique challenges for HIV
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prevention efforts (Table 2). The number and type of partners,
in large part influenced by structural factors and gender
inequality [15], affect women’s HIV risk perception and their
ability to respond to that risk [16]. For example, the ability
to use condoms consistently and correctly often varies by
partner type [9,17,18]. As Kenya considers microbicide in-
troduction, understanding current HIV prevention behaviour
and related sexual practices in Kenya may prove useful in
anticipating potential barriers and facilitators to new product
use for various audiences.
Female sex workers
The 2012 Most-at-Risk Populations (MARPs) Surveillance
Report estimates that the HIV prevalence rate among FSWs
in Kenya is between 24 and 50% [19]. Several Kenyan studies
[1924] suggest that FSWs work within a culture of vio-
lence, commonly triggered by substance use and discussions
of condom use and payment. The illegal nature of sex work
perpetuates discrimination, deterring FSWs from reporting the
violence or seeking assistance from law enforcement [2021].
Moreover, economic necessity negatively affects FSWs’ ability
to negotiate condom use; inconsistent use often results from a
client’s willingness to pay more for unprotected sex [9,25].
Nevertheless, HIV risk perception is high among many
sex workers [16,25], and many are able to respond to their
risk. FSWs report considerable awareness of STI symptoms,
high rates of treatment-seeking behaviours, HIV testing and
subsequent knowledge of HIV status [9,18]. A number of
studies conducted across Kenya report high rates of con-
sistent condom use among FSWs [9,24,26].
Yet, condom use among FSWs is strongly associated with
partner type [9,16,18,27,28]; higher rates of condom use are
reported with casual partners or clients than with regular or
primary partners. Some studies suggest that for FSWs, primary
partners are considered less risky than casual partners [23,28],
a theme which is consistent with women in other contexts.
One study assessing vaginal microbicide gel acceptability
among FSWs revealed that gel could be promoted as a
lubricant to facilitate condom use, thus enhancing protection
[10]. However, a study assessing intravaginal practices and
implications for new HIV prevention products among FSWs in
urban Kenya revealed that vaginal washing practices, often
influenced by perceived or real male preference for ‘‘dry sex,’’
and anal sex were also common [28,29]. Such practices may
reduce the effectiveness of vaginal microbicides.
412 potentially relevant studies
and reports
225 abstract selected for review
187 excluded:
23 duplicates
164 not related to target 
audience or country
123 full articles reviewed
102 excluded:
76 clinical trials with no
pertinent HIV prevention 
information
26 policy papers 
with no prevention data 
103 articles and reports included in analysis 
20 excluded : sub-Saharan African
countries that did not include Kenya or
neighbouring countries
Figure 1. Flow chart of included articles and reports.
Table 1. Geographical focus of the articles
Geographical focus Sex workers Young women Stable relationships Discordant couples Other groups Total (%)
Kenya 38 25 7 5 21 96 (93.20)
Sub-Saharan Africa 2 0 0 0 5 7 (6.79)
Total 40 25 7 5 27 103 (100)
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Women in stable relationships
According to the 2012 KAIS, HIV prevalence among women in
stable relationships was estimated to be 5.3% [1]. Moreover,
an estimated 44% of new infections are thought to occur
within stable relationships, according to the 2009 Kenya HIV
Response and Modes of Transmission Analysis [30]. Studies
suggest that women in stable relationships perceive their risk
for HIV to be low [22,31] and are therefore rarely tested for
HIV outside of antenatal contexts [32]; as part of the 2007
KAIS, most women (about 60%) reported being tested within
the context of antenatal services [2].
Within stable relationships, men and women report dif-
ferent patterns of sexual behaviour. While women report
approximately two lifetime partners, men report more than
seven. Similarly, concurrent relationships were reported by
1% of women in monogamous relationships and 2.6% of
women in polygamous relationships, compared to 7 and 10%
of men [2].
Kenyan men are important decision makers in sexual
matters, from decisions about the number and timing of
children to the use of contraceptive and disease prevention
methods. In contrast, women have been socialized to comply
with their partner’s desires for sex and pleasure [32].
Women in stable relationships face barriers to requesting
condom use, largely because such requests raise suspicions
of unfaithfulness and increase the potential for violence
[3336]. And, while condom use for contraception appears
more acceptable than for disease prevention, less than 2%
of women in stable relationships report using condoms for
contraception [37]. Cross-sectional studies across Kenya
Table 2. Focused, summary results from the literature review by audience
Female sex workers Women in stable relationships
Partner information
 Partners include clients, regular partners, boyfriends,
husbands  of unknown status
 Low decision-making power with regular partners
 Sex is often planned
 Potential for violence
HIV risk perception and information source
 High-risk perception
 Receive HIV information from peer educators
Condom use
 High condom use with clients
 Low condom use with regular partners
Microbicide considerations
 Lubrication could facilitate condom use
 Some perceive that clients prefer dry sex
 Multiple partners, substance use might affect adherence
 Vaginal washing might reduce effectiveness
Partner information
 Some have one regular partner of unknown status; others
have additional partners of unknown status
 Low decision-making power in general
 Potential for violence
HIV risk perception and information source
 Low-risk perception
 Receive HIV information and testing in antenatal care settings
Condom use
 Some condom use at start of relationship
 Low/no condom use once committed
Microbicide considerations
 Partner involvement shown to improve adherence
 High acceptability among married trial participants
 Some concerns about stigma; may imply infidelity
Discordant couples Single young women (15 to 24 years)
Partner information
 Some have one regular partner only; others have additional
partners of unknown status
 Low decision-making power with additional partners
 Potential for violence
HIV risk perception and information source
 Low-risk perception prior to testing and disclosure, but
high-risk perception after testing, disclosure
 Receive HIV information from health system
Condom use
 High condom use with negative partner, if relationship
continues
 Low condom use with additional partners
Microbicide considerations
 Could protect discordant couples who wish to conceive
 May be useful for HIV-negative women before HIV-positive
partner initiates treatment
Partner information
 Partners can include transactional, cross-generational sex
partners, regular partners, boyfriends  of unknown status
 Low decision-making power in general
 Sex is not often planned
 Potential for violence
HIV risk perception and information source
 Low-risk perception
 Receive HIV information from schools and youth-friendly
clinics and peers, but information is limited
Condom use
 Some condom use at start of intimate relationship
 Low condom use in general
Microbicide considerations
 Interest in new, effective products
 Concern about use disclosure
 Some concern about product insertion, adherence
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report low spousal communication related to HIV preven-
tion, further suggesting that women in stable relationships
have little ability to negotiate condom use or other safe sex
practices [3537].
Discordant couples
According to the KAIS 2012, there are an estimated 260,000
HIV-discordant couples in Kenya [1]. Among couples in which
both partners received HIV test results, 5% were identified
as HIV-discordant and 3% were concordant HIV-positive [1].
Yet, risk perception is generally low for these couples before
testing. Indeed, 53% of men and women who were tested
as part of the 2012 KAIS and found to be in HIV-discordant
relationships were unaware of their status [1]. Similarly, a
study conducted in Mombasa revealed that women were
unaware that their primary partners were involved in other
relationships [38].
Before diagnosis, women and men in discordant relation-
ships are like other stable couples in which women’s fidelity
and fertility are highly valued. In fact, fertility continues to
be important even within HIV-affected relationships. The 2007
KAIS reported that about one-fourth of women who self-
declared as HIV positive reported wanting a/another child
[2], yet fear of stigma is thought to limit the use of necessary
PMTCT services for HIV-positive women [3941].
Fear of stigma has also been found to inhibit HIV status
disclosure between partners, regardless of relationship length.
However, once discordancy has been disclosed, if couples
choose to remain together, both HIV risk perception and the
ability to negotiate risk reduction behaviours can increase
with effective HIV counselling [11].
Single young women
An estimated 5.6% of sexually active young women aged 15
24 were identified as HIV positive in the 2007 KAIS study [2].
Among young women who participated in the 2012 KIAS,
66% reported ever having sex [1]; other studies suggest that
women initiate sex at young ages and that sexual activity
often begins within the first month of a new relationship
[12,42].
Despite widespread reports of multiple concurrent part-
nerships among Kenyan youth [17,43,44], HIV risk perception
and subsequent condom use is low for young women [45,46];
only 11% reported consistent condom use in the 2012 KAIS
[1]. As with women in other contexts, condom use varies by
partner type; it primarily occurs at the start of a relationship
when risk is perceived to be high [12,43] and is abandoned
once ‘‘trust’’ is established [43]. Young women’s ability to
negotiate condom use is also compromised by gender, age
and economic disparities, especially in situations involving
cross-generational and transactional sex [12,46,47]. While
some use these exchanges to meet basic needs [43,48,49],
others are motivated by the potential for supplementary gifts
[46,49].
Misinformation about HIV transmission is pervasive among
many young women [17,4650]. Despite lessons on life-skills,
teachers in Kisumu and Nakuru have reported feeling un-
prepared to talk about sexuality in the classroom, in part, due
to parental concerns [51]. Similarly, cultural taboos about
adolescent sexuality pose barriers to purchasing condoms,
negotiating condom use with partners [48,52], or visiting a
health centre for HIV and STI testing. However, providing
an increase in youth-friendly HIV testing and counselling
centres in Kisumu resulted in an increase in HIV testing [44].
Montandon et al. qualitatively examined the potential
acceptability and use of microbicides among young women
in Kisumu [49] in 2008. This study suggested that the un-
planned nature of adolescent sexual activity, a fear of vaginally
inserting or trying new, ‘‘experimental’’ products, and con-
cerns about product efficacy will likely impede vaginal
microbicide use for young women [49].
Policy consultation
Results from the literature review, shared at the Naivasha
consultation, provided context for participants to prioritize
audiences they felt would be most suited for microbicide com-
munication materials. With financial and human resources
likely to be a challenge for new product implementation, some
participants felt it would be important to prioritize known
risk groups (FSWs and/or HIV-negative women in discordant
couples) already identified as a national priority for HIV
prevention.
However, participants also expressed concern about the
effects of stigma, and whether focusing on known risk groups
would inadvertently lead to the stigmatization and subse-
quent non-use of microbicides by other women. Some parti-
cipants felt strongly that while women in stable relationships
and young women may not typically be considered most-
at-risk, current HIV prevention options are not realistic for
them.
Consequently, a group of known high-risk women, (FSWs)
and two groups of at-risk women who have not traditionally
been targeted with HIV prevention information (single young
women aged 1524 and women in stable relationships) were
identified as primary audiences for the Communicating about
Microbicides with Women in Mind project. Men and health
care providers were identified as secondary audiences.
Finally, meeting participants also emphasized that civil
society organizations should work closely with the govern-
ment to develop appropriate procedures and regulations for
microbicide introduction. They agreed the government should
drive the agenda for the introduction of ARV-based HIV pre-
vention, including the development of national guidelines.
A project advisory committee (PAC), consisting of key govern-
mental and non-governmental stakeholders, was therefore
established to guide the Communicating about Microbicides
with Women in Mind project.
Discussion
Social marketing and communication strategies can poten-
tially increase the uptake of new HIV prevention technolo-
gies, including microbicides. UNAIDS has long acknowledged
the role of social marketing as an effective tool in the global
response to HIV/AIDS [53]. In a review of more than 6500
studies, PSI conducted an analysis of social marketing ap-
proaches and programmes, demonstrating the effectiveness
of social marketing for changing health behaviours. Twenty
studies demonstrated increases in HIV risk perception, knowl-
edge, and self-efficacy; 18 demonstrated increases in condom
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use and HIV testing; and eight demonstrated reductions in
HIV prevalence [54]. However, the design and implementa-
tion of effective strategies relies on a solid understanding of
priority audiences and the many factors that influence their
behaviours. This information determines the most effective
way of positioning products to generate interest in use.
Because vaginal microbicides are likely to be partially
effective, they may need to be promoted within the context
of condom use. Experience from programmes that have
promoted dual protection against pregnancy and HIV may be
useful. Unfortunately, there have been few quality studies
documenting the effectiveness of behavioural interventions
for promoting dual protection. Yet, many organizations that
have implemented dual protection interventions have docu-
mented lessons learned; these include the need to tailor
messages to specific HIV contexts and the fact that a dual
protection message is not always appropriate [55].
Microbicide introduction strategies will need to consider
how to position microbicides so they:
1) Can be used by all types of sexually active women
2) Do not connote lack of trust or infidelity
3) Are used when condom use is not possible or as a back-
up for condoms
4) Do not replace condoms when condom use is possible
To this end, it will be important to determine whether
microbicide awareness-raising materials, should focus exclu-
sively on HIV prevention or more prominently on other
benefits such as sexual pleasure, intimacy, and/or female
empowerment. Which type of framing generates the most
interest in microbicides will likely differ depending on the
target audience. At the same time, it will be important to
avoid linking microbicides to stigmatizing behaviours such as
unfaithfulness or sex work. And finally, because microbicides
are currently not as effective as condoms, materials must
avoid promoting them in a way that would result in decreased
condom use among those who use condoms with all or some
of their partners.
Widespread use of microbicides will require more than
awareness, however; it will also require intensive counselling
about risks, benefits, feasibility and correct use of microbi-
cides. Educational materials, tailored for specific audiences,
offer an opportunity for more detailed discussion about
these topics and potential adherence challenges. Educational
materials designed for FSWs and HIV-negative women in
discordant relationships, for example, will need to emphasize
the importance of combining microbicides with condom use,
as opposed to substituting condom use with microbicides.
As indicated by the literature, FSWs have high-risk perception
and an ability to negotiate condom use with clients, yet they
are also economically motivated and may view condom-less
sex as an opportunity to obtain additional cash. Materials
will need to deter this behaviour and promote dual use of
microbicides and condoms as enhancing protection and
potentially facilitating condom use.
Moreover, materials for FSWs will need to address various
contexts in which microbicides may be used, including with
primary partners. Because sex is often anticipated for these
women, materials might want to encourage daily or routine
use of microbicides. And finally, materials will need to address
various sexual practices reportedly common among some
FSWs, including vaginal douching and anal sex.
For young women and women in stable relationships,
however, educational materials will need to acknowledge
that partial protection from microbicides is better than no
protection at all. Moreover, materials should provide detailed
information on HIV risk and prevention options. As indicated
by the literature, despite widespread reports of concurrent
partnerships, many of these women do not perceive them-
selves to be at risk and have not used, or do not currently
use, condoms with their partners. Likewise, with many young
women and women in stable relationships reporting difficulty
negotiating safe sex with their partners, educational materials
should provide guidance to ensure women can decide whether
and/or how they should involve their partners in discussions
about microbicide use.
For young women, in particular, materials will need to
address the fact that many of them have limited experiences
with reproductive health services, may fear necessary HIV
testing or the insertion of new vaginal products, and often do
not plan for sex.
Limitations for this project include the fact that there are
currently few studies available on microbicide acceptability in
Kenya and HIV prevention among women in stable relation-
ships and women in discordant couples. Moreover, without
an available product, much of the work we have conducted is
based on hypothetical assessments.
Conclusions
Findings from this project address a critical gap in our current
approach to HIV prevention communication by providing
evidence-based recommendations that should be considered
for communication materials in order to support the future
introduction of vaginal microbicide gels in Kenya. We believe
that these recommendations can be used to create effective
materials and will contribute to increased use of microbicides
by women in a variety of sexual contexts  including young
women and those in stable relationships  who have not
traditionally been considered at high risk of HIV, but may
actually be some of the most-at-risk.
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Abstract
Introduction: Stakeholders continue to discuss the appropriateness of antiretroviral-based pre-exposure prophylaxis (PrEP) for
HIV prevention among sub-Saharan African and other women. In particular, women need formulations they can adhere to given
that effectiveness has been found to correlate with adherence. Evidence from family planning shows that contraceptive use,
continuation and adherence may be increased by expanding choices. To explore the potential role of choice in women’s use of
HIV prevention methods, we conducted a secondary analysis of research with female sex workers (FSWs) and men and women
in serodiscordant couples (SDCs) in Kenya, and adolescent and young women in South Africa. Our objective here is to present
their interest in and preferences for PrEP formulations  pills, gel and injectable.
Methods: In this qualitative study, in Kenya we conducted three focus groups with FSWs, and three with SDCs. In South Africa,
we conducted two focus groups with adolescent girls, and two with young women. All focus groups were audio-recorded,
transcribed and translated into English as needed. We structurally and thematically coded transcripts using a codebook and QSR
NVivo 9.0; generated code reports; and conducted inductive thematic analysis to identify major trends and themes.
Results: All groups expressed strong interest in PrEP products. In Kenya, FSWs said the products might help them earn more
money, because they would feel safer accepting more clients or having sex without condoms for a higher price. SDCs said the
products might replace condoms and reanimate couples’ sex lives. Most sex workers and SDCs preferred an injectable because it
would last longer, required little intervention and was private. In South Africa, adolescent girls believed it would be possible to
obtain the products more privately than condoms. Young women were excited about PrEP but concerned about interactions
with alcohol and drug use, which often precede sex. Adolescents did not prefer a particular formulation but noted benefits and
limitations of each; young women’s preferences also varied.
Conclusions: The circumstances and preferences of sub-Saharan African women are likely to vary within and across groups and
to change over time, highlighting the importance of choice in HIV prevention methods.
Keywords: pre-exposure prophylaxis; sub-Saharan Africa; women; ARV-based HIV prevention methods; HIV prevention.
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Background
Sub-Saharan African women at risk of HIV infection are a
heterogeneous group. They include married and unmarried
women, women whose partner(s) may have other partners,
women in serodiscordant couples (SDCs), women in poly-
gamous relationships, adolescent girls and women who
engage in a range of transactional sexual behaviours with
one or more partners. Given the diverse characteristics of
African women, their needs and preferences for HIV preven-
tion methods are likely to differ.
Stakeholders in HIV prevention continue to discuss the
appropriateness of different formulations of antiretrovirals
(ARVs) as pre-exposure prophylaxis (PrEP) for HIV prevention
among women in sub-Saharan Africa and elsewhere [1].
In particular, these women and others at risk of HIV need
formulations they can adhere to given that effectiveness
correlates with adherence [2]. This was demonstrated in the
iPrex study, which found high effectiveness of oral PrEP
among participants with high adherence [3], as well as in the
FEM-PrEP and MTN 003 trials, both of which were stopped
for futility and later reported low adherence to oral PrEP
among participants [46]. The CAPRISA 004 trial of 1%
tenofovir gel also found that the product’s effectiveness
corresponded with degree of adherence [7].
Evidence from family planning research provides an insight
into how to encourage uptake of and adherence to preven-
tion methods, thereby increasing overall coverage at the
population level. Specifically, contraceptive use, continuation
and sustained adherence may be increased by expanding the
method mix, improving features of methods and increasing
the quality of and access to family planning services [8].
Providers’ assistance with the selection and continued use of
a method has also been found to be essential to sustained
contraceptive use. Another important lesson is the key role
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of choice in uptake of and adherence to contraception 
choice in terms of the user’s ability to select a method,
a range of contraceptive methods to choose from and places
to access them [810].
Extrapolating from family planning, to explore the poten-
tial role of choice in women’s use of HIV prevention methods,
we conducted a secondary analysis of data from qualitative
research with potential user groups of ARV-based PrEP for-
mulations in Kenya (female sex workers [FSWs], men and
women in SDCs) and in South Africa (adolescent and young
women). Our objective here is to present our analysis of
these groups’ attitudes towards ARV-based HIV prevention,
including acceptability, interest and concerns, and their
preferences for different formulations  choosing from pills,
gel and an injectable.
Methods
This study was conducted in Kenya and South Africa from
2011 to 2012 in collaboration with local partners. This was
subsequent to the 2010 announcement of the positive
efficacy results of the CAPRISA 004 clinical trial on 1%
tenofovir gel [7] and the iPrex oral PrEP trial [3], but prior
to the early closure of the FEM-PrEP oral PrEP trial and the
MTN 003 results, which found that oral PrEP (FEM-PrEP and
MTN 003) and gel (MTN 003) were not effective because
women did not adhere to the products [46]. In Kenya,
the research was managed by the FHI 360 Kenya office in
collaboration with the University of Manitoba/University
of Nairobi Sex Work Outreach Program (SWOP), with data
collected in Nairobi and Nakuru. In South Africa, data were
collected in the eThekwini District of KwaZulu-Natal by MatCH
(Maternal, Adolescent and Child Health; Department of
Obstetrics and Gynecology; University of Witwatersrand).
Potential participants for focus group discussions (FGDs)
with FSWs were identified through the SWOP clinics, a group
of Nairobi, Kenya, clinics serving FSWs. Clinic staff informed
clinic clients of the study objectives and participant selection
criteria. Clients then voluntarily chose to participate. All
participants were age 18 or older, residents of Nairobi and
self-identified FSWs. To recruit SDCs, staff working with an
SDC support group at the local public hospital in Nakuru,
Kenya, discussed the study with potential participants who
then voluntarily participated. All participants were age 18 or
older, residents of Nakuru and self-identified as being in a
sexual relationship with someone of the opposite HIV status.
Participants for FGDs with adolescent and young women were
recruited with the help of a pre-existing community advisory
board (CAB) that was affiliated with the local South African
research group who conducted the data collection activities.
The CAB conducted community meetings to share informa-
tion about the research with potential participants and the
community at large. Participants for the FGDs with adolescent
women were age 14 to 17; those in FGDs with young women
were 18 to 24. After obtaining parental permission for
potential participants under the age of 18, adolescents and
young women expressing interest in the study were recruited
by phone.
The risk profile of potential participants was the key
determinant for recruitment. Aside from age (for adolescent
and young women) and partnership status (for SDCs), other
demographic factors were not examined.
The study protocol was approved in the United States by
FHI 360’s Protection of Human Subjects Committee; in Kenya
by the Kenya Medical Research Institute; and in South Africa
by the University of the Witwatersrand Human Research
Ethics Committee and the eThekweni District and KwaZulu-
Natal Provincial Departments of Health.
Written, informed consent was obtained from all parti-
cipants age 18 and above. For participants age 14 to
17, informed consent was obtained from their parents or
caregivers, and informed assent was obtained from the
participants.
Data collection
In Kenya, we conducted six FGDs  three in Nairobi with a total
of 33 FSWs aged 21 to 37, and three in Nakuru with SDCs aged
between 24 and 48 with a total of 32 participants (16 men,
16 women). In South Africa, we conducted four FGDs with a
total of 36 participants. Two were with adolescent girls age
14 to 17, and two were with young women age 18 to 24. One
FGD in each user group was with participants from informal
settlements, and one with participants from formal settle-
ments; this was a proxy for socioeconomic status, as residents
of informal settlements tend to have a lower socioeconomic
status than those of formal settlements. In the FGDs, we
explored the potential user groups’ interest in and preferences
for three different formulations of PrEP  oral PrEP, a vaginal
gel and an injectable. The FGD guides comprised a combina-
tion of standard and population-specific questions.
Prior to the FGDs, all study participants were given infor-
mation on PrEP products, including how HIV-negative indivi-
duals could use PrEP to avoid becoming infected with HIV,
that PrEP products contain ARV-based drugs similar to the
ones used to treat HIV-positive individuals, that PrEP products
are still being researched, descriptions of the different for-
mulations of PrEP and how they would be used, and how PrEP
would likely offer partial protection from HIV infection.
Each FGD was conducted by two research assistants
trained in research ethics and qualitative research methods,
and fluent in English and the local language (isiZulu in South
Africa, Kiswahili in Kenya). One research assistant served as
the moderator and the other as the note taker. All FGDs were
audio-recorded and simultaneously transcribed and trans-
lated into English as needed.
Data analysis
Through a standard iterative process, we developed a code-
book to structurally and thematically code the FGDs using QSR
NVivo 9.0. Initially, two data analysts independently coded
a sub-set of transcripts, and inter-coder agreement was
assessed. This process was repeated until inter-coder agree-
ment was reached for each set. Subsequently, each transcript
was coded once by a given analyst, with the analysts con-
sulting one another frequently to ensure that coding decisions
were made jointly. The codebook was updated as new themes
emerged. Once all data were coded, we generated code
reports and conducted inductive thematic analysis to identify
major trends and themes.




Attitudes towards PrEP, including acceptability, interest
and concerns
FSWs, Kenya
FSWs in Kenya expressed great interest in PrEP products.
However, the majority appeared to assume initially that PrEP
would provide 100% protection against HIV, and many were
disappointed to learn that they would still need to use
condoms to prevent HIV and other sexually transmitted
infections (STIs). The majority of FSWs’ concerns regarding
PrEP were related to its degree of effectiveness and to their
preference for a PrEP product that could prevent both HIV and
other STIs. They feared that some FSWs (and other users)
would forgo condoms if PrEP became available, thus increas-
ing the likelihood of transmitting HIV and STIs.
FSWs’ interest in PrEP was not only related to preventing
HIV transmission, but also to helping them earn more money
 because they would feel safer accepting more clients
or would feel more comfortable having sex without using
condoms. As one FSW described:
They [FSWs] will not have unprotected sex carelessly
because as we have heard from some of us earlier on;
they said that they usually have unprotected sex
when they are offered moremoney like 3000 [Kenyan
Shillings, about $35 US dollars] for sex without a
condom or 300 [Kenyan Shillings, about $3.50 US
dollars] for sex with a condom. PrEP will help in
protecting them from getting HIV while making more
money.
A few FSWs expressed concern about side effects, either
generally or in relation to particular formulations. Most of
these participants emphasized the need to help each woman
identify the formulation appropriate for her.
SDCs, Kenya
SDCs in all FGDs expressed enthusiastic support for PrEP. We
did not systematically survey the SDCs on whether they were
currently using condoms consistently, although some men-
tioned that they were using condoms. However, the over-
whelming consensus was that PrEP could, should, or will
replace  rather than accompany  condoms as the primary
form of HIV prevention within SDCs. Many respondents said
they would not want to use PrEP and condoms at the same
time.
SDCs also expressed great optimism and hope that PrEP
would help reanimate sex lives and draw couples closer
together by reducing or eliminating the need for condoms,
which many participants described as diminishing sexual
pleasure: You see, we forgot having unprotected sex, so our
love for each other will be revived [with PrEP]. Another
respondent explained,We will accept them [PrEP products] as
will clear the thoughts of using condoms and hence improve
the relationship with my wife. Participants frequently men-
tioned PrEP as a way to alleviate the stress associated with
condom breaks.
Few SDCs had concerns regarding PrEP, but those that did
worried about its safety or about the burden of daily-use
formulations to the user.
Adolescent girls, South Africa
Adolescents were also interested in PrEP as protection from
HIV, although a few participants appeared confused about
whether PrEP would protect them from pregnancy as well.
They found PrEP particularly appealing because it would eli-
minate concerns about being seen while obtaining condoms
from clinics and because they felt PrEP products could be used
privately. As one adolescent explained, PrEP products . . . are
much easier to use because you can just take a pill, unlike
condoms because you are scared to get them from the clinics
because you do not know who is watching you. Some girls ex-
pressed hesitation in regards to PrEP, stating that they would
be interested in using it only after seeing other girls use it.
Young women, South Africa
Young women were excited about and interested in using
PrEP products to prevent HIV infection. One concern men-
tioned by several young women was that it might be difficult
for women to use coitally dependent PrEP formulations while
under the commonly reported influence of alcohol or drugs
prior to sexual activity. Another concern was that it would be
challenging to negotiate PrEP use with a partner or that young
women simply would not use the product with trusted
partners, similar to condom use patterns. One young woman
explained that if a male partner says he does not want to use
[PrEP] today, you will not use it.
Unclear on the correct timing of the use of different
formations of PrEP, some young women were concerned that
PrEP might be difficult to use in the midst of a sexual
encounter: Once your hormones are high, you forget [. . .]
both your hormones are already high. When are you going to
insert the gel? When are you going to take the pills once you
are in the middle of it? A few women thought their peers
would be more willing to use PrEP if they could use it covertly.
No differences were identified between adolescent and young
women from informal and formal settlements.
Preferences for PrEP formulations
FSWs, Kenya
The majority of FSWs clearly preferred an injectable over
other formulations. They liked that one dose would last for
a prolonged period of time and would require little user
intervention, unlike a pill that they must remember to take
every day. In addition, injections were perceived as relatively
private, making it less likely that others would know a woman
was using the product. A few women described alcohol use as
potentially interfering with their ability to take a daily pill but
not posing a problem with injections, as this respondent
explained:
Ah okay, I would prefer the injection because it is
private and you can use it without your client
or partner knowing. Just like the family planning,
injection most women who are using it, their partners
are not aware. Secondly I personally love taking
alcohol so with the PrEP injection I will be safe
because I won’t need to remember to take it daily like
the oral pill or vaginal gel.
Most FSWs were concerned that they might forget or that
it would be burdensome to take a pill consistently. Several
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women were concerned about side effects associated with
an oral product or interactions between pills and alcohol.
A few women were worried that people would see them
taking pills, whereas others liked the idea of taking a pill
because it was daily, something they controlled and similar to
contraceptive pills.
Nearly all FSWs reported using some form of vaginal
lubricant in the past; however, there was little interest in
PrEP gel. This was because women thought they might forget
to apply it before and/or after sex and because clients might
be against its use. As one FSW noted, If asking a client to
wear a condom is challenging then you can only imagine
what they will do if they see you applying the vaginal gel
before sex. It is crazy.
Most FSWs said they would prefer to apply a gel before sex
rather than afterwards; however, they saw problems with
applying the gel at any point. For example, although the gel
might help with lubrication before sex, some FSW noted that
there would not always be time to apply it before sex and
that FSWs who are drunk or high might forget to use it. Those
who cited specific limitations with post-coital use most often
noted that women were tired after sex and unlikely to
remember to use it.
SDCs, Kenya
The majority of SDCs strongly preferred injectable PrEP
because it required little user involvement and was long-
lasting, in contrast to pills or gel. For example, one person said:
I also believe that the injection will be ideal because
one won’t be getting a jab every day, maybe it will be
three or six months instead of every time you want
to have sex, you either take the pills or apply the gel.
Another respondent said:
If it will be for three months I will know it is after
every three months, it is better than the pills as one
can forget to swallow, or maybe you did not have
the pills with you because you travelled, so one will
be at high risk.
Others said an injectable would be preferable because they
did not like swallowing pills or taking medicine. Some indi-
viduals, however, said they would not use an injectable
because they feared needles or the pain associated with
injections.
Few individuals preferred pills to the other formulations;
reasons for preferring pills included: liking the idea of an
intermittent pill taken only when having intercourse, being
accustomed to taking pills and disliking injections. Disadvan-
tages of pills included a dislike of pills, having to remember to
take them regularly and needing to remember to take them
along when leaving the house or traveling.
Only three individuals commented on the gel formulation,
but these three individuals thought it would be good because
it would not be painful like an injection and would help men
learn about the vagina. Fewer than half of the females in
the SDCs in our focus groups reported ever using a vaginal
lubricant or medicine. Among those who had used a vaginal
product, the majority had used a vaginal medicine during
pregnancy. SDCs overwhelmingly agreed that a PrEP gel
should be applied before sexual intercourse, as this respon-
dent commented: I was feeling that the gel should be applied
way before even starting to romance because I believe that
it will be ready to fight with the virus. Couples insisted that
a gel provided before sexual intercourse would be more
effective than one provided afterward. Couples noted that
condoms are used before, not after sex, and they compared
pre-coital use to ‘‘prevention’’ and post-coital use to a ‘‘cure.’’
Adolescent women, South Africa
Adolescents did not express a clear preference for a particular
PrEP formulation but noted some benefits and limitations
of each one. Participants noted that users could forget to take
all PrEP formulations. Adolescents felt that the process of
obtaining pills could be more private than obtaining condoms,
since pills in general might be taken for a variety of reasons.
Additionally, whereas PrEP injections would require users
to wait in a clinic and a gel would require privacy to insert,
pills could be taken relatively privately at any time and place.
Additionally, one adolescent noted that it would be easier
to take a pill every day than try to predict when sex might
happen. Some disadvantages associated with PrEP pills
included difficulty swallowing them and concerns that they
might cause urine to smell bad.
Adolescents’ concerns about injections included their
potential to be painful, with some preferring an injection in
the arm rather than the buttocks because they perceived it
as less painful. A few adolescents also believed walking or
sitting would be difficult after receiving an injection to the
buttocks. Several girls were uncomfortable with having to
remove their pants or skirts in order to receive the injection.
Only a few (four) adolescents commented on gel dosing.
Half felt that it was better to use a gel daily in order to
establish a routine. They also noted that daily use would limit
situations in which girls wanted to have sex but did not have
the gel with them. The other half thought a gel formulation
would be better if used intermittently, either pre or post-
coitally, especially for adolescents who did not frequently
engage in sexual relations.
Participants debated over whether gel or pills were
preferable. Advantages of gel included the perception that
coitally dependent use was less burdensome than a daily pill
and less painful than an injection. Disadvantages included the
belief that predicting sex could be difficult, inserting a vaginal
gel was unpleasant and required privacy, and a gel could have
an unpleasant odour.
Young women, South Africa
Some young women preferred PrEP pills compared to other
formulations because they believed pills were safer than
injections and more private than gel. However, others felt it
would be difficult to take a pill every day. Some young women
preferred a coitally-dependent gel over pills because they
thought it would be easier to remember to apply a gel.
Still others preferred injections over a pill because they
thought injections would be safer, longer lasting, more private
and difficult to forget. One woman expressed concern that
injections might not be effective in combination with alcohol
and drugs.
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Compared to adolescents, young women expressed less
concern over receiving an injection in the buttocks. Some
young women actually preferred that location, explaining
that they were already accustomed to receiving contracep-
tive injections there. No differences were identified between
adolescent and young women from informal and formal
settlements.
Discussion
This study contributes to existing literature on the accept-
ability of ARV-based PrEP formulations among beneficiary
groups. All four potential target populations expressed strong
interest in these products, similar to the favourable reactions
identified in previous research among other key groups
[7,1121]. Furthermore, our research introduces the concept
of choice into work on the acceptability of HIV prevention
methods. Although the importance of choice has been
recognized and incorporated into contraceptive provision, it
is an emerging idea in HIV prevention, most likely because
condoms have been the only method of protection thus far.
A range of new potential HIV prevention methods is in
development, but there continues to be tension about which
to develop and move forward  and our research suggests
that no one method will meet all needs.
Although the SDCs in our study preferred the injectable
formulation, their rationale for their support of the method is
consistent with SDC participants of the Partners PrEP trial
of oral tenofovir-only or oral Truvada (tenofovir combined
with emtricitibine) in Uganda; SDCs from both studies viewed
use of a PrEP product as a ‘‘way out’’ of the ‘‘discordance
dilemma,’’ as defined in the Partners PrEP study, that is, that
long-term condom use is unrealistic for SDCs (i.e. expensive,
inconvenient, uncomfortable and incompatible with the desire
to become pregnant), with preserving health and remaining
in the relationship seemingly incompatible [19].
Although most women in the CAPRISA 004 trial testing 1%
tenofovir gel found it acceptable [7], in our study, hypothetical
use of a PrEP gel had mixed acceptability. In particular, some
SDCs, FSWs and adolescent women found it unacceptable due
to the inconvenience of pre- and post-coital application. In
addition, FSWs cited clients’ potential disapproval of the gel as
a disadvantage, suggesting that they may not seek or be able
to use it covertly. In contrast, African, Indian and Peruvian
FSWs have been found to support covert use of gels, viewing
this as an advantage of the formulation [13,22]. It has been
suggested that for young adult women, men’s passive
acceptance of microbicide gel use may be more important
than covert use [23]. Notably, adolescent participants in our
study did not mention disclosure to partners as playing a
role in their interest in PrEP gel or other PrEP formulations.
However, we did not ask them if they were sexually active,
and those who were not would not have had experience
communicating with partners about HIV prevention or con-
sidering issues of disclosure.
This study provides some initial information on the
preferences of at-risk populations for different formulations
of PrEP, a topic about which little is yet known. In our study,
most (but not all) FSWs and SDCs in Kenya preferred an
injectable PrEP formulation, which they viewed as long-lasting
and private. There was greater variation among adolescent
and young women in South Africa regarding their preferences
for PrEP formulation, with each group noting some benefits
and limitations associated with each one. Factors affecting
method preferences among the target groups included pri-
vacy of the method (for all but SDCs). Adolescent and young
women especially were concerned with how PrEP products
could be used privately; in particular inserting gels was
seen as difficult to do privately while, conversely, pills were
viewed as a product that could be used without others such
as partners, friends, or family members noting or asking
questions. Concerns over privacy are likely linked to an
underlying stigma of adolescent and young women having
sex, an issue that must be addressed to stimulate demand for
PrEP products among this group.
Other factors that affected method preferences included:
frequency of use, painfulness, the need for user interven-
tion, side effects, interaction with alcohol and drugs, coital
dependence, partner approval and convenience. Interestingly,
efficacy was not mentioned as a factor influencing formula-
tion preference, although it was mentioned in reference
to the acceptability of formulations; however, it is possible
that participants assumed all methods would be equally
effective.
Offering PrEP users a choice of methods could also provide
an additional benefit  the process of educating users on the
methods available could serve as an opportunity to provide
individualized risk-reduction counselling. PrEP trials routinely
offer this and see benefits associated with the provision of
this information. Additionally, method distribution and the
regular HIV testing required for PrEP provision is another
opportunity for the provision of brief counselling.
Among the limitations of our study are the small number
of FGDs, the use of convenience sampling which may not
have produced a fully representative sample of the target
populations and questions about hypothetical use of these
PrEP products, which may differ from both clinical trial
use and real-world usage of available products. We also
did not systematically collect information on whether con-
dom migration would occur with the introduction of PrEP
formulations, although some groups brought this up during
the discussion. An additional limitation is that the context-
specific nature of the results may limit generalizability of
the findings to other cultures and country settings, but this
ultimately relates to our main observation and conclusion.
Conclusions
Women at risk of HIV in sub-Saharan Africa are a diverse
population and do not necessarily share the same life cir-
cumstances, social norms, risk profiles or perceived ability to
use particular PrEP formulations. Their circumstances and
needs, as well as choices, are also likely to change over time
as their lives take course, depending, for example, on age,
relationship status and parity. Sub-Saharan African women’s
preferences for HIV prevention methods and formulations
may be similar within particular user groups  or not,
highlighting the importance of ensuring the availability of
choice in HIV prevention methods.
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Abstract
Introduction: Clinical trials of new vaginal products require careful communication with participants about trial requirements.
Most microbicide trials have been multi-site studies conducted among women in sub-Saharan Africa, where literacy levels and
understanding of scientific methods differ from those designing and conducting the trials. Microbicide trials require women to
insert objects in their vagina and ensure they are present in the vagina during sex. For many women, this is a novel behaviour.
These behaviours take place within the context of clinical trial participation, which is an additional novelty. Research teams must
develop informational materials to help participants understand the clinical trial and input from local research staff and
community members can improve the content and format of these materials.
Methods: This paper discusses the development of illustrated materials developed for microbicide trial participants, presenting
examples from two studies. In both studies, research staff and community advisory groups collaborated to review and revise
materials.
Results: Collaborative efforts revealed insights about how to convey information about clinical trial participation and microbicide
use. These insights highlighted realities of the local context, details that might be misunderstood, illustrations of a sensitive
nature and concerns about blood testing. In particular, information about blood testing and product use instructions required
careful consideration. Although the research team anticipated needing advice on how best to convey information on these
topics to participants, some aspects of potential participant concerns about these topics were also new to the research team.
Community advisors and local research staff suggested better ways to convey this information, and provided guidance on how to
use the materials.
Conclusions: The collaboration served to develop informational materials for microbicide trial participants. Furthermore, staff
gained a better understanding of issues and concerns that could influence trial participation. A collaborative engagement
process can provide important insights into local culture and knowledge beyond what is needed for development of clinical trial
participant information materials. Research teams should be sensitive to this possibility, avail themselves of information and
take appropriate action.
Keywords: microbicide trials; community collaboration; participant information materials.
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Introduction
The continued need for HIV prevention methods that women
can use provides motivation for efforts to develop vaginal
microbicides, which are products inserted in the vagina and
meant to remain present during sexual intercourse to impede
sexual transmission of HIV [1]. For many women, this is
an entirely novel behaviour, and for those accustomed to
traditional vaginal practices [2], the specific use requirements
for microbicide products may be more exacting. Use require-
ments have included timing of insertion in association with
sexual intercourse, daily routine insertion of gels and inser-
tion of a vaginal ring that is left in the vagina for weeks at
a time [3]. These behaviours take place within the context
of placebo-controlled clinical trial participation, which is a
further novelty, and careful communication is required to
support meaningful informed consent and good adherence to
study requirements.
Potential study participants, research staff, community
members and the family and social network of participants
all need clear information about clinical trials conducted locally
[4]. Most microbicide trials have included research sites in
multiple countries, and research has been concentrated in sub-
Saharan Africa, where incidence of HIV infection is high [5].
In this region, study participants’ literacy and knowledge of
scientific methods and concepts often differ from those
designing and conducting trials and thus special attention is
needed to develop culturally appropriate and effective com-
munication materials about trial procedures and require-
ments. Incorporation of illustrations in educational materials
can improve communication [6,7], and community input is
increasingly used in the development of such materials.
The collaborative process for developing communication
materials provides insights into issues that influence clinical
trial participation and adherence, as well as those that could
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impact future introduction and use of products and inter-
ventions proven effective. In microbicide research, such
collaboration usually occurs through interactions with com-
munity advisory groups [810]. Communication is intended
to flow in both directions, from community to the research
group conducting the trial, and vice versa [11].
This paper reviews the collaborative and adaptive pro-
cesses to develop informational materials for participants in
two microbicide trials, one initiated in 2005 and one in 2012,
and highlights the accumulated experiences with commu-
nication needs over that time. The first trial is HPTN 035, a
Phase IIB study of vaginal gels conducted by the HPTN at sites
in Malawi, South Africa, United States and Zimbabwe from
2005 to 2009 [12]. The second study, initiated in 2012, is IPM
027 (‘‘The Ring Study’’), a Phase III safety and efficacy clinical
trial testing a vaginal ring and currently being conducted
by the International Partnership for Microbicides (IPM) at
research sites in South Africa and Uganda [13].
In the 10 years that passed between initiating design of
the HPTN 035 materials and completing materials for
participants in IPM 027, much had been learned about the
issues and communication needs for microbicide trial
participants, and this knowledge has been applied to IPM
027. After providing a summary of the types of informational
materials developed for trial participants, we discuss the
lessons learned through the collaborative process.
Discussion
Illustrated materials described here were developed for both
studies prior to study initiation, so that they would be
available for the initial informed consent process. They were
not developed using a scientific research protocol, and they
were not formally evaluated or tested. Rather, the materials
development process began with drafts prepared by a team
working at the study coordinating centre (for HPTN 035) and
study sponsor headquarters (for IPM 027). This central team
then engaged in a consultative process with staff and
community advisory groups at the local research sites.
In HPTN 035, local input on drafts of illustrated materials
was obtained from staff at the research sites, including staff
responsible for community engagement. At some of the sites,
these staff in turn asked for informal feedback from members
of their local community advisory group. For IPM 027, input
was provided by the staff at the research sites and a more
formal process was used to solicit feedback from the com-
munity advisory groups associated with the research sites
conducting the study. Draft materials were initially presented
to research site staff and revised according to feedback. Staff
then presented the second draft to their community advisory
group, and written feedback was provided to the staff
member developing the materials at IPM. Materials con-
tinued to be revised until the groups involved considered
that feedback had been appropriately incorporated. For both
studies, translations followed illustration development, using
an iterative process that sometimes required additional
adjustments to illustrations. Importantly, the community
advisory groups in IPM 027 were given formal feedback on
how their recommendations were accommodated in the
revised and final versions.
Materials were approved by ethics committees prior to
being provided to participants. Centralized training on use of
all materials developed for both studies was provided to the
research site staff, using a training-of-trainers approach.
Training manuals included a page-by-page discussion of the
purpose and intent of the illustrations, talking points and
counselling approaches to be used with the materials. Training
was completed and materials in place prior to the start of both
trials.
Types of materials
The educational materials for participants in both trials use
illustrations. In both studies, local input was used to develop
the main characters for print materials, which included a study
participant, her partner and a staff member at the research
site. Since both studies included participants from multi-
cultural settings, local staff and community advisors advised
that the characters be somewhat neutral, avoiding attire and
hairstyles that could be identified with a specific ethnic group.
For HPTN 035, separate sets of African and U.S. illustrations
were developed, although the content and text (translated
into local languages) was the same.These characters appeared
throughout the sets of illustrated materials, which included
the following items:
1) Informed consent materials: Both studies developed
table-top flipcharts to be used at the research centres
during the informed consent discussion, proving in-
formation on study design and purpose, procedures,
risks and benefits, confidentiality and what is expected
of study participants. In HPTN 035, a booklet version of
the flipchart was also given to participants to take with
them.
2) Product use instruction sheets: Both studies developed
illustrated instruction sheets to provide participants
with instructions about how to correctly use the study
products. Instructions for HPTN 035 focused on how to
correctly apply the gel before sex and dispose of the
applicator. The instructions for IPM 027 carried forward
the illustration concepts for insertion, but expanded the
instructions to explain what to do if the vaginal ring is
out of the vagina between visits.
3) Blood testing information sheets: During the period that
HPTN 035 was being conducted, experiences were
accumulating in HPTN 035 and other microbicide trials,
highlighting a number of issues that are challenging to
convey to participants [1416]. These include aspects of
blood testing in general and the HIV testing algorithm
adopted for the study. In response to this need, an
additional set of information sheets was developed for
IPM 027, to be used as needed throughout the trial.
Adapting to local context
Some of the required revisions were fairly straightforward and
would likely have become apparent in a routine review. For
example, community advisors noted that not all have access
to running water, and thus an illustration of product rinsing
was changed to convey a basin of water, rather than a spigot.
Similarly, the community advisory group in one country noted
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that motorcycle transportation is much more common in their
area than the minibus portrayed in the original illustration,
and thus a motorbike was added to the page. Although
both of these example revisions were easily accommodated, it
is worth noting that the discussion which highlighted the local
context served to further sensitize the research staff across
all sites.
Within the local context, some specific items to be
illustrated revealed sensitivities of a personal nature. For
example, community advisory groupmembers objected to one
of the initial depictions of vaginal ring insertion. The instruc-
tions show options for inserting a ring either by squatting, lying
down or standing with one foot raised. Some community
members felt that one of these illustrations could be mis-
construed as portraying masturbation. The illustration for IPM
027 was easily modified to depict the ring clearly in the
participant’s hand. The HPTN 035 informed consent flipchart
included an illustration of a woman receiving a pelvic exam,
and local advice was to not include this in the booklet version
given to women to take home, since it could be embarrassing
or confusing if seen by children.
Clarification of instructions for correct use of
microbicides
The product use instructions developed for both studies are
undoubtedly stronger because of the local input received. The
information is more in tune with the realities of participants’
lives and possible misperceptions have been clarified. The
instructions provide a convenient and appropriate visual aid to
reinforce product use-adherence. For example, the IPM 027
product use instruction sheetmakes it clear that sometimes an
expelled ring should not be reinserted, while in other cases it
can be rinsed and reinserted. The sheet depicts only ring
insertion, not removal, in order to avoid conveying the
message that the ring should be removed. The product use
instruction sheet used in HPTN 035 clearly illustrated that the
applicator should be inserted only halfway into the vagina; this
was meant help avoid a mistaken assumption that women
should strive to push the applicator in as far as possible, which
could possibly cause trauma.
Addressing blood testing concerns
An important issue that has given rise to rumours and
misperceptions in HIV prevention research, including micro-
bicide trials, concerns blood testing [1416]. In microbicide
trials, routine and repeated blood testing is required over
extended periods of time (e.g. 1 to 2 years or more), and
some scheduled tests may collect multiple vials of blood. The
volume and/or frequency of blood testing has given rise to
rumours that researchers sell blood for profit-driven or
nefarious purposes, including ‘‘Satanism.’’ Some who accept
explanations about the need for and purpose of blood testing
may nevertheless be concerned about what happens to the
blood once tests are complete (e.g. Is it stored? Is it sold? If it
is destroyed, how is that done?). On a different note, staff at
some research sites noted that participants may not under-
stand how quickly blood is replaced in the body, or how
much blood the body contains. Finally, those working in the
larger field of HIV/AIDS have long reported that people find
HIV testing algorithms confusing, and they may not believe
the accuracy of testing results.
On the advice of local staff, the HPTN 035 illustrated
materials depicted a hand holding a blood collection vial, to
counter previous rumours that cola-sized bottles of blood
were collected. For IPM 027 three illustrated sheets were
developed to explicitly address the multiple blood draw issues
that had been raised in previous trials, and by the community
advisors and staff working in the trial sites (Figure 1).
One sheet is a simple diagram of the HIV algorithm, using
illustrations and characters from the informed consent
flipchart to show the sequence of testing when an initial test
is positive. A second sheet illustrates the amount of blood
drawn at different types of visits (e.g. monthly, quarterly)
throughout the trial, using common household items, such as
a spoon or measuring cup to convey volume. This sheet is
available to supplement the informed consent discussion, as
well as at any visit when blood is taken, or the participant
expresses concerns or questions. A third illustrated sheet
shows how much blood is in the average women’s body, again
using a household item for comparison, and compares that
volume with the amounts taken during the different study
visits as well as how much blood a woman normally loses
during menses. This sheet also explains that the body
replenishes blood within 24 hours, samples are kept in a
locked location and that blood is subjected to tests for ‘‘HIV,
other health problems and dapivirine drug levels.’’
Development of all these materials benefitted from com-
munity consultation. For example, it was requested that the
algorithm sequence, which uses illustrated silhouettes, be
accompanied by the flipchart illustration of a blood draw,
which had previously been scrutinized and revised to meet
community approval. The household items to be used for
comparison with various blood volumes were discussed and
agreed upon. At the community advisors’ suggestion, an
illustration was added to explain that a participant’s blood is
never mixed with anyone else’s. This concern of participants
was previously unknown to the research team developing the
illustratedmaterials.The research teamwas unable to develop
a satisfactory illustration of how blood is destroyed (illustra-
tions depicting burning were considered too alarming), so this
concern was added to the talking points only.
Conclusions
The use of illustrations has been shown to be an effective way
to convey health information, particularly in low-literacy
settings [10]. It is incumbent on research teams to make
suchmaterials available to the larger research field, so they can
be adapted through a consultative process for use in other
settings. Indeed, over the time period covered during the two
trials discussed, the basic style for illustrated consent materials
and user instructions described in this paper has become
widely used in microbicide trials. The blood-testing informa-
tion sheets are unique, and they provide an example of how
research teams with a foundation of illustrated materials can
develop additional materials as needed throughout a study,
building on participant familiarity with the characters and
information format. Although communication about clinical
trial objectives, procedures, requirements and risks and
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benefits is particularly concentrated during the enrolment
process, such communication is needed throughout the study
period [4].
As an added benefit, the review and consultation process
provided the research staff and community advisory groups
with a deeper understanding of the trial procedures and
requirements, and community concerns and interests. The
discussions helped elucidate issues known to be problematic,
and surface new ones that required the attention of the
research staff. Moving forward, future clinical research could
continue to benefit from the accumulated lessons learned
through collaborative communication with local research
teams and community advisory groups. Knowledge of the
experiences of trial participants, the rumours that circulate in
trial communities about blood testing and continued en-
gagement with community advisors will be helpful in future
research as well as introduction of HIV prevention methods.
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Abstract
Introduction: In planning for the introduction of vaginal microbicides and other new antiretroviral (ARV)-based prevention
products for women, an in-depth understanding of potential end-users will be critically important to inform strategies to optimize
uptake and long-term adherence. User-centred private sector companies have contributed to the successful launch of many
different types of products, employing methods drawn from behavioural and social sciences to shape product designs, marketing
messages and communication channels. Examples of how the private sector has adapted and applied these techniques to make
decisions around product messaging and targeting may be instructive for adaptation to microbicide introduction.
Discussion: In preparing to introduce a product, user-centred private sector companies employ diverse methods to understand
the target population and their lifestyles, values and motivations. ReD Associates’ observational research on user behaviours in
the packaged food and diabetes fields illustrates how ‘tag along’ or ‘shadowing’ techniques can identify sources of non-
adherence. Another open-ended method is self-documentation, and IDEO’s mammography research utilized this to uncover user
motivations that extended beyond health. Mapping the user journey is a quantitative approach for outlining critical decision-
making stages, and Monitor Inclusive Markets applied this framework to identify toilet design opportunities for the rural poor.
Through an iterative process, these various techniques can generate hypotheses on user drop-off points, quantify where drop-
off is highest and prioritize areas of further research to uncover usage barriers. Although research constraints exist, these types
of user-centred techniques have helped create effective messaging, product positioning and packaging of health products as well
as family planning information. These methods can be applied to microbicide acceptability testing outside of clinical trials to
design microbicide marketing that enhances product usage.
Conclusions: The introduction of microbicide products presents an ideal opportunity to draw on the insights from user-centred
private sector companies’ approaches, which can complement other methods that have been more commonly utilized in
microbicide research to date. As microbicides move from clinical trials to real-world implementation, there will be more
opportunities to combine a variety of approaches to understand end-users, which can lead to a more effective product launch
and ultimately greater impact on preventing HIV infections.
Keywords: HIV; prevention; microbicides; end-user; user research; women; adherence; introduction planning.
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Introduction
With several ground-breaking possibilities for women-
initiated methods of HIV prevention on the horizon, it is
critical to begin planning for product introduction. Recent
trials of antiretroviral (ARV)-based prevention products have
demonstrated that pre-exposure prophylaxis (PrEP) will be
effective if adherence is sufficient [15]. Though a lack of
efficacy was observed in the FEM-PrEP [6] and VOICE (7) trials
of PrEP among young women in sub-Saharan Africa, product
use was low as measured by drug levels. Thus, hopes remain
high that trials of either dapivirine ring (in the Ring Study and
ASPIRE) and/or tenofovir gel (in FACTS 001) will confirm the
efficacy observed in CAPRISA 004 and ultimately lead to
licensure and introduction of one or more new vaginally
administered products for HIV prevention.
The importance of integrating behavioural and social
sciences in biomedical microbicide trials is widely recognized
[6,812], and behavioural science methods have been
emphasized in past and on-going HIV research and interven-
tion methodology. While it is beyond the scope of this com-
mentary to provide a comprehensive review of all literature to
date, the diversity in the quantitative and qualitative beha-
vioural science methods used to support microbicide planning
efforts is noteworthy. Previous and on-going microbicide
research has included discrete choice experiments exploring
the effect of efficacy and contraceptive potential on a woman’s
stated willingness to use microbicides [13]; focus groups,
interviews and questionnaires examining microbicide accept-
ability [1420]; analysis of disclosure of trial participation
on microbicide use and adherence [21]; and Motivational
Interviewing to identify and address trial participants’ barriers
to adherence [22]. However, although behavioural science
methods have been used in smaller studies of non-trial par-
ticipants to examine factors such as perceptions of topical
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vaginal gels [23,24] and intravaginal insertion practices [25],
studies with this broader community have not been the norm,
which has limited data related to potential microbicide end-
users. Furthermore, methods from the broader social sciences
have not been frequently utilized in HIV research and inter-
vention methodology with either trial or non-trial participants.
As microbicide product development moves from clinical
trials to real-world implementation in the coming years, there
will be more opportunities to use complementary methods
to understand women’s interaction with a real product in a
less artificial context. Deepening awareness of the barriers
to microbicide use and access in a more demographically
diverse population will be essential to ensuring this preven-
tion method meets its potential to empower women in their
sexual relationships and health. In this regard, ‘user-centred’
private sector companies (distinguished from marketing firms
by a more intensive and open-ended approach to understand
the end-user) have demonstrated success in increasing uptake
of many different types of products. This has been achieved
through utilizing a wide range of techniques to understand
the target population as well as their lifestyles and broader
environment [23,2633]. While behavioural and social sci-
ences provide the foundation for this approach, examples
of how the private sector has applied these techniques to
make decisions around product messaging and targeting for
effective product introduction can be instructive for the
public sector’s adaptation to the microbicide arena, particu-
larly in the post-licensure phase of microbicide research.
Discussion
To understand the underlying themes relevant to a new
product, user-centred private sector design and marketing
firms typically begin by speaking to and studying a wide range
of individuals  not only potential end-users outside of the
clinical trial context but also other individuals in the environ-
ment who may have widely disparate views [28,32]. Speaking
to ‘extreme’ users (e.g. those who embrace abstinence, as
well as those who prefer sex without any protection) uncovers
attitudes and beliefs that inform the understanding of the
target user [32].While prevention of HIV is the main objective
for the public health world, for the user, that may not be the
only mental framework. In the case of microbicides, percep-
tions of the product and HIV, as well as larger issues like
beauty, wellness and social norms must be considered for a
successful rollout.
Moreover, to fully understand user experiences, percep-
tions and underlying motivations, the private sector focuses
on the broader context affecting decisions that are made
around product use, investing heavily in understanding the
larger ecosystem of values, beliefs, lifestyles, habits and other
influencers of behaviour [27,28,33]. While methods used in
microbicide trials such as in-depth interviews, focus groups
and surveys are important for understanding end-users, one
potential limitation is that they can produce an artificial
situation where respondents answer according to what they
believe is expected and may not reveal what they actually
think or do [34]. The flexibility and open-ended nature of in-
context observation can potentially mitigate this social de-
sirability bias since this approach does not rely entirely on the
interviewee’s accountability and interest in articulating under-
lying motivations [33]. Additionally, it can help generate new
hypotheses since questions are not pre-determined and will
organically arise from real-time observations [26,28].
In-depth observational methods to understand end-users
One method of understanding a user’s context and lifestyle
is to follow users through their habits and routines, referred
to as ‘tag along’ or ‘shadowing’ [28]. This technique can be
used to complement in-depth interviews by revealing dis-
connects between individuals’ aspirations versus actions. ReD
Associates demonstrated this in their work in packaged food
(ReD Associates is an innovation and strategy consultancy that
employs the methods of social science and market analysis).
When interviewing mothers about how they choose between
different types of food, researchers heard an emphasis on
nutrition, organic ingredients and other aspects that empha-
sized health but found packaged foods that were primarily
convenient, fast and easy to use upon looking in the ref-
rigerator. Because similar discrepancies have been recognized
between self-reported and measured microbicide adherence
[6], these observational techniques might provide an addi-
tional source of information from lifestyles or emotional cues
to triangulate and better interpret self-reported data.
Furthermore, these techniques have been useful in reveal-
ing the role of stigma and other root causes of behaviours.
In the diabetes field, ReD Associates’ observational research
found that patients would skip shots when in public due to
a sense of self-consciousness or a fear of stigma from being
identified as diabetic, contradicting the industry’s prior as-
sumption that lack of consistency was due to forgetfulness.
This insight emphasized the need for discretion  for example,
through less intrusive product designs with syringes that
looked more like pens  over an intervention based on setting
up timed or automated reminders.
While it is understood generally that HIV-related stigma
affects microbicide use, our understanding of more specific
facilitators of, and barriers to, microbicide use might be
enhanced by direct observational research. Though it would
not be possible for a researcher to tag along in every situation,
and obviously not during sexual intercourse, a researcher may
still gain valuable insight by joining a woman as she starts
her weekend to observe her social interactions, the physical
environment of her home and the places she goes, and even
what she carries in her handbag to glean what she associates
with sex. Post-observation, the researcher can follow-up with
women to determine what sexual health choices were made.
This can provide insight into aspects of daily life routines
that influence usage of and adherence to microbicides. For
example, women might associate cosmetics with beauty and
microbicides with medication, which could result in bringing
cosmetics  but not amicrobicide  to a bar or tomeet a sexual
partner. This type of observation and usage driver can inform
microbicide design so that packaging and marketing invoke
the branding of beauty products instead of medications.
Another observational technique commonly used by the
user-centred private sector is self-documentation, or enabling
users to create photo and video diaries [32]. IDEO recently
engaged in a project to uncover women’s attitudes and
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experiences around mammography in the United States (IDEO
is an international design and consultancy firm). Rather than
accompanying each woman to individual mammogram ap-
pointments, the women were given video cameras and
recorded their reactions and thoughts before, during and after
the mammogram appointment. Giving women the freedom to
record in the intimacy of their homes, doctor’s offices and
other relevant settings enabled open and comfortable reflec-
tion, revealing that some women were sceptical of mammo-
grams, while others experienced mammograms as life-saving.
Participation in the exercise over time highlighted how reasons
for adherence to mammograms extended beyond cancer
detection to larger themes around femininity, wellness, self-
confidence and modelling behaviour for daughters.
Given the private nature of microbicide use, application of
this technique can increase users’ sense of agency in providing
feedback. The approach addresses practical needs (since it
is not feasible for researchers to ‘embed’ themselves in
women’s sexual lives), while giving users flexibility and room
for privacy. Mobile phones with photo and video capability are
becoming more common in developing country settings and
might be viewed by microbicide users as an interface that
is more approachable than options such as writing essays
or completing written questionnaires  and less subject to
social desirability bias than in-person interviews. Although
this might not be possible in all contexts due to privacy or
institutional review board concerns, technology is becoming
further integrated into research practice, and similar methods
such as PhotoVoice, are also popular in advocacy efforts and
women’s health [35,36]. Photo and video journaling can
provide insight into the subject of microbicides in users’
minds, the connection to themes beyond the direct purpose
of HIV prevention and the interlinked associations that may
influence product uptake and usage.
User journey mapping
Mapping the user journey is another user-centred private
sector approach that goes hand-in-hand with observational
research [37] and can be employed during the post-licensure
phase when microbicides are introduced. This quantitative
approach provides a framework for outlining the critical
decision-making stages a potential user passes through in order
to become a regular product user, allowing researchers to better
understand potential drop-off points and calculate attrition
rates for each stage. Illustrating this structure is part of an
iterative process of end-user research in which initial observa-
tional research can generate hypotheses regarding potential
drop-off points, and user journey mapping can calculate where
drop-off is highest. This can then inform areas where more
in-depth observational research can most efficiently and
effectively hone in on root causes for these drop-offs.
Monitor Inclusive Markets (MIM) created this type of
decision-making map through its customer research in Bihar,
India, around willingness of the rural poor to purchase toilets
(MIM is a unit of the Monitor group that focuses on market-
based solutions for social change). Mapped against the user
journey, this research revealed that financial constraints were
substantial barriers at the purchase stage, and residents who
may otherwise have bought a toilet found it unaffordable.
Upon further investigation of this stage, researchers discov-
ered that potential users wanted a long-term sanitation
solution and assumed that requiring a 10-foot deep waste pit
posed a significant cost. Armed with this knowledge, researchers
were able to suggest an alternative, long-term toilet design with
lower upfront cost, by using two five-foot deep pits [38]. The
user journey analysis also revealed that key influencers of target
users were friends, community members and local masons,
suggesting the importance of building support for this newdesign
among these trusted information sources.
Examining the cascade of care is not a foreign concept for
researchers in the HIV field. What is perhaps different in
emphasis amongst user-centred private sector firms is the
degree of rigour in focusing on the journey from the end-
user’s perspective rather than the clinical and health system
utilization components of a supply-side oriented perspective.
By focusing on the end-user experience with microbicides
over time, the user journey framework can enable stages to
be identified; examined for important barriers, drivers and
influencers of microbicide use; and prioritized for further
study to ultimately understand and address root causes of low
uptake and adherence. Figure 1 illustrates how this iterative
user journey mapping process might be used for microbicide
users as well as the information it might provide.
Applying user research to product messaging, positioning
and packaging
Synthesis of user research and resulting insights may open
possibilities beyond those provided through biomedical trials,
behavioural sciences and similar work with a greater focus
on the public health interests of disease prevention and
drug properties. Bedsider.org, a campaign designed by IDEO
with the National Campaign to Prevent Teen and Unwanted
Pregnancies, addresses unplanned pregnancy among young
women. Through stakeholder research, Bedsider focused on
five areas for behavioural change, including awareness and
motivational drivers. By offering medically accurate informa-
tion through a sex-positive brand and addressing a stigmatized
topic with humour (versus a clinical, prescriptive tone) and
various kinds of media (video, testimonials and other inter-
actions), Bedsider’s communication is more engaging and
effective for the target audience of women aged 1829,
among whom 7 out of 10 pregnancies are unplanned. To date,
over one million users have already visited Bedsider.
While in some cases ‘demedicalizing’ a product may be
important, highlighting a product’s medical nature can also
increase uptake. A psoriasis treatment manufacturer thought
potential users were anxious about side effects and marketed
their treatment as a beauty product, or ‘just like a cream’.
User research conducted by ReD Associates revealed that
patients thought it wasn’t working and stopped using it. The
manufacturer changed the packaging to emphasize potency,
and usage increased. With microbicides, user research should
similarly play an important role in informing messaging,
positioning and packaging.
Constraints and challenges
In addition to the illustrative techniques outlined above,
many other non-traditional methods to understand end-
users can be explored for microbicide introduction planning,
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including co-designing, storyboarding, role plays and drawing
as response. Whichever methods are chosen, the following
constraints and challenges may arise.
One key issue is how to best test acceptability of a new
product when it does not yet exist. Though acceptability
assessments are incorporated from phase I to phase III clinical
trials, it is critical to gain amore comprehensive understanding
of acceptability among the broader (i.e. non-clinical trial
participant) population, especially before a completely new
class of agents is introduced. One potential workaround is
developing an early prototype during the pre-licensure phase
and observing how a more diverse population of potential
users interacts with this mock product. For example, IDEO
developed an insulin starter kit that users could see and touch,
enabling researchers to understand how injection instructions
were best integrated into the kit, which visuals and text
resonated emotionally, and where the kit would be stored at
home. By enabling users to physically engage with a prototype
and role-play, researchers could better understand how users
view the product and how it would fit into users’ lives [28,30].
Prior to microbicide licensure, lubricants or contraceptive
vaginal rings that are already on the market may provide
opportunities to conduct user-focused research with products
that have commonalities with microbicides. Although motiva-
tions for using HIV prevention products are closely linked
to risk perception, there are likely to be additional marketing
cues that can encourage use, such as product packaging (e.g.
colour choice, images, similarities to other product packaging),
complexity of instructions or inserts (e.g. terminology, written
versus visual directions) and other factors. Conducting this
type of acceptability assessment with a broader population
can inform the design that is most likely to maximize use and
adherence among target demographics.
Another important aspect for user research is to recognize
the product promoter’s (or promoters’) constraints. These
can be investment ceilings, insufficient human resources, or
strict regulatory requirements that restrict the ability to act on
user insights. It is important to take stock of these constraints
early on and to conduct user research with an eye towards
producing practical, actionable recommendations. In the case
of microbicides, late-stage products using an ARV as the active
pharmaceutical ingredient are unlikely to be available for
sale over-the-counter, and thus could not be physically placed
on the same shelf as other female-focused products like
cosmetics, sanitary pads or lubricants. However, early product
design prototypes might include packaging that combines
condoms and microbicides, emphasizes beauty, promotes
sexual pleasure advantages and/or is described by health
care service providers in the context of broader issues of
women’s health and family planning. Instead of messaging
only HIV prevention, these approaches might inspire desire for
a product, modelled after consumer behaviours (versus
patient behaviours).
Lastly, ethical considerations may constrain end-user
research that can be done with regard to microbicides in
comparison to common consumer products. The examples
highlighted in this commentary  for example, contracep-
tives, diabetes medication and mammography  illustrate
Figure 1. User journey mapping for microbicide user illustrating opportunities to identify potential drop-off points and barriers, drivers and
influencers at each stage.
Lin AH et al. Journal of the International AIDS Society 2014, 17(Suppl 2):19162
http://www.jiasociety.org/index.php/jias/article/view/19162 | http://dx.doi.org/10.7448/IAS.17.3.19162
4
that these methods can be successfully and ethically applied
to sensitive medical products.
Conclusions
While biomedical HIV trials and sexual health research utilizes
multidisciplinary methods to encourage uptake and adher-
ence in introducing new products, additional user-centred
private sector techniques can be integrated outside of the
clinical trial context to enhance microbicide introduction
planning efforts. In-depth observation, user journey mapping,
early prototyping and additional approaches can be em-
ployed, as described in the examples above to gain a more
comprehensive understanding of the end-user, her environ-
ment and the systems with which she interacts. Leveraging
such methods will help the field better identify and create
opportunities to target users and their key influencers with
microbicide messages and positioning that will maximize
uptake and adherence.
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Abstract
Introduction: Two new microbicide products based on topical (vaginal) application of antiretroviral drugs  1% tenofovir gel and
the dapivirine ring  are currently in late-stage clinical testing, and results on their safety and effectiveness are expected to
become available in early 2015. WHO guidelines on the use of topical pre-exposure prophylaxis (topical PrEP) are important in
order to ensure that these new prevention products are optimally used.
Discussion: Given that these new topical PrEP products are designed to be woman initiated and will likely be delivered in
reproductive health settings, it is important to ensure that the guidance be framed in the context of comprehensive sexual and
reproductive health and human rights. In addition to the safety and effectiveness data resulting from clinical trials, and the
regulatory approval required for new products, the WHO normative guidelines on the use of topical PrEP will be essential for
rapid roll-out in countries.
Conclusions: Human rights standards and principles provide a framework for the provision of woman-initiated HIV prevention
products. These include addressing issues related to the gender inequities which are linked to the provision of HIV-prevention,
treatment and care for young girls and women. Effective programming for women and girls must therefore be based on
understanding the local, social and community contexts of the AIDS epidemic in the country, and adapting HIV strategies and
programmes accordingly. Such a framework therefore is needed not only to ensure optimal uptake of these new products by
women and girls but also to address sociocultural barriers to women’s and girls’ access to these products.
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Introduction
Two new microbicide products based on topical (vaginal)
application of antiretroviral drugs for HIV prevention  1%
tenofovir gel and the dapivirine intravaginal ring  are cur-
rently in late-stage clinical testing and results on their safety
and efficacy are expected to become available in early 2015.
To ensure that these products are able to reach women and
young girls most at risk of HIV acquisition, their launch must
be accompanied by WHO guidelines on the use of topical pre-
exposure prophylaxis (topical PrEP). These guidelines must be
evidence-based and integrate human rights standards and
principles with recommendations taking into account policy,
programmatic and community considerations. These guide-
lines are important to ensure that new topical PrEP products
are implemented in high HIV incidence countries and settings
in a manner that is equitable and effective. WHO recommen-
dations have a strong influence on policy, can accelerate
implementation in resource-limited settings and are neces-
sary for accessing funding from some donors. They contain
clinical, public health and policy recommendations about
health interventions, and provide information about what
policy makers, health-care providers or patients should do
[1]. WHO has adopted internationally recognized standards
and methods for guideline development [2] to ensure that
guidelines are unbiased and that the products or interven-
tions meet a public health need. The recommendations are
based on a comprehensive and objective assessment of the
available evidence and the process used to develop the
recommendations is clearly described. WHO guidelines are
complementary to regulatory review and approval. While
national regulatory authorities have the responsibility to
determine whether a product should be allowed onto the
market in their jurisdiction, WHO guidelines provide advice
for national programme managers and policy makers as they
decide whether and how a product should be used. This
advice addresses, for example, whether and how it should
be prioritized to certain segments of the population or risk
groups, and how to deliver the new product in an efficient
and cost-effective manner with due consideration to other
priority health interventions.
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Given that new topical PrEP products are designed to be
initiated by the woman herself and will likely be primarily
delivered in reproductive health settings, it is important to
ensure that national programmes are designed and services
delivered within a framework of comprehensive sexual and
reproductive health and human rights. Human rights stan-
dards, principles and treaties provide guarantees specifically
relating to access to contraceptives. In addition, they recom-
mend, among other actions, that states should ensure timely
and affordable access to good quality sexual and reproduc-
tive health information and services, including contraception,
which should be delivered in a way that ensures fully informed
decision-making, respects dignity, autonomy, privacy and con-
fidentiality, and is sensitive to individuals’ needs and perspec-
tives. These guarantees are essential prerequisites to ensure
women and girls are able to access and use the new HIV
prevention methods.
WHO has recently issued guidance on ensuring that human
rights are integrated into the provision of contraceptive infor-
mation and services with a total of 24 recommendations
on how this can be achieved [3]. Promotion and protection
of human rights of women and girls are at the centre of
this approach, including their right to have control over and
decide freely and responsibly on matters related to their
sexual and reproductive health, free of coercion, discrimina-
tion and violence. This requires governments to adopt and
accelerate the implementation of laws, policies and pro-
grammes which protect and enable the enjoyment of all
human rights and fundamental freedoms, including their
reproductive rights in accordance with the International Con-
ference on Population and Development (ICPD) Programme
of Action [4], the Beijing Declaration and Platform for Action
[5] and the 2004 WHO Global Reproductive Health Strategy
[6]. Human rights are guaranteed in international and regional
treaties, as well as in national constitutions and laws. They
include the right to non-discrimination; the right to life,
survival and development; the right to the highest attainable
standard of health; and the rights to education and to
information.
These rights have been applied by international, regional
and national authoritative human rights bodies  such as UN
treaty-monitoring bodies, international and regional courts,
and national courts  to a wide range of sexual and
reproductive health issues, including HIV, sexually transmitted
infections (STIs), and recently to the accessibility of contra-
ceptive information and services. This approach also reso-
nates with global health programmes such as the PEPFAR
Gender Strategy which recognizes that gender inequalities
increase women’s and girls’ vulnerability to HIV and must be
addressed in designing and implementing HIV programmes, in
particular the HIV prevention programmes [7]. The invest-
ment to develop new woman-initiated methods for HIV pre-
vention has been driven by the recognition that there remain
important gaps in HIV prevention, particularly for young
women in generalized HIV epidemic settings, who remain
at high risk of infection, even in clinical trial settings with
intensive HIV risk reduction interventions. This is well illu-
strated by the HIV incidence among women in the placebo
arms of recent randomized controlled trials of novel HIV
prevention methods  5.0 per 100 person years in the FEM-
PrEP trial of oral PrEP trial conducted in Kenya, South Africa
and Tanzania [8], 5.7 in the VOICE trial of oral and vaginal
products conducted in South Africa and Uganda [9], 5.9 in
the Phambili vaccine trial in South Africa [10] and 9.1 in the
CAPRISA 004 trial of 1% tenofovir gel [11]. While condoms
are highly effective in reducing the risk of HIV infection in
serodiscordant couples [12] and among sex workers [13], their
use and impact remains stubbornly low in sex between
regular partners [14,15].
Discussion
A significant challenge to designing and implementing
programmes to deliver new HIV prevention methods is to
ensure that they are made available to, and used by, women
at high risk of HIV infection who are not using existing
methods. Many such women visit family planning and other
reproductive health services to obtain contraceptive advice
and supplies, or to seek treatment for STIs. Thus, these family
planning and reproductive health services have a key role to
play in providing information on the new HIV prevention
methods, even if a woman can only obtain the products from
a limited number of facilities. Making the products available
to women who do not access family planning or other
reproductive health services will be a greater challenge and
innovative programmatic approaches must be developed.
Building upon existing human rights standards and princi-
ples, several issues are particularly relevant in the context of
provision of woman-initiated HIV prevention products. These
include, but are not limited to, improving quality of services
through:
1) integration of and/or linkages between reproductive
health and HIV services which provide topical HIV
prevention, condoms and contraceptive commodities,
supplies and equipment, covering a range of methods,
including emergency contraception.
2) providing evidence-based, comprehensive information,
education and counselling to ensure informed choice
with regard to contraception, and to prevention and
care for HIV and other STIs.
The ICPD Programme of Action recognizes that women and
adolescent girls, especially those who live in impoverished
and otherwise disadvantaged communities and circumstances,
disproportionately bear the greatest costs and consequences
of failure to promote and protect sexual and reproductive
health and reproductive rights. However, many women who
would benefit most from these new HIV prevention products
are young women and adolescents who, in many commu-
nities, have poor access to services. They may live in contexts
where health-care providers do not have the training or
the means to provide young people with age-appropriate
services, or choose not to do so based on their own biases.
Legal and policy barriers, such as parental consent require-
ments, can also inhibit girls’ access to services. Issues of con-
fidentiality, women’s empowerment and participation and
accountability are essential to ensure promotion and protec-
tion of sexual and reproductive health and human rights
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of women and girls. For instance, women’s privacy, including
confidentiality of medical and other personal information,
needs to be respected throughout the provision of HIV and
STI prevention and care, and contraceptive information and
services. For some women, using, or trying to use, one of
the new HIV prevention products may expose them to
violence, or exacerbate the risk of intimate partner violence.
The ICPD Programme of Action also obliges governments
to ensure availability of and access to the information,
comprehensive sexuality education, and quality sexual and
Table 1. Key operational and policy research priorities for provision of topical PrEP
Priority area Research elements
Define the core service package to deliver tenofovir gel and
dapivirine ring safely and appropriately in different service
delivery settings (family planning clinics, HIV testing sites,
sexual and reproductive health services)
 HIV testing and retesting models (including frequency, location and self-
testing or provider-led testing)
 Prescribing and resupply models (location of initial supply and refills,
frequency of product dispensing)
 Counselling approaches
 Whether and how to monitor for drug resistance in newly infected
product users
 Frequency and methods for measuring adherence
 Barriers to use (travel, time in clinic)
Determine how best to provide topical PrEP to
adolescents and young women
(aged 15 to 24)
 Clinical safety studies in women below age 18 years to allow labelling for
use in this age group
 Feasibility and acceptability of delivering tenofovir gel and dapivirine rings
to young women
 Willingness and ability to use the product
 How to offer topical PrEP without undermining condom use
 Young women’s beliefs about the products, risks and how these might
affect adherence
 Site-specific situation analyses to identify where young women go, or
would go, to access topical PrEP for HIV prevention
Support consistent product use  Tools to determine which factors influence use, and identify reasons for
non-use
 Examine factors at multiple levels that influence product use, and can be
complemented by objective measures of adherence
 Develop approaches that allow support to be tailored to the individual user
 Ongoing assessment of adherence to products known to be safe and effective
Develop provider training materials  Develop, test and adapt materials as experience in implementing
programmes and supporting users accumulate
 Draw on clinical trial documents and evidence as well as available training
materials from other sexual and reproductive health and HIV prevention
technologies
 Practical tools for screening potential users to be used by providers and
women to help identify those at high risk of HIV, those likely to adhere to
product use, and other approaches for defining users
Conduct policy analysis and synthesis to build an
enabling environment
 Synthesize evidence, outstanding questions and approaches to monitoring
and minimizing resistance to address policymaker concerns
 Synthesize evidence, outstanding questions and approaches to monitoring
and minimizing risk compensation to address policymaker concerns
 Identify the best strategies and approaches to demand creation
 Determine how best to anticipate and address social issues (partner
testing and disclosure, preventing and addressing intimate partner
violence, considerations for sex workers)
 Identify needed data to inform consistent approach and parameters for
modeling cost effectiveness, impact and other key outcomes
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reproductive health services necessary to ensure sexual and
reproductive health and enjoy human rights.
Results from the CAPRISA 004 trial announced in 2010
showed that 1% tenofovir gel used around the time of
intercourse reduced the risk of HIV infection by 39% among
women in KwaZulu-Natal [11] and the FACTS001 study of the
same product, currently underway in eight sites in South Africa,
is expected to announce preliminary results in early 2015
[16]. This is in contrast to the VOICE trial of daily gel use
which showed no reduction in HIV incidence when users
were instructed to use the product every day irrespective
of anticipated or actual sexual intercourse [9]. The failure to
show any protective effect was attributed to poor adherence
to daily product use. The product in a coitally dependent
regimen is not likely to be licensed for use for at least two
years, given the time necessary to collate data, prepare the
regulatory dossier, submit to national regulatory authorities
and allow in-depth regulatory review. It will be a further
one or two years before the product becomes more widely
available to women at high risk of HIV infection who choose
to use it. A similar process and timeframe is expected for
the second topical microbicide product in development, a
vaginal ring containing the antiretroviral dapivirine which is
currently in two parallel Phase 3 trials in Malawi, South Africa,
Uganda and Zimbabwe [17,18]. The intervening time from
the end of Phase 3 trials to product availability provides
an opportunity to implement operational research among
former trial participants, new users and/or communities that
have not been previously involved in the research. A care-
fully designed programme of operational research will inform
service delivery approaches to best make the products avail-
able and support women in their use.
In contrast, there was no opportunity to implement oper-
ational research and learn how to design access programmes
before oral PrEP was licensed in the United States in 2012.
In 2010, the iPrEx study showed that daily oral tenofovir
disoproxil fumarate and emtricitabine (TDF/FTC) reduced the
risk of HIV infection by 44% among men and transgender
women who have sex with men [19]. Additional studies
published in 2012 showed that TDF alone or TDF/FTC was
also effective in reducing HIV infection in heterosexual men
and women in known serodiscordant couples, injecting drug
users and other high HIV risk men and women [2022].
The combination TDF/FTC was approved for use in HIV
prevention by the US Food and Drug Administration and
WHO released programme guidance in July 2012 with
a provisional recommendation on use within the context
of demonstration projects for serodiscordant couples, and
men and transgender women who have sex with men [23].
The absence of programmatic experience or implementation
research on how to deliver oral PrEP to users prevented more
specific recommendations from being made at that time.
A wide array of introductory and demonstration projects on
oral PrEP are now being developed and implemented. These
demonstration projects will provide important information
over the next two years on acceptable and sustainable pro-
gramme design, how to reach men and women at risk of HIV
infection who wish to access and use oral PrEP and how to
retain them in a comprehensive combination HIV prevention
programme. However, the majority of the ongoing or planned
demonstration projects are in serodiscordant couples, sex
workers and men or transgender women who have sex with
men. Only 2 of the 26 oral PrEP demonstration projects listed
by AVAC in December 2013 involve women at risk of HIV
Table 2. Research phases and characteristics of operations research studies
Phase of research Settings/key characteristics Key outcomes
 Before product licensure
Open label extension of efficacy trials Efficacy trial sites
Participation limited to efficacy trial
participants
All are former trial participants and
successful prior users
Additional safety data to support licensure
Key questions to allow less restrictive labeling: e.g.
 Frequency of HIV testing, product resupply
 Adherence support models
 Alternative service delivery settings
Pilot introductory studies and operations
research (following safety and
effectiveness, prior to licensure)
New users
Can be in trial sites or other settings
Research requires ethical and regulatory
approvals and individual informed consent
Inform guidance and product labeling
Inform initial programme design (e.g. minimum
service package, efficient adherence support models,
feasible and sustainable service delivery models)
Extend to new user groups (e.g. extended age range,
relaxed eligibility criteria and extension to users
previously excluded due to minor contraindications)




Projects developed to inform programme
design
Research designed and conducted in the
context of ongoing programmes
Inform successful programme scale up and adaptation
Inform development of updated guidance as
experience with product delivery and use
accumulates
Address public health use of products
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infection who are neither sex workers nor in a stable, known
serodiscordant relationship [24]. It is these women at risk of
HIV infection who are likely to pioneer use of, and benefit
most from, topical PrEP.
In March 2014, WHO and CAPRISA convened a stakeholder
consultation to identify priority implementation research
on tenofovir gel and dapivirine ring to inform develop-
ment of WHO guidelines on the use of topical PrEP [25].
The consultation brought together a range of stakeholders
to determine what issues were most critical for WHO guide-
line development, and the research approaches and timing
where they can be addressed. Building on research questions
and information gaps identified at previous consultations con-
vened since the release of the CAPRISA 004 results, con-
sultation participants prioritized key operational and policy
research priorities for the provision of topical PrEP (Table 1).
In addition, stakeholders at the consultation noted that
programme implementation of tenofovir gel and dapivirine
ring could be addressed in each of the three phases of
research: 1) open label extensions of the ongoing clinical
trials; 2) pilot introductory studies and operational research
after confirmation of safety and efficacy, but before product
licensure; and 3) programmatic research following product
licensure (Table 2). The stakeholder consultation strongly
reaffirmed that implementation research and roll-out should
be prioritized in communities and countries that have hosted
clinical trials of topical PrEP and other HIV prevention trials
in women, including full support for open label extension
studies in the sites where trials of tenofovir gel and dapivirine
ring are ongoing.
Conclusions
Given the continued high rate of new infections among
women, especially young women in generalized HIV epi-
demics, it is critical to determine how best to ensure that
effective HIV prevention products, including topical PrEP, can
be delivered appropriately and sustainably. Given the gender
inequities that drive the need for women-initiated products,
WHO guidance on topical PrEP must not only build upon
relevant existing WHO guidelines but also be grounded in a
comprehensive sexual and reproductive health and human
rights framework. Such guidance will be highly influential in
determining how these products are provided, accelerating
programme uptake of new technologies in resource-limited
settings, and facilitating purchase and programme support by
international agencies and donors.
Timely design and implementation of a programme of
introductory and demonstration studies on topical PrEP will
ensure that the period between confirmation of safety and
efficacy and product licensure is best used. This period can
generate new knowledge on how to deliver the products to
users in an effective and sustainable manner, how to retain
users in prevention programmes, what mix of HIV prevention
methods can be effectively and efficiently delivered to-
gether, how to integrate with existing sexual and reproductive
health programmes and how to involve the community and
potential users in programme design, implementation and
monitoring.
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